Image-Based Hybrid Scaffold Design for Multiple Tissue Regeneration  Application in Periodontal Engineering. by Park, Chan Ho
IMAGE-BASED HYBRID SCAFFOLD DESIGN FOR 
MULTIPLE TISSUE REGENERATION APPLICATION 
IN PERIODONTAL ENGINEERING 
 
 
 
 
By  
 
 
Chan Ho Park 
 
 
 
 
 
A dissertation submitted in partial fulfillment  
of the requirements for the degree of  
Doctor of Philosophy 
(Biomedical Engineering) 
in The University of Michigan 
2010 
 
 
 
 
 
 
 
 
 
Doctoral Committee: 
 
Professor William V. Giannobile, Chair 
Professor Scott J. Hollister 
Professor Peter X. Ma 
Professor Shuichi Takayama 
 
 
 
 
 
 
 
 
 
 
© Chan Ho Park 
All rights reserved 
2010 
  ii 
 
 
 
 
DEDICATION 
 
 
 
To My Beloved Family: 
Chong Oon Park and Kyung Sun Kim (Parents) 
Chan Hyuk Park, So Young Park, Hye-Jung Han, and Ji-Yeon Park 
For Their Boundless Love, Support, and Trust
  iii 
 
 
 
ACKNOWLEDGEMENTS 
 
From the bottom of my heart, I would love to express my gratitude to my research 
advisor, Professor William V. Giannobile, for the precious mentorship and support during 
the period of my graduate study. He is the greatest advisor, life-mentor, and father-in-lab 
having passion and energy in science and engineering as well as understanding 
everything with his warm encouragement.  
 
I would also like to thank to my dissertation committee: Professor Scott J. Hollister, who 
provided valuable and thoughtful guidance to accomplish studies as a research co-
advisor; Professor Peter X. Ma and Professor Shuichi Takayama have both provided 
precious scientific comments to improve my research and thesis and shape this research 
into what is has become today.  
 
I very heartfelt appreciate my U.S. family. Due to their various support, encouragement, 
and fantastic team-work I could successfully complete my doctoral work with excellent 
academic achievements. James V. Sugai, the mother-in-lab and one of the most important 
  iv 
people in my entire life, has advised and supported everything for the graduate life as 
well as the experiments. Dr. Qiming Jin has made me inspired with enthusiasm in the 
scientific researches as a scientist and realized how to enjoy the science and life 
challenges. Dr. Mario Taba Jr. gratefully gave a lot of knowledge and background to 
understand periodontics and craniofacial biology in pre-clinical and clinical, which are 
greatly helpful to develop the periodontal engineering and pursue doctoral works. Dr. 
Joni A. Cirelli preciously advised me about animal studies and molecular biology in 
periodontal researches to design my interdisciplinary and translational Ph.D. study with 
great research motivation. Dr. Zhao Lin and Dr. Po-Chun Chang, the greatest brothers-in-
lab and science colleagues, shared biological sciences, engineering knowledge, and our 
experiences to develop the wider scientific spectra. Moreover, from my lovely sister-in-
lab, Dr. Julie T. Marchesan, I have not only learned immunological biology background 
and various clinical challenges in periodontics but also known the most attractive cultures 
of Brazil, where become my most favorites. Dr. Hector F. Rios gratefully assisted many 
animal surgeries and instructed in-vivo experimental techniques for very challengeable 
microsurgeries. I appreciate Professor Yang-Jo Seol in Seoul National University, who 
encouraged and motivated me with scientific inspiration to accomplish challengeable and 
innovative works. I would also acknowledge my undergraduate students; Seokchun 
(Scott) Lim, Megan E. Bland, Erica Yi, post-/present-lab members; Nancy Chen, Zachary 
Abramson, Drew DiGiore, Rachael Jun, Lindsay Rayburn, TJ Daws, Lea Franco, Ashley 
Chung, Kathryn Kempeinen, Min Oh, Andrei Taut, Mallory Mitchell, Alexandra Plonka, 
and Lauryn Pitts (Giannobile Lab), visiting scholars; Drs. Ana Carolina Morandini, 
Valeria Navarro (from Brazil), Reinhard Gruber, Andreas Wiesbauer, Lukas Fürhauser 
  v 
(from Austria), Gaia Rosa Pellegrini, Salvatore Batia, Andrea Ottonello, Roberto Farina 
(from Italy), and Graduate Periodontics Program; Drs. Thiago Santos, Giorgio Pagni, 
Angie Lee, Hsun-Liang (Albert) Chan. In particular, I appreciate that Dr. Darnell Kaigler 
and Dr. Rodrigo Neiva provided precious opportunities; the first clinical development 
and trial of the micro-computed tomography (micro-CT) methodology for the dental 
implantology. This clinical application has eventually become the precise and accurate 
evaluation methodology for alveolar bone regeneration for the dental implant stability.  
 
I really feel thankful to the department of Biomedical Engineering (BME) for the greatest 
interdisciplinary education and financial support to successfully complete my Ph.D. 
program. Moreover, I appreciate Orthopaedic Research Laboratories (ORL) members, 
Dr. Steven A. Goldstein, Jaclynn M. Kreider and Dr. Jeffrey Megnack to facilitate and 
support professional background about the micro-CT and other medical imaging 
technologies. I would also like to thank Dr. Sunil Kapila and Dr. Mathew D. Dunn in 
Orthodontics and Pediatric Dentistry (OPD) for the orthodontic tooth movement 
application using micro-CT methodology, Dr. Tae-Geon Kwon in Kyungpook National 
University and all post-doctoral and research fellows; Drs. Nam Eok Joo, Jinkoo Kim, 
Serkin Park, Young (Young) Hun Jung, Sungsu Kim, Susan Tarle, Sarah Volk, Jennifer 
Fox in Periodontics and Oral Medicine (POM), Dr. Young Gun Ko in Bioologic and 
Materials Sciences (BMS), and Dr. Kyung-San Min in Cariology, Restorative Science 
and Endodontics (CRSE) in School of Dentistry. Moreover, Scaffold Tissue Engineering 
Group provided significant help for scaffold manufacture; Eiji Saito, Heesuk Kang, 
  vi 
Alisha Diggs, Huina Zhang, Jessica Kempainen, Annie Mitsak, Frank Winterroth, 
Shelley Brown, Yifei (Felix) Liu.  
 
Here, I very importantly appreciate my undergraduate study advisors, Professor Sungsoo 
Kim, professor Kigook Song, and professor Sang-Hyon Paek in the Department of 
Chemical Engineering, Kyung Hee University. From undergraduate study, they have 
gratefully inculcated a sense of responsibility, ethics, and pleasure for scientific research 
even though we have physically long distance. I also have special thank to Professor 
Jinsang Kim at the University of Michigan. He has always exemplified to me as a true 
scholar with considerate and warm heart.  
 
In my entire graduate life, I want to thank K-BME (Korean Student Association in BME) 
members; Hogene Kim, Samsung Huh, Daewoo Park, Jiwon Lee, Byoung Choul Kim, 
Eunjoo Hwang, Gu Eon Kang and K-BME-Alumni members; Drs. Jongbum Seo, 
Youngseon Choi, Huynjin Park, Kyungsup Shin, Donghwan (Richie) Kim, Gwangseong 
Kim, Taegyun Moon, Woonghee Lee, Hwan Kyu Lee, Dongwoo Lim, Ga Young (Claire) 
Jeong, Hwan Joo Park, Juyoung Park, Minsoung Rhee, Joon Seok (Paul) Chung, and 
Whijae Roh. I specially appreciate my classmates; Drs. Yunseok Heo, Jungwoo Lee, and 
Yoon-Chung Kim to support and make my graduate career much more fun.  I greatly 
thank to Dr. Jinho Kim (my old roommate) and Hobin Kim.  
 
  vii 
Lastly and the most importantly, I would very much love to thank to my family, 
especially my parents; Dr. Chong Oon Park and Kyung Sun Kim with their boundless 
love and support to complete my Ph.D. work and my most lovely siblings; Chan Hyuk 
Park and Dr. So Young Park. My special thanks are given to my sister-in-law, Hye-Jung 
Han and a pretty niece, Ji-Yeon Park. If it had not been for their boundless love, support, 
encouragement, and strong trust over the years, I could not be here and complete my 
work with the great achievement. I really express my heartfelt gratitude for everything 
from my family.  
  viii 
 
 
 
TABLE OF CONTENTS 
 
DEDICATION ............................................................................................................................  ii 
ACKNOWLEDGEMENTS ..................................................................................................... iii 
LIST OF FIGURES ................................................................................................................. xiv 
LIST OF TABLES ................................................................................................................. xviii 
ABSTRACT ............................................................................................................................... xix 
 
CHAPTERS ONE:  INTRODUCTION..................................................................................1 
 1.1 Background of Periodontal Tissues and Disease Progression..............................1 
 1.2 Current Approaches in Tissue Engineering and Regenerative Medicine ...........2 
 1.3 Micro-Computed Tomography Application in Tissue Engineering....................4 
 1.4 Statements of Purpose and Dissertation Overview ................................................5 
 1.5 Figures................................................................................................................8 
  ix 
1.6 References........................................................................................................10 
 
CHAPTER TWO: MICRO-COMPUTED TOMOGRAPHIC (MICRO-CT) 
METHODOLOGY DEVELOPMENT FOR PERIODONTAL DISEASE 
PROGRESSION .........................................................................................................................16 
 2.1 Abstract ......................................................................................................................16 
 2.2 Introduction ...............................................................................................................18 
 2.3 Materials and Methods.............................................................................................21 
 2.4 Results ........................................................................................................................29 
 2.5 Discussion..................................................................................................................32 
 2.6 Figures........................................................................................................................34 
 2.7 Table ...........................................................................................................................39 
2.8 References..................................................................................................................40 
 
CHAPTER THREE: AAV2/1-TNFR:Fc GENE DELIVERY PREVENTS 
PERIODONTAL DISEASE PROGRESSION ...................................................................45 
 3.1 Abstract ......................................................................................................................45 
 3.2 Introduction ...............................................................................................................47 
  x 
 3.3 Materials and Methods.............................................................................................50 
 3.4 Results ........................................................................................................................58 
 3.5 Discussion..................................................................................................................64 
 3.6 Figures........................................................................................................................68 
 3.7 Table ...........................................................................................................................75 
3.8 References..................................................................................................................76 
 
CHAPTER FOUR: RANKL INHIBITION THROUGH OSTEOPROTEGERIN 
BLOCKS BONE LOSS IN EXPERIMENTAL PERIODONTITIS..............................84 
 4.1 Abstract ......................................................................................................................84 
 4.2 Introduction ...............................................................................................................86 
 4.3 Materials and Methods.............................................................................................89 
 4.4 Results ........................................................................................................................94 
 4.5 Discussion..................................................................................................................98 
 4.6 Conclusions .............................................................................................................101 
 4.7 Figures......................................................................................................................102 
4.8 References................................................................................................................111 
 
  xi 
CHAPTER FIVE: LOCAL DELIVERY OF OSTEOPROTEGERIN INHIBITS 
MECHANICALLY MEDIATED BONE MODELING IN ORTHODONTIC 
TOOTH MOVEMENT ...........................................................................................................116 
5.1 Abstract ....................................................................................................................116 
 5.2 Introduction .............................................................................................................118 
 5.3 Materials and Methods...........................................................................................122 
 5.4 Results ......................................................................................................................128 
 5.5 Discussion................................................................................................................133 
 5.6 Figures......................................................................................................................139 
5.7 References................................................................................................................147 
 
CHAPTER SIX: ANALYSIS OF TISSUE NEOGENESIS IN GBR-TREATED 
EXTRACTION SOCKETS: CLINICAL, HISTOLOGICAL, AND MICRO-CT 
RESTULS...................................................................................................................................153 
 6.1 Abstract ....................................................................................................................153 
 6.2 Introduction .............................................................................................................155 
 6.3 Materials and Methods...........................................................................................156 
 6.4 Results ......................................................................................................................162 
  xii 
 6.5 Discussion................................................................................................................164 
 6.6 Conclusions .............................................................................................................169 
 6.7 Figures......................................................................................................................170 
6.8 Table .........................................................................................................................176 
6.9 References................................................................................................................177 
 
CHAPTER SEVEN: ANGIOGENIC AND OSTEOGENIC POTENTIAL OF BONE 
REPAIR CELLS FOR CRANIOFACIAL REGENERATION....................................185 
 7.1 Abstract ....................................................................................................................185 
 7.2 Introduction .............................................................................................................187 
 7.3 Materials and Methods...........................................................................................190 
 7.4 Results ......................................................................................................................199 
 7.5 Discussion................................................................................................................204 
 7.6 Conclusions .............................................................................................................209 
 7.7 Figures......................................................................................................................210 
7.8 Tables .......................................................................................................................217 
7.9 References................................................................................................................220 
 
  xiii 
CHAPTER EIGHT: BIOMIMETIC HYBRID SCAFFOLDS FOR ENGINEERING 
HUMAN TOOTH-LIGAMENT INTERFACES..............................................................226 
 8.1 Abstract ....................................................................................................................226 
 8.2 Introduction .............................................................................................................228 
 8.3 Materials and Methods...........................................................................................230 
 8.4 Results ......................................................................................................................238 
 8.5 Discussion................................................................................................................241 
 8.6 Conclusion ...............................................................................................................243 
 8.7 Figures......................................................................................................................244 
8.8 Table .........................................................................................................................255 
8.9 References................................................................................................................256 
 
CHAPTER NINE: SUMMARY AND DISCUSSION .....................................................260 
 
CHAPTER TEN: FUTURE DIRECTIONS ......................................................................266
  xiv 
 
 
 
LIST OF FIGURES 
 
 
Figure 1.1 Schematic Illustration of Periodontal Tissue and Limitations of 
Periodontal Therapy.............................................................................................8 
Figure 1.2 Experimental Periodontitis Model in Rats Using Micro-Computed 
Tomographic (Micro-CT) Images Visualized by Reconstructing into 3-
Dimensional Images ............................................................................................9 
Figure 2.1 The Schematic Illustration of Micro-Computed Tomography (Micro-CT) 
and Its Scanning Procedure...............................................................................34 
Figure 2.2 Method for Creating 3-D ROIs Used in Analysis of Alveolar Bone ..........35 
Figure 2.3 Linear Measurements of Interdental CEJ-ABC and Volumetric 
Measurement of ROF-RA.................................................................................36 
Figure 2.4 Representative Specimens Displaying Bone Loss in Healthy and Diseased 
Periodontia ..........................................................................................................38 
  xv 
Figure 3.1 Histological Sections of Subepithelial and Bone Crest Levels of 
Periodontal Tissues around the Maxillary Second Molar ............................68 
Figure 3.2 Preventive Effect of AAV2/1-TNFR:Fc Administration on Alveolar Bone 
Loss Induced by Pg-LPS Injections ................................................................70 
Figure 3.3 Real Time PCR Results for Cytokines, RANKL and OPG Expressions in 
the Palatal Gingival Tssue, at 4 and 8 Weeks Timepoints ...........................71 
Figure 3.4 Short-Term Quantitative Real Time PCR Results for TNF-α and IL-1β 
Cytokines Expression in a Time Course Experiment After Single Pg-LPS 
Injections .............................................................................................................72 
Figure 3.5 TRAP Immunohistochemistry for Detection of Osteoclasts-Like Cells in 
the Bone Surface of the Alveolar Bone Crest in the Palatal Side of the 
Maxillary Molars................................................................................................73 
Figure 3.6 Serum TNFR Protein Levels After Intramuscular Administration of 
AAV2/1-TNFR:Fc Vector to Rats Afflicted with Pg-LPS Experimental 
Periodontitis ........................................................................................................74 
Figure 4.1 In-Vivo rh OPG-Fc Pharmacokinetics After a Single Subcutaneous 
Administration ..................................................................................................102 
Figure 4.2 Serum rhOPG Levels After Twice Weekly Subcutaneous Administration 
and TRAP-5b Levels After Repeated Subcutaneous Administration.......104 
Figure 4.3 OPG-Fc Blocks Alveolar Bone Loss in Experimental Periodontitis ........106 
  xvi 
Figure 4.4 OPG-Fc Blocks Alveolar Bone Loss in Experimental Periodontitis as 
Measured by Linear and Volumetric Micro-CT ..........................................108 
Figure 4.5 OPG Administration Inhibits Osteoclast Formation at the Alveolar Bone 
Crest in Experimental Periodontitis...............................................................110 
Figure 5.1 Intraoral Photographs of Orthodontic Appliances and 3-D Coronal and 
Sagittal Micro-CT Views ................................................................................139 
Figure 5.2 Inhibition of Tooth Movement by Local Delivery of OPG-Fc..................141 
Figure 5.3 TRAP Stained Histological Sections Counterstained with Hematoxylin 
Taken from the Mesial Tooth Root of the Maxillary First Molar .............143 
Figure 5.4 Osteoclasts per Root Surface on the Tooth Compression Surface ............144 
Figure 5.5 Comparison of Bone Volume Fraction Measured from the Furcation Area 
to Tooth Root Apex of the Maxillary First Molar with Micro-CT ...........145 
Figure 5.6 Concentrations of TRAP-5b in Serum as Measured by ELISA ................146 
Figure 6.1 Timeline of Study Procedures in Months .....................................................170 
Figure 6.2 Steps of Clinical Assessment of GBR Therapy for Extraction Sockets ...171 
Figure 6.3 Subtraction Radiography.................................................................................172 
Figure 6.4 Micro-CT Analysis ..........................................................................................173 
Figure 6.5 Histomorphometry ...........................................................................................174 
Figure 6.6 GRB Promotes Bone Repair as Measured Histomorphometrically ..........175 
  xvii 
Figure 7.1 Bone Repair Cell (BRC) Production .............................................................210 
Figure 7.2 Multipotent and Osteogenic Potential of BRCs...........................................211 
Figure 7.3 In-Vitro Angiogenic Phenotype of BRCs .....................................................213 
Figure 7.4 Grafting of BRCs into Localized Jawbone Defects ....................................214 
Figure 7.5 BRC Regeneration of Highly Vascular Bone in Jawbone Defect .............215 
Figure 8.1 Schematic Illustration of the 3-D Wax Printing System and Dimension of 
Hybrid Scaffold Shows Polymeric Architecture Manufacturing ..............244 
Figure 8.2 3-D Reconstructed Colorized Micro-CT Images and Hematoxylin and 
Eosin (H&E) Stained Histology.....................................................................246 
Figure 8.3 Quantitative Analysis of Micro-CT and Histomorphometry for 
Cementum-Like Tissue Length......................................................................248 
Figure 8.4 Cellularity and Cell/Tissue Orientation in PDL Interface Using H&E 
Staining and Immunofluorescence Images...................................................250 
Figure 8.5 The Reverse-Engineered Periodontal Defect-Fit Scaffold Modeling and 
the Adaptation of Customized Designed Scaffold on the Root Surface...252 
Figure 8.6 Immunohistochemical Staining to Probe Transplanted Human Cells ......254 
  xviii 
 
 
 
LIST OF TABLES 
 
Table 2.1 Statistical Results for Reliability and Reproducibility in Developed 
Methodology with Intraclass Correlation Coefficient (ICC) and 
Coefficient of Variation (CV) .........................................................................39 
Table 3.1 Bone Volumetric Fraction (BVF) and Bone Mineral Density (BMD) ......75 
Table 6.1 Clinical Open Bone Measurements Following GRB of Contained 
Extraction Sockets............................................................................................176 
Table 7.1 Polymerase Chain Reaction Primer Pairs .....................................................217 
Table 7.2 Frequency of Cell Phenotypes in Bone Repair Cells Produced by Single-
Pass Perfusion...................................................................................................218 
Table 7.3 Presense and Enrishment of Vascular Phenotypes in Bone Marrow 
Mononuclear Fraction and Bone Repair Cell Product ................................219 
Table 8.1 Statistical Analysis for Mineralized Tissue Formations in PDL Interface 
and Bone Region of the Hybrid Scaffold......................................................255 
  xix 
 
 
 
 
ABSTRACT 
 
Periodontal disease is a common chronic inflammatory disease, which if left untreated, 
can cause periodontal tissue breakdown. The periodontal complex is a micron-scaled, 
tooth-supporting structure with a complicated topology, which makes it difficult to 
predict and quantify periodontal tissue destruction. Unlike conventional assessment 
methods, 3-D micro-computed tomography provides very accurate, precise high 
resolution images of the periodontal topology. 
 
Using natural spatiotemporal landmarks to create a region-of-interest from the roof-of-
furcation to the root-apex, volumetric image analysis of the bone-tooth interface was 
performed. The results demonstrated excellent examiner reproducibility and reliability 
(ICC>0.99 and CV<1.5%) for both linear and volumetric bone parameters. In an 
orthodontic tooth movement study, micro-CT quantified the activity of osteoprotegerin 
stimulation to prevent bone resorption and tooth mobility. Human alveolar bone core 
biopsies were analyzed to obtain mineral tissue density profiles in order to  predict dental 
implant stability. Because of this high reproducibility and reliability, other wide-reaching 
applications have potential for predicting periodontal therapy outcomes, orthodontic tooth 
movement, as well as evaluation of clinical dental implant stability. 
  xx 
 
A major challenge in periodontal tissue engineering is the control of periodontal tissue 
neogenesis; micron-scaled and complicated multi-interface regeneration with a functional 
architecture. To promote this compartmentalized, multiple tissue regeneration with 
perpendicularly-oriented periodontal ligament fiber, a multi-layered hybrid scaffold was 
designed and manufactured using the rapid prototyping technique. To produce a 
periodontium-like environment, the polymeric hybrid scaffold was assembled with a 
periodontal cell/tissue guidable micro-architecture; a highly porous bone region, a 
vertically-oriented PDL architecture, and a human tooth dentin slice. This complex was 
subcutaneously transplanted with untreated human PDL cells and BMP-7 transduced 
human gingival fibroblast cells using the ectopic model system. In spite of non-
biomechanical loading conditions, this approach resulted in periodontal-structural 
similarity. There was a perpendicular/oblique orientation of the fibrous connective PDL 
cells/tissues to the dentin surface, and mineralized tissue formation without any 
mineralized tissue formation in the PDL interface of the hybrid scaffold at both the 3 and 
6 weeks.  
 
This dissertation study provides potential for functional restoration of tissue interface 
neogenesis applications and shows promise for both pre-clinical and clinical applications 
for translational regenerative medicine. 
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CHAPTER ONE 
       
INTRODUCTION 
 
1.1 Background of Periodontal Tissues and Disease Progression 
The periodontium is composed of four different tissues: alveolar bone, cementum, 
periodontal ligament (PDL), and gingiva (Fig. 1.1A). Cementum is the calcified tissue 
covering the tooth root surfaces from the cementoenamel junction (CEJ) to the tooth root 
apex. It is an important component because it is the site where the PDL is attached to the 
tooth root. PDL is a fibrous, viscoelastic, vascularized soft tissue with a specific 
orientation, perpendicularly anchored between alveolar bone and cementum [1]. By 
providing a well-organized fibrous network to the periodontium, the PDL has a nutritive 
function for various cell types to survive and maintain the vitality of the periodontium. 
The gingiva covers and protects the tooth and alveolar bone through attachment of the 
connective tissues.  
 
Periodontitis is a common, highly prevalent inflammatory infectious disease affecting 
periodontal tissues in adult humans [2]. This disease is initiated by bacteria and bacterial 
products such as lipopolysaccharides (LPS), which can stimulate cytokines to then signal 
precursor cells to differentiate and activate osteoclasts [3]. Disease progression will lead 
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to  destruction of the periodontal complex, followed by hard tissue resorption and 
subsequent tooth loss. 
 
1.2 Current Approaches in Tissue Engineering and Regenerative Medicine 
Tissue engineering and regenerative medicine are emerging areas within medical dental, 
engineering, and other research disciplines. Current studies seek to regenerate hard or soft 
tissues lost as a consequence of disease by using developed biocompatible and 
osteoconductive polymeric biomaterials, containing bioactive signaling molecules [4, 5]. 
However, periodontal tissue regeneration is limited and unpredictable for regeneration of 
biologically complex structures [5-7]. In order to improve tissue restoration rate and 
quality, bone morphogenetic proteins (BMPs), growth factors such as platelet-derived 
growth factor (PDGF), vascular endothelial growth factor (VEGF), and fibroblast growth 
factor (FGF), or other biomolecules, have been used for the stimulation of tissue 
formation. These growth factors have been used in order to optimize bioavailability and 
bioactivity within tissue regeneration applications. PDGF has been extensively 
researched in periodontics in order to improve healing of periodontal defects [8, 9]. 
PDGF can lead to migration, proliferation, and differentiation of various cell types within 
the periodontium. Our lab has demonstrated PDGF can enhance alveolar bone formation 
as well as promote periodontal soft tissue wound healing and tissue regeneration [10, 11]. 
We have also shown PDGF delivery stimulates cells isolated from the periodontium 
(fibroblasts, PDL, cementoblasts) and induces osteoblast mitogenesis and proliferation 
in-vitro  and in-vivo [12, 13].  
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As the paradigm shifts in orthopedic or dental research from tissue replacement to tissue 
regeneration, scaffold designing and manufacturing has rapidly developed in order to 
provide appropriate biological microenvironments in desired disease or defect sites. It is 
still difficult to deliver signaling proteins or recombinant growth factor genes targeting 
specific regions of disease using systemic administration. Systemic administration 
strategies for genes, proteins, drugs, or other factors have other limitations for delivery: 1) 
the availability to affect other organs, 2) requirement of high concentrations and amounts 
of factors, and 3) uncontrolled and unpredictable bioactivities of factors at distant wound 
sites. To overcome these limitations, localized and sustained delivery of growth factors is 
one approach using biodegradable scaffolds. For example, ceramic, hydroxyapatite (HA), 
material has osteoconductive characteristics to stimulate osteoblast cells for mineralized 
tissue formation [14-16]. Polymeric materials such as PGA, PLA, or their copolymers 
have also been used for hard and soft tissue regeneration in orthopedic wound healing 
processes with interconnective structures [17, 18]; For complex, heterogenous tissue 
formation, hybridized microarchitectures with polymer/polymer or polymer/ceramic 
materials are being developed and applied to periodontal tissue or hard/soft tissue repair 
[9, 19-23]. Polyglycolide/poly-L-lactide (PGA/PLLA) composite scaffolds have been 
suggested for use to develop embryonic teeth. A heterogenic polymeric scaffold was used 
to generate enamel, dentin, and pulp tissues over a period of 25 weeks [24]. PGA and 
polyglycolide-co-lactide (PLGA) scaffolds led to regeneration of hybrid tooth-alveolar 
bone in the omenta of adult rats in order to repair periodontal tissues lost due to disease 
[25]. Drug-loaded biodegradable scaffold approaches used to heal wounds and regenerate 
tissues showed potential to control release rates of gene therapy vectors and provide a 
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suitable 3-dimensional microenvironment for the growth and differentiation of cells [26-
29]. These approaches can release growth factors or drugs at desired sites following 
designed scaffold degradation rates. Various local delivery systems using 
microenvironments of scaffolds in combination with growth factors have been utilized 
for tissue formation [30-33].  
 
These scaffold implant studies in periodontal disease defects have demonstrated well-
developed tissue regeneration. However, unpredictable tissue overgrowth and ankylosis 
has been a limitation for current periodontal regeneration studies. It is advantageous to 
apply sophisticated and streamlined architectures in order to implant or transplant 
complex geometrical scaffolds into irregular periodontal defects. In periodontal tissue 
engineering, accuracy can be provided by computer-based designed scaffolds with 
digitized imaging techniques of micro-CT.  
 
1.3. Micro-Computed Tomography Applications in Tissue Engineering 
Micro-computed tomography (micro-CT) imaging techniques allows for 3-D 
determination of precise anatomical periodontal defects and periodontal disease 
progression by analyzing bone volumetric parameters: bone volume, bone volume 
fraction (BVF), bone mineral content, and bone mineral density (BMD). Basically, 
micro-CT uses radiography to detect elements such as calcium and phosphate within 
mineralized tissue with high intensities rather than other organic or non-mineralized 
materials. Micro-CT is a new technology which avoids destruction of specimens and is 
highly reproducible [34]. Three-dimensional images are generated and analyzed to 
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accurately model the size of particular cavities or periodontal defects [35]. An image-
based scaffold design with photopolymerizing synthetic materials has been developed by 
Hollister, et al. Based on micro-CT or micro-magnetic resonance imaging (micro-MRI) 
information, three-dimensional structures can be reconstructed. With computer-aided 
design (CAD), complicated, solid geometric models can be designed and produced by 3-
D printing [36] or selective laser sintering (SLS) techniques, such as ink-jet printing and 
photopolymerization manufacturing, respectively, or a soft-lithographic technique which 
has been used for fabrication of PLGA scaffolds [37-40]. Solid Free Form (SFF) 
fabrication  [41] and computer-based design techniques are advantageous and useful 
because they provide anatomical accuracy and appropriate three-dimensional geometry of 
the craniofacial complex [37, 42-44]. From computer-aided scaffold fabrication, 
mechanical properties also can be characterized and structures can be designed with 
internal and external architectural pores [32, 40, 45-47]. Recently, simple computer-
designed scaffolds have limitations in-vivo because the pore sizes used are larger than 
cells and they cannot provide enough cell-adhesion affinity [31, 37]. Therefore, one 
method for manufacturing smaller pores is indirect SFF fabrication. Because each tissue 
has been grown within its microenvironment, hybrid or composite scaffold design by 
computer has been suggested [16, 48].  
 
1.4. Statements of Purpose and Dissertation Overview 
As in Figures 1.1B and 1.2B, ankylosis on the root surface resulted in design and 
implantation of single, homogeneous scaffolds. Scaffolds are customized to match 
accurate periodontal defect shapes with computer software and each scaffold is 
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incorporated as one hybrid scaffold. Each different scaffold can play a role as a critical 
tissue barrier, such as for PDL or alveolar bone, and provide microenvironments to 
regenerate each periodontal tissue. The physical interface between dissimilar materials of 
the hybrid scaffold will help prevent osteoblast or fibroblast cell migration toward either 
a polymeric scaffold or ceramic scaffold, respectively. The interface from this multi-
layered design with different materials provides physical barriers to block undesired 
tissue growth and penetration. Different biomaterials are selected for the interface 
between polymeric and composite scaffolds, and play a key role in preventing undesired 
tissue penetration. Moreover, polymer channels for PDL restoration in a PGA/PLA 
scaffold help to align the fibrous cells and regenerated fibrous tissue. That is, this tissue 
will be generated with a specific orientation following the channel-type scaffold. 
Therefore, computer-designed hybrid scaffolds can precisely fit anatomical defect sites 
and micro-CT imaging techniques provide an important role in guiding the formation of 
new alveolar bone and fibrous ligament tissues into the desired shapes in periodontal 
tissue regeneration. 
 
Currently, restoration or regeneration of tissue lost from disease progression are focused 
on regeneration of a single tissue using systemic or local delivery of various growth 
factors or bioactive molecules with synthetic material scaffolds as a carrier. Based on the 
background information, the proposed hybrid scaffold design, incorporated with micro-
CT imaging techniques, will improve and promote multiple tissue formation, in one 
localized delivery system. This hybrid scaffold will be designed using micro-CT digitized 
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images according to surgical defect sites or anatomical configuration of the periodontal 
apparatus. 
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1.5 FIGURES 
 
Figure 1.1 Schematic illustration of periodontal tissue and limitations of periodontal 
therapies. (A) The terminologies of tooth and tooth-supporting structures with the red-
colorized text signifying periodontal tissues. (B) Typical limitations of current 
periodontal treatment. Red circles indicate examples of the failures of periodontal 
regeneration treatments. 
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Figure 1.2. (A) Experimental periodontitis model in rats using micro-computed 
tomographic (micro-CT) images visualized by reconstructing into 3-dimensional 
images. Non-diseased or healthy rat maxilla (left image). The specimen shows the bone 
crest level is flat and even in height. In the periodontal diseased rat maxilla after 8 weeks 
(right image), the alveolar bone crest level is measurably decreased and roots are visibly 
exposed. With this specimen, the periodontitis progression can be diagnosed around all 
molar teeth. (B) Visualization of conventional scaffold implantation and ankylosis in 
a regeneration study in rats. Periodontal surgical defects were created around the 1st 
molar on the buccal side of mandible.  Single polymeric scaffold (yellow block) with 
growth factor genes will be designed and implanted to the defect area for 5 weeks (left 
panel). The result of reconstructive therapy is represented as alveolar bone regeneration 
on the root surfaces. The highlighted area (purple-colorized area) shows ankylosis on 
mesial and distal root surfaces (right panel). 
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2.1. ABSTRACT 
 
BACKGROUND: Micro-computed tomography (micro-CT) offers significant potential 
for identifying mineralized structures. However, three-dimensional (3-D) micro-CT of 
alveolar bone has not been readily adapted for quantification. Moreover, conventional 
methods are not as sensitive for analyzing bone loss or bone gain following periodontal 
disease or reconstructive therapy. The objective of this investigation was to develop a 
micro-CT methodology for quantifying tooth-supporting alveolar bone in 3-D following  
preclinical situations of periodontitis or reconstructive therapy.  
 
METHODS: An experimental in vivo bone loss and prevention model was developed to 
validate the micro-CT imaging technique. Twenty mature Sprague-Dawley rats were 
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divided into two groups: bone loss (Porphyromonas gingivalis lipopolysaccharide-
mediated bone resorption) and regenerative therapy. Micro-CT software-digitized 
specimens were three-dimensionally reconstructed for linear and volumetric parameter 
assessment of alveolar bone (linear bone height, bone volume, bone volume fraction, 
bone mineral content, and bone mineral density). Intra- and inter-examiner 
reproducibility and reliability were compared for methodology validation.  
 
RESULTS: The results demonstrated high examiner reproducibility for linear and 
volumetric parameters with high intraclass correlation coefficient (ICC) and coefficient 
of variation (CV). The ICC showed that the methodology was highly reliable and 
reproducible (ICC >0.99; 95% confidence interval, 0.937 to 1.000; CV <1.5%), 
suggesting that 3-D measurements can provide better alveolar bone analysis than 
conventional 2-D methods.  
 
CONCLUSIONS: The developed method allows for highly accurate and reproducible 
static measurements of tooth-supporting alveolar bone following preclinical situations of 
bone loss or regeneration. Future investigations should focus on using in vivo micro-CT 
imaging for real-time assessments of alveolar bone changes. 
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2.2. INTRODUCTION 
Because of the non-uniformity and porous structure of alveolar bone and its close 
proximity to dental structures, it is difficult to quantify. Current approaches that attempt 
to quantify alveolar bone include histomorphometry, two-dimensional (2-D) radiography, 
and more recently, micro-computed tomography (micro-CT) [1, 2]. Although 
histomorphometry provides high resolution and direct representation of alveolar bone 
levels, there are obvious limitations, such as tissue sample destruction and challenges  
reconstructing a three dimensional (3-D) image [3]. Radiographic methods overcome 
many of these challenges by providing non-destructive 2-D imaging capabilities using 
sequential or serial images of alveolar bone and teeth while monitoring disease 
progression. However, the inconsistency in maintaining nearly identical alignment of 
successive radiographic images complicates this process [4].  
 
Micro-CT or medical CT is a non-invasive technique that can be used in 3-D to image 
specimens on a micron-resolution level and allows for computer-aided reorientation 
following image scanning, thus assuring nearly identical alignment [1]. Micro-CT use for 
preclinical applications provides higher spatial resolution images than medical or dental 
CT for clinical assessments [5]. Using this technique, micro-CT scans will show slight 
deviations in periodontal defects or cases of alveolar bone loss on a 3-D level [5, 6]. In 
contrast, a study examining the reliability and accuracy of 2-D dental radiographs 
demonstrated differences of up to 25% between calculations quantifying alveolar bone 
from 2-D radiographs and 3-D CT scans [7].  
  19 
Conventional radiographic approaches assessing alveolar bone structure are limited by 
the fact that 3-D microarchitecture cannot be inferred from isolated 2-D images [8]. 
However, micro-CT produces 3-D images of bone, allowing for detailed analysis of 3-D 
bone architecture and anisotropy. A study using micro-CT allowed examination of the 
mechanical behavior of bone in the attainment and maintenance of dental implant 
osseointegration. Assessment of the cancellous bone structure of maxillae and 
mandibulae from human cadavers revealed useful information about prognosis following 
implant reconstruction [9].  
 
Despite these advantages associated with micro-CT imaging, certain challenges have 
been raised regarding reproducible osseous quantification of bone loss from periodontal 
disease or regeneration following post-regenerative therapy. Alveolar bone poses unique 
quantification problems because of the difficulty distinguishing it from surrounding 
dental hard tissues as a result of similarities in their x-ray attenuation [10]. Typically, 
computer-assisted image analysis facilitates this process when the tissue of interest 
differs in density from the surrounding structures. For example, during quantification of 
trabecular bone, which significantly differs in density from non-bony constituents in the 
marrow space, an analysis algorithm can be devised to accurately separate bone from 
non-bone elements within the region of interest (ROI). In contrast, the anatomy and 
morphology of tooth-associated periodontal defects make density thresholding quite 
challenging. In periodontal tooth–bone defects, there is little difference in density 
between the tooth-supporting alveolar bone and the tooth roots, which are composed of 
  20 
hard tissue dentin and cementum separated by a thin fibrous tissue area (~150 to 200 µm) 
of intervening periodontal ligament. 
 
For this investigation, a reproducible method was developed for quantifying and 
assessing alveolar bone using high-resolution micro-CT employing an interactive image 
analysis technique to evaluate selected 3-D ROIs for tooth-supporting alveolar bone 
defects. This new methodology is readily and easily adaptable for preclinical assessments 
of linear and volumetric alveolar bone parameters following disease, trauma, or 
regeneration. 
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2.3. MATERIALS AND METHODS 
Experimental specimens 
All animal procedures were performed under guidelines approved by the University of 
Michigan, Unit of Laboratory Animal Medicine (ULAM) for the use of animals in 
scientific research.  
 
Experimental Bone Loss: Periodontal Disease Model  
Experimental alveolar bone loss was induced utilizing Porphyromonas gingivalis 
lipopolysaccharide (P. gingivalis LPS). In brief, 12 adult male Sprague-Dawley rats 
(approx. weight 250 g each; Harlan World Headquarters, Indianapolis, IN USA) had 
experimental periodontitis induced by delivery of P. gingivalis W83 endotoxin (10 µL of 
a 1.0 mg/mL preparation) by injection into the interdental gingivae between the maxillary 
first (M1), second (M2), and third molars (M3), and the mesial aspect of M1 under 
isoflurane general anesthesia. These administrations were repeated three times per week 
over an 8-week period.  The injections were performed utilizing custom-designed 0.375 
in x 33 ga, 30º bevel needles attached to 50µL Hamilton syringes (Hamilton Company, 
Reno, NV USA). The animals were divided into 3 groups: 1) pre-treatment baseline 
(n=4), 2) no disease post-protocol at 8 weeks (n=4), and 3) LPS-mediated bone loss 
group (n=4). At baseline for group 1 and at 8 weeks for groups 2 and 3 the animals were 
sacrificed. Maxillary block biopsies were harvested, fixed in 10% formalin for 2 days, 
and stored in 70% ethanol for micro-CT scanning.   
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Experimental Bone Regeneration: Periodontal Fenestration Defect Model 
An alveolar bone fenestration defect model was used to measure bone repair following 
surgical creation of bone defects at the mesial root of the mandibular first molar as 
previously described by Jin et al. In brief a total of eight ~250 g athymic rats (Hsd:RH-
rnu/rnu) (n= 4 per group), were anesthesized using ketamine (Ketaset®, Fort Dodge 
Animal Health, Fort Dodge, IA USA) and xylazine (AnaSet®, Lloyd Laboratories, 
Shenandoah, IA USA). Alveolar bone defect osteotomies were created by initially 
preparing an extraoral 2-cm superficial skin incision at the lower border of the mandible. 
The superficial fascia and underlying masseter muscle were separated with sharp 
dissection and the ligamentary attachment of the masseter muscle to bone was severed at 
its inferior base, and both the masseter and periosteum were elevated from the bone to 
expose the buccal plate of the mandible.  The oral mucosa on the superior wall of the 
surgically created osteotomy was identified, and its attachment to the intraoral keratinized 
gingival margin was maintained during defect preparation.  The bone overlying the 
mandibular first molar was removed with a high-speed handpiece under saline irrigation 
while visualizing with a surgical microscope (Model: SMZ 1000, Nikon, Melvile, NY 
USA). The distal root of the first molar tooth (d-M1) was carefully denuded of 
periodontal ligament, overlying cementum, and superficial dentin.  The defects measured 
approximately 0.3w x 0.2h x 0.15d cm in dimension. Polylactic glycolic acid (PLGA) 
scaffolds seeded with 2.5 x 105 non-transduced cells (scaffold-alone control) were placed 
in the defects or PLGA scaffolds 2.5 x 105 with genetically-modified stem cells as 
previously described. The internal wounds were approximated with resorbable 5-0 
chromic gut sutures and the external skin incisions closed with surgical staples. The 
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animals were administered supplemental antibiotics (ampicillin 268 mg/ml of drinking 
water) provided daily for 14 days.  At five weeks, the animals were euthanized and 
mandibular block biopsies were harvested, fixed in 10% formalin for 2 days, stored in 70% 
ethanol for scanning by micro-CT.  
 
Micro-computed tomography instrumentation and image capture 
All maxillary and mandibular block biopsies were subjected to micro-CT image analysis 
as described below. The cone-beam micro-CT scanner utilized in this study was 
developed by General Electric Enhanced Vision Systems Ltd. (EVS). Fig. 2.1 illustrates 
the main components of the scanner for alveolar bone applications: an x-ray source, a 
specimen stage, an image detector and camera, an image processing system, and a micro-
computer cluster for visualization and analysis. The x-ray generator was operated at an 
accelerated potential of 80kV with a beam current of 80µA. The x-ray source combines 
with a 2-D detector operating with a shutter speed of 1100 ms, which produces images 
with a voxel size of 18 x 18 x 18µm3. We used an internal reference in micro-CT units 
(i.e. bone mineral density, mg/cc ) for each scan. 
The 3-D volume viewer and analyzer eXplore MicroView v. 2.0. (Analysis Plus™, GE 
Healthcare, London ON Canada). MicroView is the software tool for the visualization 
and quantification of 2-D and 3-D data on a personal computer output.  Post-processing 
images were colorized using Adobe Photoshop CS2 v. 9.0 (Adobe Systems Inc., San Jose, 
CA USA). 
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Linear and Volumetric Alveolar Bone Measurements 
Linear measurements 
Linear measurements (mm) were from the cemento-enamel junction (CEJ) to the alveolar 
bone crest (ABC) in the interdental region between either the first and second molar teeth 
(M1-M2), or between the second and third molar teeth (M2-M3) respectively. All images 
were reoriented such that both the CEJ and the root apex (RA) appeared within the 
micro-CT slice to be analyzed. Root length measurements (in mm) from CEJ to the RA 
were also taken from each root in order to assess the percentage of vertical bone 
remaining (Fig. 2.2b). In order to assess the amount of regenerated bone tissue in the 
reconstructive therapy group, the exposed root length of the d-M1 was measured (in mm). 
The linear fractions as noted below in equation 3 represent the linear amount of 
regenerated bone tissue covering the surgically created dehiscence lesion. 
 
Volumetric micro-CT measurements 
Volumetric measurements were carried out following selection of each 3-D ROI. Two 
examiners (CHP and ZA) were guided by morphological landmarks when drawing ROIs 
in order to ensure repeatability. While artificial landmarks could have been placed prior 
to the scanning of the specimens, it was more reproducible and more accurate to use 
given morphological features (e.g., outer root prominences and root furcations). In the 
case of periodontal defects resulting from experimental periodontitis, the majority of 
bone loss was noted around the roots of the teeth, below the roofs of the furcations (ROF), 
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and above the root apices. Our method took advantage of this feature by using both the 
ROFs and the RAs as references identifying the borders of the ROIs (Fig. 2.2a). 
 
The most mesial root of M1 (m-M1) and the most d-M3 served as endpoint landmark 
borders since they were the most consistent among specimens.  Thus, reorientation of 
specimens from examiner to examiner relied upon the capturing of these landmarks, 
which essentially maximized the ROI of the alveolar bone housing of the alveolus. This 
critical reorientation of 3-D reconstructed images provided reproducible and reliable 
criteria to quantify and assess alveolar bone. In contrast, based on the examination of 
maxillae using the orientation stated above, the relative heights of the ROFs varied 
greatly. Thus, for all cases it was not feasible to start with one specific furcation each 
time. Consequently, contours were drawn immediately upon scrolling through the top of 
a furcation landmark (Fig. 2.2a). 
 
Utilizing the landmarks RA, ROF, and RL, region contours were drawn at regular 
intervals (Fig. 2.2a and equations 1-3). The objective in drawing these contours was to 
maximize the quantification of bone, minimize the inclusion of tooth roots, and use as 
many reproducible landmarks as possible. All contours were drawn beginning 
immediately below the ROFs in the coronal plane moving in the apical direction. Using 
an advanced ROI tool, 2-D contours were drawn at regular intervals (every 8 data planes), 
depending on the variability between planes; greater variability between planes required 
contours to be drawn at smaller intervals (1-2 planes). Contours were drawn until 
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reaching the apices of m-M1 and d-M3. Next, a 3-D ROI was generated by the software 
based on the resultant 2-D contours (Fig. 2.2a and 2.2c). Finally, volumetric alveolar 
bone parameters of bone volume (BV), bone volume fraction (BVF), bone mineral 
content (BMC), and bone mineral density (BMD) in the volume of selected ROI were 
determined (Fig. 2.2c) using equations 4 and 5. 
 
Equations used in 3-D image-measurement 
 Equation 1 
: Distance from CEJ to ABC 
 
     Equation 2 
: Distance of the ith molar root from CEJ to RA 
 
    Equation 3 
Total length of d-M1 root: Distance of the d-M1 root from CEJ to RA 
 
 Equation 4 
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 Equation 5 
 
Examiner Reliability and Statistical Analysis 
Validation measures were conducted for both linear and volumetric micro-CT 
measurements. For the linear validation, eight different samples were analyzed by two 
independent examiners (CHP and ZA). After a period of 24 hours, linear distance 
measurements were repeated by both examiners in order to assess inter- and intra-
examiner variability. Analogously, for the volumetric validation, one image was taken 
and six planes were selected for analysis: two planes near the crowns, two near the apices, 
and two in the mid-portion of the roots. The examiners independently prepared contours 
in the selected planes in order to assess volumetric parameters; BV, BVF, BMC, and 
BMD according to the formulae 4-5. Again, all volumetric measurements were repeated 
after 24 hours by both examiners to assess inter- and intra-examiner variability. In 
addition, one image was chosen and completely analyzed by both examiners, twice each, 
to determine agreements.  
 
Mean values were generated for each of the groups evaluated.  Coded specimens were 
analyzed using one-way analysis of variance (ANOVA) and Bonferroni’s multiple 
comparison test to measure statistical differences among groups. The reliability and 
reproducibility was derived from the intra-class correlation coefficient (ICC). The range 
of values in ICC is from 0 to 1. When ICCs are closer to 1, reliability and reproducibility 
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are stronger and above 0.75 of ICC values show good reliability. The values were 
calculated with single measurements from a two-way random model and absolute 
agreement type. The reproducibility of measurement is represented with coefficient of 
variation [CV % = (Standard Deviation / its mean value) x 100] as well. The 
reproducibility and repeatability of duplicate micro-CT scanning also was calculated 
statistically by CV in which one sample was scanned once a day for 3 days. All 
volumetric results from the scans and the MicroView software and calibration 
measurements were statistically evaluated using SPSS v.12 (SPSS Inc., Chicago, IL 
USA).  
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2.4. RESULTS 
The methodologies for image capture, orientation, landmark identification, and 
measuring of linear and volumetric bone change, were noted to be reproducible and these 
methods are highlighted in Fig. 2.2 (method) and Fig. 2.3 (resultant changes in disease or 
repair).  Moreover, 2-D and 3-D topographical alterations in bone levels in a bone loss 
situation (disease) or the bone gain situation (regeneration therapy) are shown in Fig. 2.4. 
 
Linear micro-CT measurements 
In the alveolar bone loss specimens, linear measurements within the interdental regions 
M1-M2 and M2-M3 demonstrated significant differences between the healthy and P. 
gingivalis LPS-induced periodontitis specimens. We measured CEJ-ABC distances 
among baseline and follow-up as shown in Fig. 2.3. As Figure 3a reveals, there was no 
significant difference between the baseline and vehicle only groups (p>0.05). However, 
when diseased periodontia were compared with healthy specimens at follow-up, 
statistically significant differences were found (p<0.05). In the reconstructive therapy 
specimens, the residual tooth root exposure was significantly reduced by genetically-
modified cell therapy when compared to the control group (Fig. 2.3d; p<0.05). Colorized 
images depict bone gain over the previously debrided tooth root surface following 
reconstructive therapy (Figs. 2.4h-k; p< 0.01).  
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Volumetric Micro-CT Measurements 
Using this methodology, we could obtain volumetric measurement results for multiple 
bone loss indices including BV, BVF, BMC, and BMC. For bone loss specimens, no 
statistically significant differences in volumetric bone parameters were found between the 
baseline and follow-up healthy (control) group (p>0.05). However, LPS-induced 
experimental periodontitis led to robust and statistically significant bone loss (BMD and 
BVF) when compared to the control group (Fig. 2.3b and 3c; p<0.05). As a result, among 
both experimental groups (disease and repair) we could quantitatively determine the 
amount of bone changes in both 2-D and 3-D (Figs. 2.3 and 4).  
 
Reliability 
The ICC for continuous agreement analysis was found to be highly reproducible. In 
summary, both examiners presented a very high inter-examiner and intra-examiner 
agreement, highlighting the reliability and reproducibility of this method (Table 2.1). 
Highly sensitive, reliable and reproducible measures were shown for the intraclass 
correlation coefficient (ICC>0.99; 0.937 95% C.I. 1.000) leading to a standardized 
measurement method. CV demonstrated precise error for reproducibility with volumetric 
measurements. CV was less 1.5% in inter- and intra-examiner calibrations demonstrating 
excellent reproducibility and reliability of measurement. Moreover, micro-CT scanning 
was also highly reproducible and repeatable with very low precision errors. BVF and 
BMD had 0.837% and 2.0618% precision errors, respectively. Using our methods in 
these experimental preclinical situations revealed ability to quantify disease progression 
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in the situation of P. gingivalis LPS-mediated periodontitis or alveolar bone repair using 
regenerative cell therapy (Table 2.1.). 
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2.5. DISCUSSION 
Traditionally, 2-D radiographic images and histomorphometry have provided linear data 
to enable investigators to make quantitative measurements associated with alveolar bone 
affected by periodontitis or following regenerative therapy [16, 17]. Although new 
technologies are available for 3-D assessment of bone volume, in general, approaches 
still measure 2-D images linearly after projection from 3-D real structures [18, 19]. These 
methods have limitations, such as the accuracy or the precision of measurements [20, 21]. 
Micro-CT techniques have the potential to overcome these limitations and provide a more 
accurate quantification method for 3-D assessment of bone [22, 23]. The volumetric 
technique described here demonstrated accurate and precise measurements of bone in 
cases of no disease, disease, and postreconstructive therapy (Fig. 2.4). Furthermore, intra- 
and interexaminer reliability data demonstrate no significant differences between 
examiners, suggesting that the method is reproducible. In fact, the inclusion of a third 
examiner also provided high agreement of reproducibility; CV <3% (data not shown). 
Our reorientation criteria and methodology provided reliability and consistency for 
quantifiable assessments for volumetric parameters (BV, BVF, BMC, and BMD), despite 
variability within micro- CT scan images. 
 
Although histologic techniques provide spatial data from calcified and decalcified tissues, 
micro-CT enables visualization of detailed 3-D microarchitecture without artifactual 
alterations in anatomical tissue structure due to tissue processing, embedding, and 
sectioning. The correspondence between histologic and micro-CT data was explored by 
comparing digitized images from histologic sections to matching micro-CT 2-D planes; 
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both methods are qualitatively similar (6 to 8 µm thick and 18 µm thick; Figs. 2.4c and 4d) 
[5, 24]. Although cells cannot be observed in present micro-CT images, discrete changes 
in alveolar bone morphology and trabeculation can be assessed three-dimensionally (Fig. 
2.4) [3, 25, 26]. High resolution 3-D micro-CT images provide a distinct advantage for 
observing hard tissues without tissue-processing treatments, which can result in the 
distortion of osseous structures [27, 28].  
 
Wilensky et al. [10] showed that micro-CT imaging could overcome several problems of 
previous 2-D approaches and verified the quantification of bone loss following 
periodontitis. Central to our method was the use of enhanced image analysis which 
provided the technological ability to overcome many of the previous challenges in the 
quantification of alveolar bone [17, 19].  
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2.6. FIGURES 
 
 
Figure 2.1 Schematic illustration of micro-computed tomography (micro-CT) and 
its scanning procedure. (A) Micro-CT composes a cone-beam x-ray source, filter with 
the shutter system, sample-holding chamber, and CCD camera and x-ray detector. (B) 
Cone-beam micro-CT for assessment of alveolar bone. Specimens are exposed to 
polychromatic x-rays on a rotating stage. X-rays that penetrate the mandible or maxilla 
pass through an image intensifier and are captured by a camera, producing 2-D slices of 
18µm thickness. Finally, cross-sectional images are reconstructed into a 3-D structure by 
a host computer. 
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Figure 2.2 Method for creating 3-D ROIs used in analysis of alveolar bone. (A) 2-D 
contours are drawn at regular intervals from the ROFs to the RAs. Once all contours are 
drawn, a 3-D ROI is generated for reconstruction. (B) Linear measurements are made for 
alveolar bone loss (ABL) within the interdental space from the CEJ to ABC and RLs 
from the CEJ to RA (in millimeters). (C) Volumetric measurement using 3-D generated 
ROIs. Software assesses the quantity of bone and analyzes volumetric parameters within 
the volume of interest that are from 3-D generated contours.  
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Figure 2.3 Linear measurements of interdental CEJ-ABC and volumetric 
measurement of ROF-RA. The analyses of linear measurements and volumetric 
measurements at baseline and among healthy and diseased groups. (A) Linear bone loss 
distances represented as CEJ-ABC length. Bone loss in the P.gingivalis LPS –induced 
periodontitis group with significant differences were observed between diseased and 
other tops in BVF (B) BMC (not shown), and BMD (C). (D) After reconstructive cell 
therapy, exposed defects at the distal root areas of M1 were measured linearly as a 
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proportion of the total RL. There was significant difference between non-transduced and 
transduced cell therapy groups. *p<0.05. 
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Figure 2.4 Representative specimens displaying bone loss in healthy (A) and 
diseased (B) periodontia. Cross-sectional histologic image with hematoxylin and eosin 
(H&E) staining (C) and the corresponding micro-CT slice (D) demonstrate similarity of 
sections. Three-dimensional isosurfaces in a Cartesian coordinate system display an 
extracted rat maxilla including all three molars (E), rat maxilla with teeth extracted 
digitally (F), and alveolar bone within a preselected ROI used in bone volume 
determination (G). Surgically-induced dehiscence osseous defects in a mandibular defect 
biopsied at 5 weeks post-therapy. (H) Control group. (I) Reconstructive therapy group 
demonstrating bone repair over the previously dehisced lesion of the M1 distal root. Red 
= crown; yellow = tooth root; blue = regenerated bone; red arrows = standardized root 
fenestration osseous effects; black arrows = top side of the scaffold implanted site on the 
osseous defect. 
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2.7. TABLE 
 
Table 2.1 Statistical results for reliability and reproducibility in developed 
methodology with intraclass correlation coefficient (ICC) and coefficient of 
variation (CV). 
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CHAPTER THREE 
 
AAV2/1-TNFR:Fc GENE DELIVERY PREVENTS PERIODONTAL DISEASE 
PROGRESSION 
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3.1. ABSTRACT 
Periodontal disease is a chronic inflammatory condition induced by oral  microbial 
biofilms that induce a host immune response. Control of progressive tissue destruction in 
high-risk patients is a significant challenge in clinical therapy. Soluble protein delivery of 
antagonists to tumor necrosis factor-alpha (TNF-α) inhibits alveolar bone resorption due 
to periodontitis. However, protein therapy raises several concerns, such as recurrence of 
disease activity after treatment cessation requiring repeated dosing regimens. In this study, 
we used pseudotyped adeno-associated virus vector based on serotype 1 (AAV2/1) to 
deliver the TNF receptor-immunoglobulin Fc (TNFR:Fc) fusion gene to rats subjected to 
experimental Porphyromonas gingivalis (Pg)-lipopolysaccharide (LPS)-mediated bone 
loss. Animals received intramuscular delivery of pseudotyped AAV2/1-TNFR:Fc vector 
(1 x 1011 DNase I-resistant particles) and either Pg-LPS delivered to the gingivae thrice 
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weekly for 8 weeks or vehicle alone, AAV2/1-TNFR:Fc therapy led to a sustained 
therapeutic level of serum TNFR protein and protected against Pg-LPS-mediated loss of 
bone volume and bone density. Furthermore, AAV2/1-TNFR:Fc administration reduced 
local levels of multiple proinflammatory cytokines and osteoclast-like cells at the 
periodontal lesion sites. These findings suggest that delivery of AAV2/1-TNFR:Fc may 
be a viable approach to modulate periodontal disease progression. 
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3.2. INTRODUCTION 
Periodontitis is a common oral inflammatory disease that in severe cases, is the leading 
cause of tooth loss in adults. Periodontal disease has also been associated with increased 
risk of systemic diseases, such as coronary heart disease, bacterial pneumonia and stroke 
[1,2]. Although triggered by bacterial biofilms on the tooth surface, tissue destruction and 
disease progression are driven primarily by mediators of the host immune-inflammatory 
response to persistent gram-negative pathogens [1]. Activation of pathogen recognition 
receptors (e.g. toll-like receptors - TLRs) by bacterial LPS and other pathogen-associated 
molecular patterns (PAMPs) stimulate the production of pro-inflammatory cytokines 
(Interleukin-1 (IL-1), IL-6 and tumor necrosis factor (TNF-α) and chemokines (IL-8) 
followed by a cascade of immune-inflammatory events [3]. Thus, therapeutic approaches 
that target the host response to local oral infection offer significant potential for 
periodontal disease management [4, 5]. 
 
TNF-α is a multifunctional cytokine that plays a crucial role in the pathogenesis of 
periodontitis [6]. TNF-α is released by activated monocytes, macrophages and T 
lymphocytes and contributes to both innate and adaptive immune responses, regulating 
growth, differentiation, survival and physiological function of a variety of different cells 
and further production of other cytokines, inflammatory mediators and enzymes [6-10]. 
TNF-α is a potent bone resorption inducer that stimulates osteoclast differentiation and 
activation [7, 11, 12]. TNF-α’s functions are mediated by two receptors, p55 and p75 
TNF receptor (TNFR), which, respectively, up-regulate and dampen inflammation [13, 
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14]. P75 TNFR knockout mice display defects in osteoclastogenesis and inflammation-
mediated periodontal tissue destruction [15, 16]. 
Host-modulation therapies using TNF-α blockers have been successfully used in humans 
for the treatment of rheumatoid arthritis (RA) [17-19]. One class of drugs consists of 
monoclonal anti-TNF-α antibodies or fusion proteins containing p75 TNFR linked to the 
Fc portion of human IgG1. In both cases, the drug binds to TNF-α with high affinity and 
prevents it from interacting with its cognate cell surface receptors [20]. TNF-α blockers 
significantly improve clinical outcome by reducing erosive bone damage [21], through 
inhibition of the receptor activator of nuclear factor kappa B ligand (RANKL) expression 
in the synovial tissue [22]. In periodontitis management, protein delivery of antagonists 
to IL-1β and TNF-α lead to reduction in periodontal tissue destruction in vivo [23-27]. 
However, the use of recombinant protein raises several concerns, such as recurrence of 
disease activity after cessation of therapy and repeated dosing regimens [28]. Recently, 
delivery of an adeno-associated virus (AAV) vector encoding the p75-TNFR:Fc fusion 
gene has been evaluated as an alternative approach for TNF-α blockade in animal models 
of RA and demonstrated long-term disease suppression [29, 30]. The main advantages of 
gene therapy are maintenance of sustained and therapeutically relevant concentration of 
the protein [29], eliminating the previously described limitations of recombinant protein 
delivery. 
 
In this study, AAV2/1-TNFR:Fc was delivered for the prevention of periodontal disease 
induced by local, chronic, oral exposure of Porphyromonas gingivalis lipopolysaccharide 
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(Pg-LPS) in vivo. The results of this study show that AAV2/1-TNFR:Fc led to potent 
inhibition of periodontal disease progression. 
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3.3. MATERIALS AND METHODS 
3.3.1. Plasmids/Vector production and purification 
Recombinant AAV2 vectors were produced by a standard calcium phosphate transfection 
method in adherent human 293 cells, using the Ad helper, trans-packaging, and AAV 
vector plasmids as described previously [49]. Vector titers were determined by real-time 
PCR, using a Perkin-Elmer Applied Biosystems Prism 7900 sequence detector (Foster 
City, CA), and were between 5 and 20×1012 DRP/mL. Vector infectivity was assessed in 
a TCID50 assay using the HeLa-based B50 cell line [50]. 
 
3.3.2. Porphyromonas gingivalis lipopolysaccharide (Pg-LPS) 
Pg-LPS was isolated from P. gingivalis strain W83, following a previously described 
protocol [51]. Briefly, Pg strain W83 was cultured in an anaerobic chamber with 
modified Brucella-Broth medium. After growth, bacteria were centrifuged at 5,000 rpm 
for 30 min, resuspended in sterile water for washing and the final pellet was sequentially 
treated with lysozyme, DNAse, RNAse and proteases to extract and purify the 
lipopolysaccharide [51]. 
 
3.3.3. Animal model of Pg-LPS-induced periodontal disease 
A total of 45 adult male Sprague-Dawley rats (approximated weight 200 g, 8-10 weeks), 
were purchased from Charles River Laboratories (Wilmington, MA). All animal 
experimental procedures were approved by the University of Michigan Committee on the 
Use and Care of Animals. Animals were allowed to acclimate for seven days before 
experimentation and were given water and chow ad libitum. For all the procedures, 
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animals were anesthetized with isoflurane (5% with O2 for induction and 3% 
maintenance) (Baxter Healthcare Corp., Deerfield, IL). Experimental periodontal disease 
induction was performed by administering 10 µL of Pg-LPS (1.0 mg/mL) into four 
palatal gingival tissue sites (total of 40 µL/animal) at the base of the interproximal 
gingival papillae between maxillary molars bilaterally as previously described [52]. The 
injections were performed three times weekly using custom-designed 0.375 in × 33 ga, 
30° bevel needles attached to a 50 µL Hamilton syringe (Hamilton Company, Reno, NV). 
Disease induction was performed in two groups of animals (n=10/group): diseased group 
(Pg-LPS group) and treatment group (AAV2/1-TNFR:Fc + Pg-LPS group). Pg-LPS 
administrations were performed from baseline to sacrifice, for four or eight weeks after 
the first injection (n=5/group/timepoint). 
 
3.3.4. Administration of AAV2/1-TNFR:Fc vector 
After anesthesia, the skin overlying the quadriceps muscle areas was exposed by shaving 
and disinfection. A single dosage of rAAV2/1-TNFR:Fc viral vector (100 µl of 1×1011 
DRP/animal) was delivered im, equally divided to both quadriceps (50 µl in each muscle), 
four weeks before Pg-LPS disease induction. AAV2/1-TNFR:Fc was administered via 
Hamilton syringes and the animals were placed in a recovery cage and observed for 
normal ambulation. Two groups of animals received vector therapy 
(n=5/group/timepoint): AAV2/1-TNFR:Fc only or AAV2/1-TNFR:Fc + Pg-LPS groups. 
The vehicle controls were treated as above with formulation buffer containing 20 mM 
Tris pH 8, 200 mM NaCl, 2 mM MgCl in 1% glycerol. 
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3.3.5. Short-term experiment 
Based on the cytokine expression results for TNFα and IL1β found in this study, a short-
term experiment was performed subsequently to evaluate the early cytokine response to a 
single injection of Pg-LPS in the palatal gingival tissue. A total of 52 rats were divided 
into three groups: Vehicle, Pg-LPS, or AAV2/1-TNFR:Fc + Pg-LPS. The rats received 
the same treatment described for animals within the main experiment, except for Pg-LPS 
administration, which consisted of a single injection. Subgroups of animals (n= 
4/group/timepoint) were sacrificed at baseline, 12, 24, 48 and 72 h after Pg-LPS injection 
and TNFα and IL1β cytokine expression was evaluated by real-time PCR as described 
below. 
 
3.3.6. ELISA TNFR serum level determination 
Serum was obtained from blood samples collected by tail bleeding at -4 weeks (pre-
baseline), 0 (baseline, disease induction), 4 and 8 weeks. Serum TNFR levels were 
determined by ELISA. Briefly, 96-well plates were coated with a goat anti-murine TNF 
receptor II antibody (R&D Systems, Minneapolis, MN) overnight at 4°C. Plates were 
washed 3x with phosphate-buffered saline supplemented with 0.05% Tween-20 (Fisher, 
Houston, TX), and blocked with 1% bovine serum albumin (Sigma, St Louis, MO) for 3 
h at RT on an orbital shaker. After washing, the plates were incubated with serum 
samples for 1 h at RT on a shaker plate. Following sample incubation, the wells were 
washed, and incubated with a biotin-conjugated mouse anti-rat immunoglobulin G1 
antibody (PharMingen/BD Biosciences, San Jose, CA) for 1 h, washed and then 
incubated with streptavidin-horseradish peroxidase (Zymed, San Francisco, CA) for 30 
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min at RT. The presence of rat TNFR:Fc protein was detected using the 
tetramethylbenzidine (TMB) colorimetric substrate (Pierce, Rockford, IL) and stopped 
with 1 M sulfuric acid (Sigma, St Louis, MO). Quantitation of rat TNFR:Fc protein was 
based on OD 450 values (Multiskan Ascent, Thermo Fisher Scientific Inc., Waltham, MA) 
compared with a standard curve of purified rat TNFR:Fc protein. The limit of detection 
of the assay was 0.219 ng/mL. 
 
3.3.7. Histological analysis of the inflammatory cell infiltrates 
Rats were sacrificed in a CO2 chamber at designated timepoints. Hemi-maxillae were 
harvested and fixed for 48 h in 10% neutral-buffered formalin and transferred to 70% 
ethanol for µCT scanning. Samples were subsequently decalcified with 10% 
ethylenediaminetetraacetic acid disodium salt (EDTA) for 3 weeks, embedded in paraffin, 
and cut into 4- to 5 µm-thick serial sections. Transverse sections of the maxillary 2nd 
molar teeth parallel to the long axis were stained with H&E for stereometric analysis by a 
masked, calibrated examiner. The presence of inflammatory cell infiltrate and tissue 
destruction was evaluated in the periodontal region. A point-counting technique was used 
to evaluate the proportion of the following structures: fibroblastic cells, collagen, 
vascular structures and inflammatory cells on the H/E-stained sections. Two areas were 
assessed individually in comparison to the experimental groups: a submarginal area, 
representing the connective tissue subjacent to the gingival sulcus (apical border of 
junctional epithelium and tooth structure as the coronal and medial limits, respectively); 
and a bone crest region, representing the connective tissue in adjacent to the bone crest 
(coronal portion of the bone crest and tooth structure as apical and medial limits, 
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respectively). A 500 µm2 rectangular-lattice grid with 50 intersection points was 
constructed using image software and the type of structure found on the intersection of 
the grid lines was counted on an optical microscope (Diastar-Cambridge Instruments) 
under 200X magnification. 
 
3.3.8. Microcomputed Tomography scanning and bone loss analysis 
Microcomputed tomography provides high qualification and accurate quantification of 
the mineralized tissues such as alveolar bone and teeth [52]. Each maxillary specimen 
was scanned and reconstructed at 18µm3 voxels using a µCT system (GE Healthcare, 
London, ON, Canada). A 3-D volume viewer and analyzer software (Microview 
Analysis+ v.2.1.2 software, GE Healthcare) was used as the tool for both 3-D and 2-D 
visualization and quantification as previously described [52]. In brief, linear bone loss 
was measured as the distance from the cementoenamel junction (CEJ) to the alveolar 
bone crest or to the base of the alveolar intrabony defect at the palatal surface of the 
mesio- and disto-palatal roots of the maxillary second molar teeth. For the volumetric 
analysis, the roof of the furcation and the root apex of the 2nd maxillary molars, the 
mesial roots of the 3rd molars and the distal roots of the 1st molars were used as 
reproducible landmarks for estimation of alveolar bone loss. 2-D ROIs were drawn at 
regular intervals, (average 8 data slices) on a coronal view and reconstructed as a 3-D 
structure in order to quantify volumetric parameters, bone volume fraction (BVF), and 
bone mineral density (BMD) (mg/cc). The measurements of coded specimens were made 
by two independent, calibrated examiners. 
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3.3.9. Real time PCR for detection of pro-inflammatory cytokines and bone resorption 
related molecules 
Total RNA was extracted from gingival tissue biopsies harvested from a standardized 
region of the palatal region of the maxillary molar teeth, comprising an ~5 × 2 mm 
rectangular area from the medial of the first molar to the distal of the third molar 
extending from the gingival margin to the palatine suture. RNeasy Mini Kit (Qiagen, 
Valencia, CA) complemented with RNase-Free DNase Set (Qiagen) for RNA purification 
were used following the protocols recommended by the manufacturer. After determining 
RNA concentration and purity by spectrophotometry, complementary DNA (cDNA) was 
synthesized using 1µg of RNA by a reverse transcription reaction (TaqMan Reverse 
Transcription Reagents, Applied Biosystems, Foster City, CA). Real time quantitative 
PCR was performed in an ABI Prism 7500 Real Time PCR System using TaqMan Gene 
Expression Assays (Applied Biosystems). For each reaction (30 µL), 1 µL of cDNA was 
added to 1.5 µL of specific TaqMan Gene Expression Assay, 15 µL of TaqMan 2x PCR 
MasterMix (Applied Biosystems) and 12.5 µL of RNase/DNase free water. The PCR 
conditions were 50°C (2 min), 95°C (10 min), followed by 40 cycles of 95°C (15 sec) 
and 6 0°C (1 min) and by the standard denaturation curve. The target gene, ABI ID # and 
reporter probe sequence of each specific TaqMan Gene Expression Assay were: 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ID Rn99999916_s1, 
CGGGAAACCCATCACCATCTTCCAG; interleukin-1 beta, ID Rn00580432_m1, 
CATAAGCCAACAAGTGGTATTCTCC; tumor necrosis factor alpha, ID 
Rn99999017_m1, CACACTCAGATCATCTTCTCAAAAC; interleukin-6, ID 
Rn00561420_m1, GAGAAAAGAGTTGTGCAATGGCAAT; interleumin-10, ID 
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Rn00563409_m1, osteoprotegerin, ID Rn00563499_m1, 
GCTGTGCACTCCTGGTGTTCTTGGA; Receptor Activator of Nuclear Factor-Kappa 
B Ligand (RANKL), IDRn00589289_m1, TGCCGACATCCCATCGGGTTCCCAT. 
 
3.3.10. Immunohistochemistry of TRAP following gene delivery 
Serial sections of the maxillary second molar teeth were prepared as previously described 
and immunostained for TRAP detection. Deparaffinized tissue sections were pretreated in 
antigen retrieval buffer (Dako; Glostrup, Denmark) in a pressure chamber (Biocare 
Medical; Concord, CA) for 20 min. and cooled at RT. ABC Staining System (sc-2023, 
Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was used following the manufacturer’s 
instructions. Primary antibody was raised in goat and consisted of: TRAP (K17): sc-
30833 (4 µg/mL, Santa Cruz Biotechnology, Inc). Control sections were incubated with 
normal IgG (R&D Systems) pre-immunoserum in the same concentrations to assess 
background staining. All sections were counterstained with Hematoxylin Gill’s 
Formulation #1 (Fisher Scientific). 
 
Osteoclast enumeration was based on the presence of TRAP-positive multinucleated cells, 
adjacent to the alveolar bone surface in a pit area. Photomicrographs of the most coronal 
1 mm of the palatal bone crest were analyzed by a masked, calibrated examiner and the 
number of osteoclast-like cells on the palatal bone plate surface were enumerated and in 
response to Pg-LPS administration. 
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3.3.11. Statistical analysis 
Statistical analysis was performed using GraphPad Prism software. Data were pooled by 
experimental group and the mean ± SD were calculated. One-way ANOVA followed by 
Tukey’s post hoc test were performed to determine the presence of any significant 
difference between groups for serum TNFR:Fc levels, linear bone loss and cytokine 
expression. P-values less than 0.05 were considered statistically significant. 
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3.4. RESULTS 
3.4.1. Single administration of AAV2/1-TNFR:Fc results in sustained serum rat TNFR:Fc 
protein levels 
The circulating serum levels of rat TNFR:Fc protein were monitored by enzyme linked 
immunosorbent assay (ELISA) during the study period to confirm the transduction 
efficiency of AAV2/1-TNFR:Fc after a single IM administration of 1011 DNase-resistant 
particles (DRP). The injections were performed four weeks prior to the Pg-LPS delivery 
to allow for therapeutic levels at the time of disease induction. The administrations 
resulted in mean TNFR serum levels of 8.2±1.8 µg/mL, by 4 weeks (time of disease 
induction). These levels were sustained during the 8 week experimental period (Fig. 3.6). 
In the other groups not treated with the AAV2/1-TNFR:Fc, including Pg-LPS, Vehicle 
only (Veh) or no treatment group (NT), TNFR:Fc serum levels were significantly lower 
than AAV2/1-TNFR:Fc treated animals with results at or below the detection level. The 
result is in agreement with a previous report, which demonstrated a long-term and 
sustained secretion of TNFR after a single IM injection of AAV2/1-TNFR:Fc [30].  
 
3.4.2. AAV2/1-TNFR:Fc inhibits local inflammatory cell infiltrates induced by Pg-LPS in 
vivo 
Animals were sacrificed at four and eight weeks after Pg-LPS disease induction. 
Stereometric histological analysis using hematoxylin and eosin (H/E) staining was 
performed to evaluate the inflammatory cell infiltrate induced by an 8-week course of 
local Pg-LPS administration with or without IM AAV2/1-TNFR:Fc gene therapy. At 
both timepoints, an intense inflammatory cell infiltrate was consistently observed in the 
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subepithelial connective tissue and surrounding alveolar bone of the periodontia of Pg-
LPS-treated animals (Fig. 3.1b, e). In contrast, a significantly less intense inflammatory 
reaction was observed in the AAV2/1-TNFR:Fc + Pg-LPS-treated animal (Fig. 3.1c, f). 
Control animals (Veh, NT and vector only) did not display evidence of significant 
inflammatory cell infiltrates (Fig. 3.1a, d). Statistical analysis demonstrated higher 
number of inflammatory cells for diseased group (Pg-LPS) in both analyzed areas at 4 
weeks timepoint and in subepithelial area at 8 weeks timepoint when compared to treated 
animals (AAV2/1-TNFR:Fc + Pg-LPS) (Fig. 3.1). These results demonstrate the anti-
inflammatory effect of TNFR:Fc in the face of continued Pg-LPS challenge. 
 
3.4.3. AAV2/1-TNFR:Fc prevents alveolar bone loss and preserves bone mineral density 
in Pg-LPS exposed animals 
To investigate the preventive effect of AAV2/1-TNFR:Fc on alveolar bone loss induced 
by an 8-week course Pg-LPS delivery, bi-dimensional (2-D) and three-dimensional (3-D) 
microcomputed tomography (µCT) images of maxillae and associated teeth were 
evaluated by linear and volumetric measurements. Linear bone loss was measured from 
the cementum enamel junction (CEJ) to the bone crest (BC) at the palatal surface of the 
maxillary second molar teeth, which were the sites most directly affected by Pg-LPS 
local delivery. Significant alveolar bone destruction was observed in the Pg-LPS group 
continuously over the course of eight weeks, demonstrating a progressive loss of tooth-
supporting bone (Fig. 3.2, Pg-LPS).Administration of the AAV2/1-TNFR:Fc vector 
prevented linear bone resorption during the entire study observation period, represented 
  60 
by significant preservation of tooth-supporting bone during Pg-LPS challenge, at both 
timepoints (Fig. 3-A.2, AAV2/1-TNFR:Fc + Pg-LPS). 
 
This preservation corresponded, on average, to 61.2% and 48.5% of bone loss reduction 
at 4 and 8 week timepoints, respectively, compared with the Pg-LPS only-treated group 
that was normalized to Veh-treated animals. Interestingly, a single administration of 
AAV2/1-TNFR:Fc vector to a group of healthy animals also resulted in preservation of 
alveolar bone level compared with the vehicle. This bone-sparing effect was significantly 
greater than that of the vehicle-treated healthy controls, demonstrating a preventive effect 
in the normal physiologic alveolar bone loss observed in rats (Fig. 3.2). These results 
clearly show the beneficial effect of the TNF-α blockade on alveolar bone preservation. 
 
Volumetric bone loss was measured in a specific region of interest (ROI) captured from 
the 3-D images, based on fixed reference points. ROI involved furcation and 
interproximal alveolar bone around the maxillary second molars and detected the 
extension of the destructive effect of local Pg-LPS delivery. The results were comparable 
to linear measurements, showing more severe bone loss around molar teeth of the Pg-
LPS group and a preventive effect for the AAV2/1-TNFR:Fc vector-treated groups. This 
response was more pronounced after longer periods of disease progression (8 weeks) 
(Table 3.1). Bone mineral density measures also demonstrated that the AAV2/1-
TNFR:Fc vector preserved bone quality in Pg-LPS exposed animals, after longer periods 
of disease induction. Vector alone-treated animals displayed bone density values similar 
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to that observed in healthy animals and superior to diseased Pg-LPS treated animals 
(Table 3.1). 
 
Taken together, these results strongly suggest that anti-inflammatory TNFα-blocking 
therapy prevents disease-induced bone loss and preserves bone density in the 
periodontium. 
 
3.4.4. AAV2/1-TNFR:Fc suppresses inflammatory and bone resorptive cytokine 
expression in periodontal tissues exposed to Pg-LPS 
To better understand the mechanisms by which TNF-α blockade, in AAV2/1-TNFR:Fc-
treated animals, suppress the progression of Pg-LPS-mediated tissue destruction, the 
expression of relevant inflammatory cytokines (IL-1 β, TNF-α, IL-6, IL-10) and bone-
related molecules [receptor activator of nuclear factor kB ligand (RANKL) and 
osteoprotegerin (OPG)] involved in periodontal disease progression were evaluated in the 
gingival tissues, at the RNA level by real-time PCR. Significantly higher RNA 
expression of IL-6, IL-10, RANKL and OPG was observed at four weeks in Pg-LPS-
exposed animals, but not in animals previously treated with the AAV2/1-TNRF:Fc vector 
(Fig. 3.3), suggesting an inhibition of the Pg-LPS-mediated inflammatory and bone 
destructive effects. IL-1β and TNF-α expression levels were not affected by continuous 
Pg-LPS administration and were similar for all the groups at four and eight weeks. These 
results corroborate previous in vitro [31] and in vivo [16] studies showing that long term, 
repeated administration of Pg-LPS induces cytokine tolerance to Pg-LPS. Based on these 
observations, a time course experiment was performed to determine IL-1β and TNF-α 
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gene expression over a short interval (12-72h). This parallel study demonstrated 
significant up-regulation of IL-1β and TNF-α expression, 24 to 48h after a single 
injection of Pg-LPS when compared to NT or vehicle injected animals (Fig. 3.4). 
Animals previously treated with AAV2/1-TNFR:Fc presented higher expression of both 
cytokines than NT or vehicle-injected animals, yet significantly lower than Pg-LPS only 
animals. Taken together, these results suggest that AAV2/1-TNFR:Fc gene therapy has 
an inhibitory effect on inflammatory and bone resorptive cytokines such as IL-1 and TNF 
during the short-term and to a lesser degree long-term. 
 
3.4.5. AAV2/1-TNFR:Fc IM administration reduces TRAP+ osteoclasts-like cells 
associated with the alveolar crest in Pg-LPS-treated animals 
To evaluate the effect of AAV2/1-TNFR:Fc administration on osteoclast differentiation 
at the alveolar crest in Pg-LPS-treated animals, histological sections were immunostained 
and osteoclast-like cells enumerated by image analysis for tartrate-resistant acid 
phosphatase (TRAP), an enzyme highly expressed in osteoclasts and activated 
macrophages. Pg-LPS-treated animals displayed significantly higher numbers of TRAP+ 
osteoclasts-like cells on the palatal bone surface compared with all other groups (Fig. 3.5). 
Administration of AAV2/1-TNFR:Fc vector reduced osteoclast number in animals 
challenged with Pg-LPS yielding results statistically similar to the other control groups. 
The same results were observed when the linear cumulative distance of the palatal bone 
surface in contact with multinucleated osteoclast-like cells was measured in the coronal 1 
mm of the bone crest. From these results we conclude that AAV2/1-TNFR:Fc gene 
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therapy reduces active osteoclast presence at the alveolar bone crest level and, 
consequently, prevents alveolar bone resorption. 
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3.5. DISCUSSION 
Host modulation therapies are rising as promising alternatives for the treatment of 
periodontal diseases [4]. These new strategies are based on advances in the knowledge of 
periodontal disease pathogenesis, which indicates the host response against pathogenic 
bacteria as the major driver of periodontal tissue destruction. However, similar to other 
chronic diseases, periodontal disease management require long-term treatment that can be 
affected by patient compliance. In developed countries, the level of adherence to long-
term treatment of chronic diseases is 50%, and the problem is significantly worse in 
developing countries [32], suggesting the necessity of new therapies to overcome this 
problem. In this study, we evaluated the application of gene therapy technology, using an 
AAV vector encoding the TNFR:Fc transgene for modulation of the host immune-
inflammatory response in periodontal disease. This new approach has been successfully 
evaluated for the treatment of other chronic diseases, such as neurological, cardiovascular 
and autoimmune diseases [33]. The AAV2/1-TNFR:Fc vector used in the present study 
led to high level transduction efficiency, prolonged gene expression and therapeutic 
efficacy in a RA model, encouraging this new application [29, 30]. Both periodontal 
disease and RA are chronic inflammatory diseases with complex etiology and clinically 
characterized by sustained over-expression of pro-inflammatory cytokines culminating in 
progressive bone destruction [34]. In this study, AAV2/1-TNFR:Fc administration 
resulted in a significant prevention of experimental periodontal disease progression, 
illustrating another approach for blocking cytokine production, one driven by pathogenic 
LPS. 
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The results of this study found that gene delivery achieved systemically therapeutic 
circulating levels of soluble TNFR protein, which were maintained during the entire 
observation period, consistent with our previous studies in RA [30]. To investigate the 
potential efficacy of a single delivery of AAV2/1-TNFR:Fc in prevention of alveolar 
bone loss and inflammation, we used a Pg-LPS-induced experimental periodontal bone 
resorption model. This model has the advantage to simulate the complex disease process 
occurring in human periodontitis. Pg-LPS was extracted from a highly pathogenic strain 
of Porphyromonas gingivalis, W-83, which is an important putative periodontal pathogen 
[35]. This bacterium stimulates the destructive innate host response through releasing 
high level LPS containing vesicles into the periodontal tissues. Pg-LPS is recognized by 
host cells transmembrane receptors TLR-2 and TLR-4 that activate key intracellular 
pathways (e.g., mitogen-activated protein kinases) and, thereafter, target genes involved 
in the activation of the host defense, especially pro-inflammatory cytokine production 
[36]. In this study, the Pg-LPS-induced disease model stimulated expression of key 
inflammatory and bone-related cytokines, detected at the mRNA level by real time PCR 
at short timepoints, 24-48h after single Pg-LPS administration (TNF-α and IL-1), or at 
longer intervals, 4 weeks after multiple Pg-LPS injections (IL-6, IL-10, RANKL and 
OPG). The time course experiment demonstrated an initial stimulatory effect of Pg-LPS 
on TNF-α and IL-1 expression, not observed after multiple Pg-LPS administration, 
suggesting an endotoxin tolerance process. TLRs and pro-inflammatory cytokines may 
become tolerised as a mechanism used in the oral mucosa to attempt to regulate local 
immune response [31, 37]. In addition, IL-10, an anti-inflammatory cytokine that was 
highly expressed in Pg-LPS challenged animals, also appears to participate in the 
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tolerance process by mediating immunosuppression and affecting production of pro-
inflammatory cytokines [38]. In a previous study, cytokines showed dissimilar 
susceptibility to LPS challenge, consistent with our findings that TNF and IL-1 generated 
greater tolerance than other cytokines (e.g., IL-6) after LPS challenge [31]. TNF-α and 
IL-1 have been shown to be key molecules that contribute to several events essential for 
the initiation of an inflammatory response and, ultimately, tissue destruction [39]. They 
can also induce expression of other cytokines that amplify or sustain the inflammatory 
response and bone resorption as IL-6 and RANKL [40]. RANKL has been demonstrated 
to be increased during active periodontal disease in both soft and hard tissues [16, 53, 54]. 
We believe that, in this study, TNF-α and IL-1, followed by IL-6, RANKL and other pro-
inflammatory molecules, trigger a cascade of progressive bone destruction that persists 
during the experimental period, suggesting a similar mechanism of action to what is 
observed in natural disease. The observed up-regulation of IL-10 and OPG expression 
after Pg-LPS challenge is in parallel with previous studies that demonstrate a stimulatory 
effect of LPS on the expression of cytokines in gingival [41, 42] and periodontal ligament 
fibroblasts [43]. As mammalian cells are challenged by polymicrobial infection, they 
appear to display a defensive mechanism against tissue destruction elicited by bacterial 
challenge, once IL-10 and OPG stimulate anti-inflammatory and osteoclastogenesis 
inhibitory effects. 
 
Pg-LPS challenged animals that were previously treated with AAV2/1-TNFR:Fc vector 
presented reduced inflammatory infiltrates in the palatal gingival tissue parallel to an 
inhibition of the expression of inflammatory cytokines and bone resorptive-related 
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molecules (Figs. 3.1, 4-5), which resulted in significantly less alveolar bone loss when 
compared with Pg-LPS treated animals (Fig. 3.2). Taken together, these results support 
the central role of TNF-α on the TLR-mediated immune-inflammatory cascade of events 
responsible for the tissue destruction in the chronic periodontal disease. More specifically, 
TNF-α stimulates the expression of chemoattractants and their receptors for inflammatory 
cells, OPG and RANKL by periodontal ligament fibroblasts, T and B lymphocytes, and 
osteoblastic/stromal cells [10, 16, 43, 45, 46]. TNF-α also has direct effects on osteoclast 
differentiation independent of the RANK-RANKL axis [11, 12].  
 
To better investigate the AAV2/1-TNFR:Fc therapeutic effect on the alveolar bone 
resorption induced by Pg-LPS, we evaluated the presence of osteoclast-like cells at the 
bone crest surface and the expression of OPG and RANKL, which are key molecules in 
osteoclastic differentiation and activation [47]. In parallel with inhibition of cytokine 
expression, AAV2/1-TNFR:Fc-treated animals demonstrated lower levels of RANKL 
and OPG expression in the gingival tissue, confirming the association of TNFα and other 
pro-inflammatory cytokines on osteoclast differentiation/activation and subsequent bone 
loss [47, 48]. 
 
In summary, delivery of an AAV2/1-TNFR:Fc gene therapy vector suppresses 
experimental periodontal disease progression through key cytokine and bone-related 
molecule modulation, reminiscent to the effects observed in RA. AAV2/1-TNFR:Fc is a 
promising host modulation approach for use in periodontal disease co-management with 
anti-infective therapy. 
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3.6. FIGURES 
 
Figure 3.1. Histological sections (H/E, 200X) of subepithelial (upper panels) and bone 
crest (lower panels) levels of periodontal tissues around the maxillary second molar of 
Vehicle (a and d), Pg-LPS (b and e) and AAV2/1-TNFR:Fc + Pg-LPS (c and f) treated 
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animals, at 4 weeks. The number of inflammatory cells was determined by stereometric 
analysis using a point-counting technique. A 500 µm2 rectangular-lattice grid with 50 
intersection points was constructed and the type of structure found on the intersection of 
the grid lines was counted on a optical microscope. (One-way ANOVA and Tukey’s post 
hoc tests). 
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Figure 3.2. Preventive effect of AAV2/1-TNFR:Fc administration on alveolar bone loss 
induced by Pg-LPS injections. Linear vertical bone loss was measured in digitalized 
micro CT 2D images in the palatal roots of the maxillary second molars at 4 and 8 weeks 
after Pg-LPS-disease induction. Data expressed as means ± SD (n=5/group/timepoint).* 
Statistically different from all other groups (One-way ANOVA and Tukey’s post hoc 
tests). 
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Figure 3.3. Real time PCR results for cytokines (IL-1β, IL-6, TNF-α, IL-10), RANKL 
and OPG expressions in the palatal gingival tissue, at 4 and 8 weeks timepoints, for 
groups: AAV2/1:Fc-TNFR + Pg-LPS, Pg-LPS only and Veh injection. Data expressed as 
means ± SD (n=5/group/timepoint). (One-way ANOVA and Tukey’s post hoc tests). 
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Figure 3.4. Short-term quantitative real time PCR results for TNF-α and IL-1β cytokines 
expression in a time course experiment after single Pg-LPS injection. Data expressed as 
means ± SD (n=5/group/timepoit). (One-way ANOVA and Tukey’s post hoc tests). 
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Figure 3.5. TRAP immunohistochemistry for detection of osteoclasts-like cells in the 
bone surface of the alveolar bone crest in the palatal side of the maxillary molars of 
animals from the vehicle, Pg-LPS only and AAV2/1:Fc-TNFR + Pg-LPS groups, at 4 
and 8 weeks after experimental disease induction. 
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Figure 3.6. Serum TNFR protein levels after intramuscular administration of AAV2/1-
TNFR:Fc vector to rats afflicted with Pg-LPS experimental periodontitis. Four weeks 
prior to disease induction, animals were administrated intramuscularly with 1011 DRP of 
AAV2/1-TNFR:Fc vector. Serum levels (µg/mL) of TNFR protein were monitored, at the 
timepoints indicated, using ELISA. The data are expressed as the means ± SD 
(n=5/group/timepoint).  
* Statistically different from other groups at the same timepoint (One-way ANOVA and 
Tukey’s post hoc). 
  75 
3.7. TABLE 
 
Table 3.1. Bone Volumetric Fraction (BVF) and Bone Mineral Density (BMD), 
according to measures 4 and 8 weeks after experimental periodontal disease induction. A-
k Similar letters mean statistically significant difference between groups, in the same 
time point (one-way ANOVA with Tukey’s post-hoc test) 
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CHAPTER FOUR 
 
RANKL INHIBITIONS THROUGH OSTEOPROTEGERIN BLOCKS BONE 
LOSS IN EXPERIMENTAL PERIODONTITIS 
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4.1. ABSTRACT 
Background: Prevention of alveolar bone destruction is a clinical challenge in 
periodontal disease treatment. The receptor activator of nuclear factor-kappa B ligand 
(RANKL) inhibitor osteoprotegerin (OPG) inhibits osteoclastogenesis and suppresses 
bone resorption. 
 
Methods: To study the effects of RANKL inhibition on alveolar bone loss, an 
experimental ligature-induced model of periodontitis was used. A total of 32 rats were 
administered human OPG-Fc fusion protein (10 mg/kg) or vehicle by subcutaneous 
delivery twice weekly for 6 weeks. Negative or positive controls received no treatment or 
disease through vehicle delivery, respectively. Biopsies were harvested after 3 and 6 
weeks, and mandibulae were evaluated by microcomputed tomography (µCT) and 
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histology. Serum levels of human OPG-Fc and tartrate-resistant acid phosphatase-5b 
(TRAP-5b) were measured throughout the study by enzyme-linked immunosorbent assay 
(ELISA). Statistical analyses included analysis of variance (ANOVA) and Tukey tests. 
 
Results: Human OPG-Fc was detected in the sera of OPG-Fc–treated animals by 3 days 
and throughout the study. Serum TRAP-5b was sharply decreased by OPG-Fc treatment 
soon after OPG-Fc delivery and remained low for the observation period. Significant 
preservation of alveolar bone volume was observed among OPG-Fc–treated animals 
compared to the controls at weeks 3 and 6 (P <0.05). Descriptive histology revealed that 
OPG-Fc significantly suppressed osteoclast surface area at the alveolar crest. 
 
Conclusion: Systemic delivery of OPG-Fc inhibits alveolar bone resorption in 
experimental periodontitis, suggesting that RANKL inhibition may represent an 
important therapeutic strategy for the prevention of progressive alveolar bone loss. 
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4.2. INTRODUCTION 
Periodontitis is a destructive disease that targets tooth-supporting structures through 
complex and multifactorial pathogenic processes. It is triggered by an interaction between 
bacterial components of tooth-associated biofilms and host response mechanisms [1]. 
Alveolar bone destruction, a hallmark of periodontitis progression and one of the major 
causes of tooth loss in humans, is mediated by the host immune and inflammatory 
response to microbial challenge. In recent decades, studies on cellular and molecular 
mechanisms of bone loss in periodontitis have suggested that the use of host modulation 
agents is an important adjunctive therapy to antimicrobial strategies [2].  
 
The discovery of the receptor activator of nuclear factor-kappa B (RANK)/RANK ligand 
(RANKL)/osteoprotegerin (OPG) axis has improved the knowledge of bone metabolism 
regulation and created a new field for the study of treatment of bone destruction–related 
diseases, including rheumatoid arthritis, metastatic bone cancer, and periodontal disease. 
The RANKL/RANK interaction is needed for differentiation and maturation of osteoclast 
precursor cells to activated osteoclasts and for the survival of mature osteoclasts. 
Stimulatory factors such as hormones (vitamin D3, parathyroid hormone, parathyroid 
hormone–related protein), cytokines (interleukin-1, -6, -11, and -17), growth factors 
(tumor necrosis factor-α and bone morphogenetic protein-2), and other molecules 
(prostaglandin E2, cytoplasmic domain-40L, and glucocorticoid), upregulate the 
expression of the RANKL gene in osteoblasts/stromal cells [3, 4]. Sequentially, RANKL 
triggers osteoclastogenesis through RANK on preosteoclast cells. Acting as a soluble 
decoy receptor, OPG binds to RANKL and inhibits osteoclast development. Several 
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studies have shown the opposing effects of RANKL and OPG on bone turnover. Genetic 
ablation of RANKL in mice results in osteopetrosis [5,6], whereas genetic deletion of 
OPG in mice results in high bone turnover and severe osteoporosis [7-9]. Moreover, 
several factors initiating bone resorption not only upregulate RANKL expression but also 
inhibit OPG expression in osteoblasts/stromal cells [3, 10]. Upregulation of RANKL has 
also been seen in inflamed periodontal tissues, indicating that RANKL participates in the 
processes of periodontal tissue destruction [11, 12]. On the other hand, the RANKL/OPG 
ratio is increased in periodontitis compared to non-diseased individuals, suggesting that 
this molecular interaction may be important in modulating local bone loss. The 
RANKL/OPG ratio was found to be significantly increased in gingival crevicular fluid 
(GCF) of patients with periodontitis compared to healthy individuals [13]. 
 
As a therapeutic drug for preventing bone loss, OPG has recently been evaluated in 
preclinical studies relating to estrogen deficiency, skeletal tumors, and specific cancers [6, 
14-17], as well as in clinical trials involving postmenopausal women, juvenile Paget's 
disease, and lytic bone disease associated with cancer [18-20]. All of these results 
showed that OPG has significant effects on the inhibition of bone loss. 
 
The use of OPG as an inhibitor of alveolar bone destruction in periodontal disease was 
studied in mice orally infected with Actinobacillus actinomycetencomitans. Inhibition of 
RANKL function with OPG treatment significantly reduced the number of osteoclasts 
and alveolar bone loss [21, 22]. The aim of this study was to evaluate the therapeutic 
effects of human recombinant OPG fusion protein (rhOPG-Fc) on preventing alveolar 
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bone loss in an acute model of ligature-induced experimental periodontitis as assessed 
histologically and morphometrically. 
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4.3. MATERIALS AND METHODS 
4.3.1. Experimental Design 
All animal experiment procedures in this study were approved by the University of 
Michigan Committee of Use and Care of Animals. 
 
To explore the OPG-Fc effects on alveolar bone loss in experimental periodontitis, 32 
male Sprague-Dawley rats (Harlan, Indianapolis, IN USA; weight: 250 to 300 g) were 
divided into four experimental groups: group A, animals receiving no treatment (normal 
healthy control or NT); group B, animals receiving rhOPG-Fc (Amgen, Thousand Oaks, 
CA USA) subcutaneous administration twice weekly (OPG-treated healthy controls or 
OPG alone group); group C, animals exposed to disease induction and OPG 
subcutaneous injection twice weekly (OPG-treated diseased animals); and group D, 
animals exposed to disease induction and subcutaneous vehicle administration twice 
weekly (vehicle-treated diseased animals). There were four animals at each designated 
time point for each group. Block biopsies were harvested at 3 and 6 weeks after disease 
induction and/or OPG administration. 
 
To further study the in vivo pharmacokinetics of injected rhOPG-Fc, four normal healthy 
animals received a single subcutaneous administration of rhOPG-Fc, and serum rhOPG-
Fc was measured by an enzyme-linked immunosorbent assay (ELISA) at designated time 
points. 
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4.3.2. Experimental Periodontal Disease Induction and OPG Administration 
Sprague-Dawley rats were anesthetized using inhalation anesthesia with isoflurane. 3/0 
cotton ligatures were placed bilaterally into the gingival sulci of the mandibular first 
molar teeth. The ligatures were evaluated twice weekly, gently displaced apically into the 
gingival sulci to ensure a subgingival position, and replaced when necessary. The use of 
ligatures for induction of experimental periodontitis elicits rapid alveolar bone 
destruction through two combined mechanisms: an inflammatory process induced by 
increased microbial biofilm formation around the cervix of the teeth and an acute 
physical irritation factor as a consequence of the subgingival placement of the ligature, 
typically leading to the loss of approximately one-half of the bone support over a period 
of 3 to 6 weeks. The rhOPG-Fc was administered subcutaneously at a dose of 10 mg/kg 
animal body weight twice a week during 3 or 6 weeks. 
 
4.3.3. In Vivo Pharmacokinetics of Injected rhOPG-Fc 
To study the pharmacokinetics of a single subcutaneous injection of rhOPG-Fc at a dose 
of 10 mg/kg rat body weight, ~600 µl blood was drawn from the tail vein of each animal 
at 0, 0.5, 1, 3, 7, 14, and 21 days. The samples were transferred into serum separator 
tubes (Becton Dickinson, Franklin Lakes, NY USA) and centrifuged at 4,000 rpm for 10 
minutes at 4°C. The supernatants were collected and stored at −80°C until needed for 
analysis. The content of serum rhOPG-Fc was measured using a commercially available 
human OPG ELISA kit (American Laboratory, Windham, NH USA). The ELISA 
procedures were performed according to the manufacturer's instructions. 
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4.3.4. Serum rhOPG-Fc and Tartrate-Resistant Acid Phosphatase-5b (TRAP-5b) 
Measurements During Disease Progression 
To measure rhOPG-Fc serum concentration after twice weekly OPG injections as a part 
of the experimental protocol, the blood from the tail vein was drawn at 0, 1.5, 3, 4.5, and 
6 weeks, and serum was collected according to the methods outlined above. 
Serum rhOPG-Fc and TRAP-5b levels were measured by commercially available human 
OPG (ALPCO Diagnostics, Salem NH USA) and rat TRAP-5b (RatTRAP Assay, SBA 
Sciences, Oulu, Finland) ELISA kits, respectively. The ELISA procedures were 
performed according to the manufacturer's instructions. 
 
4.3.5. OPG-Fc Clearance From Bone 
Young male rats were injected once (intravenously [IV]) with rhOPG-Fc at 5 mg/kg. 
Groups of rats (N = 6) were sacrificed at various times after treatment. Histologic 
sections of the proximal tibial metaphysis were subjected to immunohistochemistry 
analysis for human Fc (immunoglobulin [IgG]1). Deparaffinized 4-µm sections were 
blocked (CAS Block, Zymed Laboratories, San Francisco CA USA), and sections were 
incubated with rabbit anti-human IgG (Jackson Laboratories, West Grove, PA USA) at 
1:4,000 for 1 hour. Antibody was detected by biotinylated goat anti-rabbit IgG (Vector 
Laboratories, Burlingame, CA USA) and followed with alkaline phosphatase ABC 
complex (Vector Laboratories). The reaction was visualized with red alkaline 
phosphatase substrate (Vector Laboratories). All sections were counterstained with 
hematoxylin. 
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4.3.6. Microcomputed Tomography (µCT) Scanning and Analysis 
In vitro µCT provides high qualification and accurate quantification of mineralized 
tissues such as alveolar bone and teeth [23]. Each mandibular specimen was scanned and 
reconstructed at 18 × 18 × 18-µm voxels using a µCT system (GE Healthcare, London, 
ON Canada). A three-dimensional (3-D) volume viewer and analyzer software 
(MicroView Analysis+ v.2.1.2 software, GE Healthcare) were used as the tool for both 3-
D and 2-D visualization and quantification. 
 
Linear and volumetric analyses were based on a previously developed methodology [23]. 
In brief, vertical, linear bone loss was obtained by measuring the distance from the 
cemento-enamel junction (CEJ) to the alveolar bone crest or to the base of the alveolar 
intrabony defect at the mesial surface of the mandibular first molar teeth. In terms of 3-D 
analysis, the most mesial root of the first molar (m-M1), the second molar (m-M2), the 
roof of the furcation, and root apex of M1 were used as reproducible landmarks for 
estimation of alveolar bone loss. Two-dimensional regions of interest (ROIs) were drawn 
at regular intervals (average, eight data slices) on a coronal view and reconstructed as a 3-
D structure to quantify volumetric parameters, bone volume fraction (BVF), and bone 
mineral density (BMD; mg/cc). The measurements of coded specimens were made by 
two independent, calibrated examiners (JAC and CHP). 
 
4.3.7. Histology and TRAP Immunostaining 
TRAP immunohistochemical staining was performed to identify and quantify osteoclast-
like cells. Harvested mandibulae were fixed for 48 hours in 10% neutral-buffered 
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formalin, decalcified with 10% EDTA for 2 weeks, embedded in paraffin, and cut into 4- 
to 5-µm-thick sections. TRAP immunohistochemical staining was performed on these 
sections with anti-TRAP antibody (sc-30833, Santa Cruz Biotechnology, Santa Cruz, CA 
USA) and an immunostaining kit (Goat ABC Staining System kit (sc-2023), Santa Cruz 
Biotechnology) to identify osteoclast-like cells covering the bone surface. 
 
Images of coded specimens were captured using a microscope (Eclipse 50i, Nikon, 
Melville, NY USA) fitted with a digital camera (Digital Sight DS U1, Nikon) for analysis 
using software (Image Pro Plus, Media Cybernetics, Silver Spring, MD USA). The length 
of the bone surface covered by osteoclasts in a 0.5-mm coronal ROI at the alveolar crestal 
bone was measured by a single calibrated examiner (QJ). 
 
4.3.8. Statistical Analysis 
The differences among groups for linear and volumetric bone loss measurements, serum 
level of rhOPG-Fc and TRAP5b, and osteoclast-like cell surface area were statistically 
assessed by one-way analysis of variation (ANOVA) with Tukey multiple comparison 
post hoc test using a statistical software package (GraphPad Prism version 4.0, GraphPad 
Software, Sandiego, CA USA). The level of significance was set as P ≤0.05. 
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4.4. RESULTS 
4.4.1. In Vivo rhOPG-Fc Pharmacokinetics 
The healthy animals receiving a single injection of rhOPG-Fc displayed an increase in 
serum rhOPG within 12 hours after administration, reaching a maximal level of 23.2 ± 
5.1 µg/ml at 3 days. Serum rhOPG subsequently decreased to 1.2 ± 1.4 µg/ml at 14 days 
and 0.125 ± 0.152 µg/ml at 21 days (Fig. 4.1). 
 
4.4.2. OPG-Fc Clearance From the Vasculature of Rat Bone 
After IV injection of human OPG-Fc, OPG primarily was circulated in blood rather than 
in the bone matrix. At 12 hours after administration, the peak level of serum OPG was 
reached and subsequently decreased over time. At 20 days, no circulating OPG was 
found in the blood vessels of bone (Fig. 4.1B). 
 
4.4.3.Serum rhOPG-Fc and TRAP-5b Levels During Disease Progression 
Figure 4.2 shows serum rhOPG and TRAP-5b levels after rhOPG-Fc administration twice 
a week. By 10 days after injection, the serum rhOPG levels of OPG-treated healthy and 
diseased animals rose sharply to 31.6 ± 12.3 µg/ml and 34 ± 28.4 µg/ml, respectively. 
The serum OPG within the OPG-treated diseased animals steadily increased over 6 weeks, 
whereas the serum OPG level within the OPG-treated healthy control showed no changes 
through 6 weeks. At 6 weeks, the OPG levels in OPG-treated diseased animals were 
significantly greater than the OPG-treated healthy controls (P <0.01). Compared to the 
vehicle-treated diseased animals, OPG levels of OPG-treated animals were significantly 
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higher at each designated time point (P <0.01; Fig. 4.2A). The endogenous OPG levels in 
normal healthy controls and vehicle-treated animals were low (data not shown). 
 
The changes in serum TRAP-5b levels within the rhOPG-Fc–injected and nonrhOPG-Fc–
injected animals are shown in Figure 3-B.2B. During the first 10 days after rhOPG-Fc 
administration, serum TRAP-5b levels in rhOPG-Fc–injected animals sharply declined to 
undetectable levels, whereas TRAP-5b levels in non-rhOPGFc–treated animals decreased 
only slightly or remained unchanged. After 10 days, the serum TRAP-5b levels of 
rhOPG-Fc–treated animals sustained lower levels, but the serum TRAP-5b levels of non-
rhOPG-Fc–treated animals slowly decreased. At all time points except baseline, the 
TRAP-5b levels in rhOPG-Fc–delivered animals were significantly lower than those of 
non-rhOPG-Fc–injected animals (P <0.01). No other groups displayed differences in 
TRAP-5b levels (Fig. 4.2B). 
 
4.4.4. µCT Analysis 
The alveolar bone crest at 3 weeks within the vehicle-treated animals significantly 
decreased from 0.83 ± 0.1 mm (no treatment group) to 1.28 ± 0.2 mm, which indicates 
that ~50% bone loss was elicited by experimental periodontitis (Figs. 4.3 and 4.4A). At 6 
weeks, the bone crest within the vehicle-treated animals also decreased from 1.05 ± 0.1 
mm (no treatment group) to 1.4 ± 0.2 mm, resulting in 40% bone loss. Significant 
differences of CEJ to bone crest (C-C) distance were only found in the vehicle-treated 
animals compared to the other three groups. 
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For volumetric measurements at the 3-week time point, experimental periodontitis 
resulted in the lowest BVF in the vehicle-treated animals compared to the other three 
groups, whereas the OPG-treated healthy controls had the highest BVF (Fig. 4.4B). At 6 
weeks, the vehicle-treated animals again showed the lowest BVF among all groups, 
whereas the OPG administration groups had significantly higher BVF compared to the no 
treatment group (Fig. 4.4B). In terms of BMD, the OPG-treated healthy controls showed 
the highest BMD, whereas the vehicle-treated animals had the lowest BMD at 3 weeks. 
At 6 weeks, the vehicle-treated animals had the lowest BMD, and there was a significant 
difference found between the normal healthy and OPG-treated healthy controls (Fig. 
4.4C). 
 
4.4.5.TRAP Immunostaining and Osteoclast Surface Analysis of Alveolar Bone 
Histologic analysis of four animals in each group at 3 and 6 weeks revealed increases in 
TRAP-stained osteoclasts in the region of the alveolar bone crest in diseased vehicle-
treated animals compared to healthy controls (Fig. 4.3). In accordance with histologic 
observations, the coverage of osteoclasts at the alveolar bone crest showed that 
osteoclasts in vehicle-treated animals occupied ~50% the surface of the alveolar bone 
within the coronal 0.5 mm, which was the highest of all the groups (Fig. 4.5). In contrast, 
very few TRAP-stained osteoclasts were observed in OPG-treated animals. OPG 
treatment of healthy animals was associated with a virtual absence of osteoclasts along 
the alveolar bone crest, whereas OPG treatment of diseased animals resulted in a three-
fold reduction in osteoclast surface compared to vehicle-treated diseased animals (Fig. 
4.5). This level of suppression reduced osteoclast surface area to levels found in normal 
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healthy animals. In addition, compared to the linear bone loss measurement, the bone loss 
is related to the osteoclast surface area covering the bone (Fig. 4.5). The vehicle-treated 
diseased animals showed the highest osteoclast coverage and the most extensive bone 
loss. 
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4.5. DISCUSSION 
To the best of our knowledge, this study showed for the first time a protective effect of 
OPG in an acute model of experimental periodontitis. To evaluate the effect of human 
OPG on the alveolar bone changes of rats at physiologic and pathologic conditions, it is 
imperative to show adequate systemic drug exposure. Human proteins including OPG-Fc 
can be immunogenic in rats, which would lead to rapid clearance of the drug and 
inadequate drug exposure. Single-dose pharmacokinetic assessment of human OPG-Fc 
revealed a Cmax at day 3, which indicates that twice-weekly administrations would ensure 
maximal exposure. After twice-weekly OPG administration, >30 µg/ml serum OPG 
concentration was obtained and sustained, which proved to be the effective serum OPG 
level to reduce the number of osteoclasts and inhibit bone loss (Figs. 4.4 and 4.5). This 
serum OPG concentration is similar to the serum OPG level (26.1 ± 5.2 µg/ml) found to 
be optimal for preventing bone resorption as previously reported by Capparelli et al [24]. 
However, inflammation may influence in vivo OPG degradation. Serum OPG levels in 
OPG-treated diseased animals remained elevated and were two-fold higher at 6 weeks 
compared to the OPG alone group, which may result from the decrease of the OPG 
degradation-related enzymes elicited by periodontal inflammation. 
 
Three-dimensional images of the mandibular molars generated by µCT were used to 
evaluate the preventive effects of OPG on alveolar bone loss. Linear measurements 
indicated that the vehicle-treated animals displayed higher levels of bone loss compared 
to other groups, whereas both groups receiving OPG injection showed similar bone levels 
compared to the healthy controls. This suggests that OPG inhibits alveolar bone loss 
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induced by experimental periodontitis. Protective effects of OPG on alveolar bone 
resorption were previously shown in an A. actinomycetencomitans oral inoculation-induced 
periodontitis model [21, 22] and a tooth biomechanical movement model (our 
unpublished data). In addition, measurements of the BVF, representing the percentage of 
bone volume of the delineated region, were statistically lower in the vehicle-treated 
animals compared to all other groups at 3 and 6 weeks, showing that experimental 
periodontitis stimulated more bone loss in the absence of OPG administration. Therefore, 
OPG seems to rescue not only alveolar bone height but also loss of BMD induced by 
experimental periodontitis. 
 
To evaluate the effects of OPG on the osteoclast formation in alveolar bone, the coronal 
0.5 mm of bone crest at the mesial surface of the first molars was chosen because those 
areas are under the direct influence of experimental periodontitis and most subject to 
osteoclast formation. Our results showed that the vehicle-treated diseased animals 
showed a higher percentage of bone surface covered by TRAP-positive osteoclasts than 
the other groups at 3 weeks, whereas the OPG-treated diseased animals had the same 
bone surface coverage of TRAP-positive osteoclasts as normal rats, which suggests that 
OPG inhibits osteoclast formation. Similar results were also seen in the application of 
OPG to situations of increased osteoclastic bone resorption, which results from certain 
types of cancers, rheumatoid arthritis [25] or A. actinomycetencomitans inoculation [21, 22]. 
In addition, OPG administration also causes a decrease in serum TRAP-5b, a marker of 
osteoclastic resorption [26]. This indicates that the reduction of osteoclast number elicited 
by OPG application results in a decrease of TRAP-5b originating from osteoclasts. 
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A potentially important advantage for clinical application of OPG is the lack of 
incorporation of OPG into bone matrix, as shown in Figure 3-B.1B. As a result, its effects 
on osteoclasts and bone remodeling are fully reversible [24, 27]. This mechanism of 
action could have benefits versus agents such as bisphosphonates, which are directly 
incorporated into bone matrix and thus have poor reversibility. Bisphosphonates have 
shown efficacy in patients with osteoporosis, Paget's disease, and tumor bone disease 
[28], and these agents have shown potent effects as host-modulating agents for 
periodontal disease treatment [29-31]. However, bisphosphonate therapy has also been 
associated with osteonecrosis of the jaw (ONJ) [32, 33], a condition described by the 
persistent exposure of necrotic bone in the oral cavity. The etiology of bisphosphonate-
related ONJ is poorly understood, but periodontal disease has been the most common 
comorbidity in bisphosphonate-treated patients with ONJ [32]. In cancer patients on IV 
bisphosphonates, the relative risk of developing ONJ increases markedly after several 
years of bisphosphonate use [33]. Bisphosphonate accumulation in bone matrix is a direct 
function of the total administered dose [34], and the skeletal uptake of bisphosphonates is 
not reduced by prior high-dose bisphosphonate therapy [35]. These observations suggest 
that skeletal accumulation of bisphosphonates continues despite the ability of these 
agents to markedly suppress bone turnover. Because periodontitis can be a chronic 
disease, it may be inappropriate to use long-term bisphosphonates for the prevention of 
alveolar bone loss until the etiology of bisphosphonate-related ONJ is elucidated 
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4.6. CONCLUSIONS 
In this study, OPG revealed strong preventive effects on alveolar bone loss in 
experimental periodontitis, thus showing promising therapeutic potential of OPG for 
treatment of periodontal disease. Future studies will need to examine the ability of OPG 
to block progression of established disease and human application. 
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4.7. FIGURES 
 
Figure 4. 1. In vivo rhOPG-Fc pharmacokinetics after a single subcutaneous 
administration. A) The maximum level of serum rhOPG was seen at 3 days after 
administration. Serum rhOPG decreased within 14 days. At 21 days after injection, the 
delivered rhOPG was eliminated completely. Bars represent SDs. *P <0.01 compared to 
baseline. B) Human OPG immunostaining in the proximal tibial metaphysis. Young male 
rats received a single infusion IV with human OPG-Fc at 5 mg/kg. The delivered human 
OPG circulated primarily in the blood rather than integrating into the bone matrix. The 
highest serum level of administered human OPG appeared 12 hours after IV infusion, and 
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the serum OPG was eliminated over time. N = 6 animals per group. Bars = 25 µm. RBCs 
= red blood cells; h = hours; d = days. 
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Figure 4. 2. A) Serum rhOPG levels after twice weekly subcutaneous administration. 
Higher serum rhOPG levels were seen in OPG delivery groups, whereas rhOPG levels 
remained almost undetectable in vehicle-treated animals. At 6 weeks, the serum rhOPG 
levels between the OPG + disease and the OPG alone groups were statistically 
significantly different (†P <0.05). *P <0.05 compared to the vehicle group. Bars represent 
SDs. B) Serum TRAP-5b levels after repeated subcutaneous administration. Serum 
TRAP-5b levels in rhOPG-injected animals decreased sharply at 10 days and remained 
very low until 6 weeks, whereas the serum TRAP-5b levels in non-rhOPG-injected 
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animals gradually declined. Except at baseline, the TRAP-5b levels in non-rhOPG-treated 
groups were significantly higher than those in rhOPG-injected groups. *P <0.05 
compared to non-rhOPG-treated groups. Bars represent SDs. N = 4 animals per group. 
Veh = vehicle. 
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Figure 4. 3. OPG-Fc blocks alveolar bone loss in experimental periodontitis. Left 
panels show the mesial view of µCT 3-D images of mandibular first molars of each 
group at 3 weeks. The vehicle + disease group shows the greatest degree of bone loss. 
Right panels show the histology of the alveolar bone at the mesial side of mandibular first 
molars of each group at 3 weeks (TRAP immunostaining; magnification, ×200). TRAP-
positive osteoclasts are stained brown. Higher numbers of positively stained osteoclasts 
were noted on the surface of alveolar bone in the vehicle + disease groups. Few 
osteoclasts were seen at the alveolar bone crest in the OPG + disease group. Furthermore, 
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no positively stained cells were found in the OPG alone group. Blue arrows demarcate 
the CEJ. Yellow arrows indicate the alveolar bone crest. Black arrows indicate positive 
TRAP-stained osteoclast-like cells. Veh = vehicle; B = bone crest; D = dentin. N = 4 
animals per group. 
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Figure 4. 4. OPG-Fc blocks alveolar bone loss in experimental periodontitis as 
measured by linear and volumetric µCT. A) The linear measurement of the distance 
from the CEJ to alveolar bone crest at the mesial roots of mandibular first molars in each 
group. The greatest difference was seen in the vehicle + disease group at both 3 and 6 
weeks, whereas there was no significant difference among other groups. B) The fractions 
of bone volume versus the total volume surrounded by the superficial surfaces of five 
roots of first mandibular molar. At 3 and 6 weeks, the vehicle + disease group showed the 
smallest BVF, whereas the OPG alone group displayed the greatest BVF. No significant 
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difference was found between the no treatment and OPG + disease groups. C) BMD for 
the regions surrounded by the superficial surfaces of all roots of first mandibular molars 
of each group. At 3 and 6 weeks, BMD in the vehicle + disease group was the lowest, 
whereas the OPG alone group displayed the highest BMD. No significant difference was 
found between no treatment and OPG + disease groups. N = 4 animals per group.*P 
<0.05; †P <0.01; bars represent SDs. Veh = vehicle. 
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Figure 4. 5. OPG administration inhibits osteoclast formation at the alveolar bone 
crest in experimental periodontitis. The osteoclast surface coverage at the coronal 0.5-
mm region of interest in alveolar bone at the mesial of the mandibular first molars was 
evaluated histomorphometrically at 3 and 6 weeks using TRAP immunostaining. At 3 
weeks, osteoclast coverage area was the greatest in the vehicle + disease group, whereas 
there were no significant differences noted among the other three groups. At 6 weeks, the 
vehicle + disease group had the greatest osteoclast coverage at the alveolar crest 
compared to OPG administration groups, with no significant difference with the no 
treatment group. *P <0.05. N = 4 animals per group. Veh = vehicle. 
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LOCAL DELIVERY OF OSTEOPROTEGERIN INHIBITS MECHANICALLY 
MEDIATED BONE REMODELING IN ORTHODONTIC TOOTH MOVEMENT 
 
Dunn MD, Park CH, Kostenuik PJ, Kapila S, Giannobile WV. 
Bone, 2007 41(3): 446-455. 
 
 
5.1. ABSTRACT 
Introduction: The RANKL-OPG axis is a key regulator of osteoclastogenesis and bone 
turnover activity. Its contribution to bone resorption under altered mechanical states, 
however, has not been fully elucidated. Here we examined the role of OPG in regulating 
mechanically induced bone modeling in a rat model of orthodontic tooth movement. 
 
Methods: The maxillary first molars of male Sprague-Dawley rats were moved mesially 
using a calibrated nickel–titanium spring attached to the maxillary incisor teeth. Two 
different doses (0.5 mg/kg, 5.0 mg/kg) of a recombinant fusion protein (OPG-Fc), were 
injected twice weekly mesial to the first molars. Tooth movement was measured using 
stone casts that were scanned and magnified. Changes in bone quantity were measured 
using micro-computed tomography and histomorphometric analysis was used to quantify 
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osteoclasts and volumetric parameters. Finally, circulating levels of TRAP-5b (a bone 
resorption marker) was measured using enzyme-linked immunosorbent assay. 
 
Results: The 5.0 mg/kg OPG-Fc dose showed a potent reduction in mesial molar 
movement and osteoclast numbers compared to controls (p<0.01). The molar movement 
was inhibited by 45.7%, 70.6%, and 78.7% compared to controls at days 7, 14, and 21 
respectively, with the high dose of OPG. The 0.5 mg dose also significantly (p<0.05) 
inhibited molar movement at days 7 (43.8%) and 14 (31.8%). While incisor retraction 
was also decreased by OPG-Fc, the ratio of incisor to molar tooth movement was 
markedly better in the high-dose OPG group (5.2:1, p<0.001) compared to the control 
group (2.3:1) and the low-dose OPG group (2.0:1). 
 
Conclusions: Local delivery of OPG-Fc inhibits osteoclastogenesis and tooth movement 
at targeted dental sites. 
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5.2. INTRODUCTION 
Bone deposition and resorption result from the interaction between bone-forming 
osteoblasts and bone-resorbing osteoclasts. Cells of the osteoblast lineage are not only 
involved in bone formation, but also regulate osteoclast formation, activation, and 
survival. This regulation is indirectly mediated by receptor activator of nuclear factor κB 
ligand (RANKL), a member of the tumor necrosis factor (TNF) superfamily. RANKL is 
produced by osteoblast lineage cells, periodontal ligament (PDL) cells, and by T 
lymphocytes. RANKL binds to a receptor called RANK, which is located on the surface 
of osteoclasts and osteoclast precursors. The binding of RANKL to RANK induces 
osteoclastogenesis, activates mature osteoclasts, mediates their attachment to bone, and 
promotes their survival. The activity of RANKL is controlled by a soluble decoy receptor 
called osteoprotegerin (OPG), which binds to RANK and inhibits osteoclast formation, 
activation, and survival [1]. 
 
While the contribution of RANKL–OPG in bone turnover mediated via systemic and 
local biologic agents has been well studied [2, 3], less is known of the contribution of 
these proteins to mechanically induced bone turnover. Several in vitro studies provide 
important insights into the potential role of mechanically regulated OPG and RANKL in 
modulating bone turnover in altered strain environments. Compressive mechanical 
loading of isolated PDL cells leads to a substantial upregulation of RANKL with little 
change or slight increase in OPG expression which in turn increases osteoclastogenesis 
when loaded cells are co-cultured with peripheral bone mononuclear cells [4, 5]. Also, 
conditioned media from osteoblasts subjected to microgravity show an increase in the 
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RANKL/OPG ratio, which is accompanied by increased osteoclastogenesis and bone 
resorption in mouse bone marrow cultures when compared to cells grown at 1 g. In 
contrast, dynamic tensile loading upregulates OPG mRNA and concentration of OPG in 
conditioned medium, while having little effect on the levels of RANKL in human PDL 
cells [6], and conditioned media of PDL cells subjected to cyclical tensile force inhibit 
osteoclastogenesis [7]. Similarly, human osteoblasts demonstrate increased OPG 
expression but also a decrease in soluble RANKL when subjected to cyclic tensile strain 
[8]. Moreover, osteoblasts cultured on artificial substrates and subjected to bending also 
demonstrate increased levels of OPG relative to RANKL [9]. Finally, ST-2 murine bone 
marrow stromal cells exposed to oscillating fluid flow show a maximal reduction in 
RANKL/OPG immediately after the end of flow with a significant increase in OPG and 
decrease in RANKL[10]. RAW 264.7 monocytes co-cultured with ST-2 cells and 
subjected to fluid flow showed a decrease in osteoclast formation when compared with 
control cells. Together, these studies demonstrate that different types of mechanical 
strains by differentially regulating OPG and RANKL result in important differences in 
the net osteolytic responses. Specifically, the findings suggest that while microgravity 
and cyclic compressive forces likely contribute to a net increase in osteolytic activity by 
enhancing the RANKL/OPG ratio, the reverse is true for cyclic tensile strain and 
oscillating fluid flow. While these in vitro studies may not precisely represent the 
complex nature of mechanical strains experienced by loaded bone in vivo, including that 
in the PDL during orthodontic tooth movement, they indicate that cells are capable of 
perceiving and responding differently to diverse strain histories. 
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Limited in vivo data also point to the role of RANKL and OPG in modulating 
mechanically mediated bone turnover. This includes the effects of the administration of 
recombinant human OPG in reversing the decrease in bone mineral content (BMC), bone 
mineral density (BMD), and bone strength back to normal levels in limbs of immobilized 
rats [11]. It has also been demonstrated that excess OPG actually impairs bone 
remodeling in a situation such as callus repair following fracture indicating that the ideal 
ratio of OPG to RANKL is dependent on the mechanical model being employed [12]. 
Finally, local OPG gene transfer to sites significantly diminishes while RANKL gene 
transfer significantly enhances orthodontic tooth movement possibly by respectively 
inhibiting or enhancing RANKL-mediated osteoclastogenesis [13, 14]. Orthodontic tooth 
movement is a well-utilized in vivo model for determining the contributions of various 
exogenous and endogenous agents to mechanically mediated bone modeling [15-19]. It 
results from the application of forces to teeth that cause bone resorption under pressure 
and bone deposition under tension. The entire process is based on bone turnover in which 
the bone surrounding the roots undergoes degradation and active reparative mechanisms 
as a response to orthodontic forces. 
 
Recently, a fusion protein OPG-Fc and other RANKL inhibitors have been shown to 
reduce bone resorption systemically and preserve bone in a variety of clinical and 
preclinical disease settings. Examples include primary osteoporosis, Paget’s disease, 
rheumatoid arthritis, hypercalcemia of malignancy, osteolytic metastases, 
postmenopausal bone loss, and periodontal disease [1, 20-27]. While the potential 
benefits of these RANKL inhibitors in systemic conditions resulting in significant bone 
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loss are evident, there are also possible uses for local RANKL inhibition such as during 
mechano-modulation of bone modeling during orthodontic tooth movement, where it is 
often necessary to minimize unnecessary movement of teeth. The stability of anchor teeth, 
which tend to inadvertently move during treatment, is a critical shortcoming in 
orthodontics. In order to combat this undesirable movement, orthodontists have 
developed several mechanical methods of improving anchorage. However, these have 
substantial limitations including the need for compliance, discomfort, cost or lack of 
efficacy [28, 29]. Given these disadvantages, a pharmacological approach aimed at 
utilizing the known biological mechanisms underlying tooth movement may provide an 
effective, non-compliant, non-visible means of anchorage. If the resorptive process of 
modeling during tooth movement can be inhibited, tooth movement may be inhibited as 
well. Accordingly, if OPG is involved in mechano-modulation of bone modeling, its local 
inhibition of RANKL may provide a novel pharmacological approach for preventing 
unneeded tooth movement that is highly desirable for preserving orthodontic anchorage. 
In this study we tested the hypothesis that local delivery of OPG-Fc will inhibit 
mechanically induced bone modeling in a rat model of orthodontic tooth movement at the 
site of OPG-Fc delivery. The specific objectives of this study were to: (1) assess the 
magnitude of movement of molar and incisor teeth at sites closest and distant, 
respectively, to the administration of OPG-Fc; (2) quantify the bone resportive activity by 
histomorphometric assessment of osteoclasts; (3) determine the effects of OPG-Fc on 
bone density through micro-CT analysis; and (4) assay for serum levels of a bone 
resorption maker, TRAP-5b. 
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5.3. MATERIALS AND METHODS 
5.3.1. Animals 
A total of 39 male Sprague-Dawley rats (approximate weight 250–300 g) were utilized in 
this study. Thirty animals divided into groups of ten were subject to orthodontic forces in 
addition to volumetrically equivalent injections of 5.0 mg/kg human OPG-Fc (AMGEN, 
Inc., Thousand Oaks, CA), 0.5 mg/kg OPG-Fc, or phosphate-buffered saline (PBS) 
vehicle. Three animals received no appliances or injections and were sacrificed at 
baseline; three animals were vehicle-injected with no appliances, and three animals 
received high-dose OPG and no appliances. All injections were administered into the 
palatal mucosa adjacent to the mesial surface of the first molar teeth using 33-gauge 
microneedles (Hamilton Company, Reno, NV). The animals were evaluated at baseline, 
3,7,10,14,17, and 21 days after appliance placement. All procedures were approved by 
the University of Michigan Committee of Use and Care of Animals. For baseline 
procedures including appliance placement, the animals were anaesthetized as described 
below. 
 
5.3.2. Appliance placement 
We utilized a previously established rat tooth movement model and appliance design (Fig. 
3-C.1A) [30]. Animals were first placed under general anesthesia with ketamine (87 
mg/kg) and xylazine (13 mg/kg) for initial appliance placement. A closed coil nickel-
titanium spring (Sentalloy®, GAC, Ctr. Islip, NY) calibrated by an Instron Universal 
Testing Machine (Model 5565, Norwood, MA) providing a force of 54±2 g at 4 mm 
activation was connected between the maxillary first molar and maxillary central incisor 
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teeth with 0.010-in. steel ligatures. Previous studies have demonstrated that a 40–60 g 
level of force stimulated substantial molar tooth movement in rats [23, 30-34]. A nickel–
titanium spring was used to provide a relatively constant force level over the course of 
the experiment. 
 
For placement of springs, grooves were prepared along the distolingual line angles of the 
maxillary first molars to allow easier ligature placement as well as prevent the ligatures 
from slipping over the contact areas once the teeth started to move [30]. In addition, 
grooves were prepared on the facial, mesial, and distal surfaces of the maxillary central 
incisors to prevent the ligatures from dislodging from the teeth due to their lingual 
curvature and eruption pattern. After the ligatures were tied and cut, composite resin 
(Transbond XT Light Cure Adhesive Paste, 3M Unitek, Monrovia, CA) was placed over 
the wire to prevent slipping as well as pulpal irritation due to exposed dentin. Finally, the 
mandibular incisors were reduced to prevent appliance breakage. 
 
5.3.3. Measurement of tooth movement 
Tooth movement was measured as previously described, with minor modifications 
[14,19]. At each time point including baseline, polyvinylsiloxane (Dimension Garant 2 L 
Quick, 3M/ESPE, St. Paul, MN) impressions were taken of the maxillary arches. 
Following fabrication of precise stone models (Jade Stone, Whip Mix Corp., Louisville, 
KY), the occlusal tooth surfaces were scanned (Epson Expression 1680, Epson America, 
Inc., Long Beach, CA) adjacent to a 100 mm ruler and then magnified 100× using 
calibrated imaging software (Adobe Photoshop 7.0.1, Adobe Systems, Inc., San Jose, 
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CA). Using Adobe Photoshop’s measuring tool, a single masked, calibrated examiner 
(ICC>0.972; 0.954 ≤ 95% confidence interval ≤ 0.983) made measurements from the 
distobuccal groove of the maxillary first molar to the most distal surface of the maxillary 
third molar at each time point. The amount of tooth movement was calculated as the 
difference between the pre-treatment, intra- and post-treatment measurements. In addition 
to molar movement, the amount of incisor retraction was also measured relative to the 
distal surface of the third molar teeth. Incisor position was measured from the mesiodistal 
center of each central incisor at the facial gingival margin. The amount of tooth 
movement was calculated as the difference between the measurements made during and 
at the end of treatment and the measurement at baseline. Given that maxillary growth also 
results in a change of incisor position relative to the third molar reference point, the 
amount of incisor retraction was calculated in terms of incisor position relative to that of 
untreated controls at day 21. The impressions did not include the incisors during the 
intra-study time points to avoid altering the springs involved in the promotion of tooth 
movement. Therefore, since the untreated controls showed a mean of 1.42 mm of forward 
incisor displacement, this value was added to all values of incisor movement derived 
from the models of the experimental animals. 
 
5.3.4. Biopsy harvest and histological preparation 
The animals were sacrificed by CO2 euthanasia at 21 days following appliance placement. 
After taking final impressions, block biopsies of the right and left maxillae were 
harvested, immediately fixed and stored in 10% formalin for 48 h, and then transferred to 
70% ethanol. Samples were divided randomly (right and left) so that half the samples 
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were imaged using micro-computed tomography and the other half prepared for histology. 
Samples used for histology were decalcified with 10% vol./vol. EDTA and the embedded 
in paraffin. Sagittal sections (4–5 µm thick) were obtained of the mesial root of the 
maxillary first molar. The mesial root was chosen because it is the largest of the first 
molar’s five roots, is in approximately the same plane as the applied force and is most 
commonly evaluated in tooth movement studies [30, 35-37]. The sections were stained 
with hematoxylin and eosin (H & E) for descriptive histology. 
 
5.3.5. Immunohistochemical analysis 
Tartrate-resistant acid phosphatase (TRAP) immunohistochemical staining was 
performed to identify and quantify osteoclasts. A minimum of six, randomly selected 
midsagittal sections per animal were deparaffinized and then incubated in 
DakoCytomation Target Retrieval Solution (Dako Corp., Capinteria, CA) for 30 m. 
TRAP immunohistochemical staining was performed with a goat ABC Staining System 
kit (sc-2023; Santa Cruz Biotechnology) and anti-TRAP antibody (sc-30833; Santa Cruz 
Biotechnology). 
 
Images of coded specimens were captured using a Nikon Eclipse 50i microscope (Nikon, 
Inc., Melville, NY) fitted with a Nikon Digital Sight DS U1 camera (Nikon, Inc., 
Melville, NY) for analysis using Image Pro Plus™ software (Media Cybernetics, Silver 
Spring, MD). A single masked, calibrated examiner examined the images and quantified 
tension side, compression side, and total osteoclasts (TRAP-positive cells) present on the 
alveolar bone surface adjacent to the entire mesial root. 
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5.3.6. Micro-computed tomography 
Micro-CT analysis was done to quantify alveolar bone in the proximity of the first molar 
roots. Regions of fixed, non-demineralized rat maxillae were scanned in de-ionized water 
using a cone beam micro-CT system (GE Healthcare, London, ON, Canada). Each scan 
was reconstructed at a mesh size of 18 µm × 18 µm × 18 µm, allowing a three-
dimensional digitized image to be generated for each specimen (Fig. 5.1B). Using GE 
Healthcare Microview Analysis+ software, the images were rotated into a standard 
orientation and threshold to distinguish the degree of mineralization of tissues such as 
bone, tooth roots and tooth crowns. For each specimen, a gray voxel value histogram was 
generated to determine an optimal threshold value. An average of the individual threshold 
values was calculated and a representative value was used to threshold all images. 
 
Measurements of the bone volume fraction (BVF) in the first molar furcation area were 
carried out as previously described [38]. The furcation area and root apex was chosen 
because they provide reproducible, morphological landmarks. Briefly, the most mesial 
and distal roots of the first molar were selected as endpoint landmark borders. Two-
dimensional regions of interest (ROIs) were then drawn at regular intervals (mean =144 
µm) in order to quantify tooth-supporting alveolar bone. 
 
Systemic measure of osteoclast activity was determined by assaying for TRAP-5b by 
ELISA (RatTRAP Assay, SBA Sciences, Finland), in accordance with manufacturer’s 
instructions. TRAP-5b is specific for osteoclast activity thus providing a marker of bone 
resorption [40]. 
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5.3.7. Statistical analysis 
Descriptive statistics (mean, standard error) for each parameter were calculated for all 
groups. Each animal was used as the experimental unit. Comparisons of tooth movement 
were made using repeated measures, analysis of variance and Tukey’s HSD post-hoc 
comparison. Osteoclast number, bone volume fraction, serum OPG, and serum TRAP-5b 
comparisons were made using analysis of variance (ANOVA) and Tukey’s HSD post-hoc 
comparison. Kruskal–Wallis analysis of ranks was used to compare ratios of incisor 
retraction to molar movement. Differences with p<0.05 were considered statistically 
significant. 
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5.4. RESULTS 
5.4.1. Animal status 
Appliance placement and injections did not appear to hinder the animals’ ability to thrive. 
There were no significant differences in weight gain among the groups. The mean + SD 
starting weight of all animals at baseline was 272.6±13.4 g. At 21 days, the animals 
weighed 372.0±25.8 g, 377.4±15.8 g, and 353.5±25.5 g in the vehicle, 0.5 mg/kg OPG-
Fc, and 5.0 mg/kg OPG-Fc groups, respectively. There was 100% appliance success rate 
as no tooth movement appliances broke or needed to be replaced over the 3-week 
experimental period. 
 
5.4.2. Tooth movement 
Local delivery of OPG-Fc resulted in a substantial decrease in mesial movement of the 
first molar tooth when compared to vehicle-injected control animals (Fig. 5.2A). At day 7, 
there was a significant decrease in molar movement in both the 0.5 mg/kg OPG-Fc group 
(0.15±0.02 mm, p<0.05) and 5.0 mg/kg OPG-Fc group (0.14±0.02 mm, p<0.01) when 
compared to controls (0.27±0.03 mm). However, at this time-point there was no 
significant difference in amount of molar movement between groups receiving the two 
doses of OPG-Fc. By day 14, not only was there a significant decrease in mesial molar 
movement in the low (0.37 ± 0.05 mm, p<0.05) and high (0.16±0.03 mm, p<0.001) OPG 
groups compared to controls (0.54±0.05 mm) but there was also a significant difference 
between the low- and high-dose OPG groups p<0.05). Only the high-dose OPG group 
(0.20±0.03 mm, p< 0.001) showed a significant decrease in molar movement at day 21 
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compared to controls (0.93±0.07 mm). The high-dose OPG group also had significantly 
less (p< 0.001) mesial molar movement than the low-dose OPG group (0.75±0.10 mm). 
Using the data reported in Figure. 5.2A to determine percentages of tooth movement, it 
was noted that rats administered a dose of 5.0 mg/kg OPG-Fc demonstrated only 54.3%, 
29.5%, and 21.3% of the total mesial molar movement compared to that observed in 
control rats at days 7,14, and 21, respectively. These differences were all statistically 
significant. Rats receiving 0.5 mg/kg OPG-Fc had a statistically significant 56.2% and 
68.2% of the molar movement relative that that in control rats at days 7 and 14, 
respectively. At day 21, animals treated with 0.5 mg of OPG-Fc did not demonstrate 
significant molar tooth movement compared to controls. At days 14 and 21, the 5.0 
mg/kg OPG-Fc group showed significantly less (p<0.05) percent molar movement 
compared to the 0.5 mg/kg OPG-Fc group. 
 
The amount of incisor retraction appeared also to be inhibited dose dependently (Fig. 
5.2C). Animals without active springs demonstrated 1.42±0.06 mm of forward maxillary 
incisor movement over the 3-week experimental time period. The vehicle-injected 
animals with active springs showed 2.17 ± 0.05 mm of incisor retraction relative to the 
untreated controls corrected for the abovementioned growth-associated anterior 
movement of the incisors. The 0.5 mg/kg OPG-Fc-injected group showed significantly 
less incisor retraction (1.53±0.03 mm, p<0.0l) than the vehicle-injected group. Likewise, 
the 5.0 mg/kg OPG-Fc group showed significantly less incisor retraction (1.05±0.03 mm, 
p<0.0l) than either the vehicle or 0.5 mg/kg OPG-Fc-injected animals. No tooth 
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movement was noted for the three groups not receiving appliances (i.e., the no-treatment 
control, vehicle-control or high-dose OPG treatment control, data not shown). 
 
In order to evaluate the relative effect of OPG on movement of the first molars and 
incisors, the ratio of incisor to molar tooth movement was calculated (Fig. 5.2D). In the 
vehicle-injected rats, the incisors were retracted 2.3 mm for every millimeter of 
anchorage loss at the first molar. Injecting 0.5 mg/kg OPG-Fc, allowed for only 2.0 mm 
of incisor retraction for every millimeter of anchorage loss. Finally, the 5.0 mg/kg OPG-
Fc group demonstrated 5.2 mm (p<0.001) of incisor retraction for every millimeter of 
molar anchorage loss. 
 
5.4.3. Descriptive histology 
The control and low-dose OPG groups showed many osteoclasts, inflammatory cells, and 
areas of bone resorption (Fig. 5.3). In contrast, very few osteoclasts and areas of bone 
resorption were found in the high-dose OPG group. The periodontal ligament appeared to 
be normal in all groups and there was no evidence of ankylosis. Isolated areas of root 
resorption were noted but did not appear to correlate with any particular treatment group 
(data not shown). 
 
5.4.4. Immunohistochemical analysis 
Osteoclasts were enumerated along the compression and tension sides of the mesial tooth 
roots of the maxillary first molars (Fig. 5.4). The 5.0 mg/kg OPG-Fc group showed 
significantly fewer osteoclasts (3.2±1.7) than either the vehicle-(23.3±2.9, p<0.001) or 
  131 
0.5 mg/kg OPG-Fc-injected(16.0±4.2, p<0.05) groups in terms of osteoclasts along the 
compression side of the mesial root (Fig. 5.4A). Along the tension side, the high-dose 
OPG group also showed fewer osteoclasts (3.1±1.2) compared to the low-dose OPG 
group (13.4±2.5, p<0.05), but was not significantly different than controls (8.9±2.0) (Fig. 
3-C.4B). Finally, the high-dose OPG group had significantly less total osteoclasts 
(6.3±2.8) than either the control (32.2±3.3, p<0.00l) or the low-dose OPG (29.4±4.7, 
p<0.001) groups (Fig. 5.4C). One animal in each of the low- and high-dose OPG groups 
could not be evaluated because the tissue sections demonstrated histological artifacts 
abrogating analysis. 
 
5.4.5. Micro-computed tomography 
BVF was measured in the first molar furcation area. Compared to the baseline group that 
received no treatment (0.524 ± 0.020), there were no significant differences in BVF (Fig. 
5.5) in the vehicle (0.515±0.029) and 0.5 mg/kg OPG (0.374±0.133) groups. The 5.0 
mg/kg OPG group (0.666±0.049), however, demonstrated a significant (p<0.001) 
increase in BVF compared to all other groups. In addition, the low-dose OPG group 
showed significantly (p<0.01) less BVF than the control group. One animal in the low-
dose OPG group was excluded because the specimen was damaged during biopsy 
retrieval. 
 
5.4.6. ELISA of serum TRAP-5b 
At baseline, animals showed 1.9±0.4, 1.7±0.3, and 1.5 ± 0.2 U/L of serum TRAP-5b in 
the control, low-dose OPG, and high-dose OPG groups, respectively (fig. 5.6). By day 7, 
  132 
the high-dose group (0.0±0.0 U/L) demonstrated a significant decrease (p<0.05) 
compared to controls (1.2±0.2 U/L). The low-dose group showed a non-significant 
decrease (0.5±0.4 U/L). At day 14, the high-dose group remained significantly lower 
(0.3±0.2 U/L, p<0.05) than the control group (2.1±0.5 U/L). Serum TRAP-5b levels in 
the low-dose group rebounded to 2.5 ± 0.6 U/L. At day 21, the animals demonstrated 
1.5±0.3, 2.2±0.5, and0.9 ± 0.4 U/L of serum TRAP-5b in the control, low-dose OPG, and 
high-dose OPG groups, respectively. The differences were not statistically significant. 
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5.5. DISCUSSION 
The binding of RANKL to RANK is critical for osteoclastogenesis and bone resorption. 
By preventing this binding, the soluble decoy receptor OPG inhibits osteoclast formation, 
activation, and survival [41]. Considering OPG is a competitive inhibitor, the ratio of 
RANKL to OPG ultimately is responsible for the activation of RANK and inducing 
osteoclast progenitor cells to form mature osteoclasts. At the cellular and molecular 
levels, tooth movement is the result of the interaction between bone-forming osteoblasts 
and bone-resorbing osteoclasts. Given the critical role osteoclasts play in tooth movement, 
it follows that the RANK/RANKL/OPG pathway is likely to be critical in this process. 
Indeed, it has been shown that application of orthodontic forces results in the expression 
of RANKL protein in osteoblasts, osteocytes, fibroblasts, and osteoclasts [42]. In our 
studies, we utilized the knowledge of the basic biologic mechanisms of 
osteoclastogenesis and the important role played by the OPG–RANKL axis in osteoclast 
function to test the hypothesis that OPG participates in mechano-modulation of osteolysis 
to diminish orthodontic tooth movement and could therefore serve as a biologic mediator 
for enhancing orthodontic anchorage. 
 
Bearing in mind the shortcomings of traditional orthodontic anchorage approaches, a 
number of different groups have attempted to alter rates of tooth movement with a variety 
of bioactive molecules. Bisphosphonates [15, 19], nitric oxide synthase inhibitor [17], 
echistatin [16], and matrix metallo-proteinase inhibitors [18] have all been shown to 
decrease tooth movement. Bisphosphonates are not indicated for orthodontic use 
currently, and osteonecrosis of the jaw has recently become a concern with 
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bisphosphonate therapy [43, 44]. Bisphosphonates incorporate directly into bone where 
they reside for many years, and their effects are not readily reversible. In contrast, 
RANKL inhibitors including OPG are not incorporated into bone and have reversible 
effects on bone resorption [23]. As such, RANKL inhibitors may be desirable when 
transient osteoclast suppression is desirable in clinical situations such as with tooth 
anchorage. 
 
While multiple studies have demonstrated the ability to alter rates of tooth movement, the 
agents used affect osteoclasts indirectly rather than directly targeting the 
RANK/RANKL/OPG pathway. Using an in vivo gene transfer approach, molar 
movement was decreased by 47.8% (p<0.001) after 3 weeks of twice weekly OPG 
plasmid DNA injections [14]. In contrast to RANKL plasmid DNA injections that 
resulted in 31.6% (p<0.01) more molar movement [13]. These two gene therapy studies 
showed the potential of directly targeting this pathway in altering tooth movement. 
 
Using the recombinant fusion protein, OPG-Fc, we successfully inhibited molar 
movement by 78.7% (p<0.001) with a 5.0 mg/kg twice weekly local injection protocol. 
Even with a 10-fold reduction in dose (0.5 mg/kg), there was still a significant reduction 
(p<0.05) in molar movement until day 21. It is likely that the 0.5 mg/kg OPG-Fc-treated 
animals’ inability to maintain anchorage throughout the study was due to an inadequate 
dose compared to the level of RANKL expression that is induced during tooth movement. 
As we were using a human protein in a rat, we used higher and more frequent dosing than 
would likely be required for a human in order to overcome the animal’s immune response 
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to foreign human OPG-Fc. In a human study, using the same protein, a single 
subcutaneous dose (3.0 mg/kg) of OPG-Fc demonstrated a half-life of 6–7 days and 
remained effective for at least 30 days [22]. In addition, AMG 162 [21], a specific fully 
human monoclonal antibody to RANKL based on OPG, has demonstrated an 81% 
suppression in bone turnover six months after a single injection of 3.0 mg/kg. However, 
this human antibody cannot be studied in the rat model to directly compare its efficacy to 
humans. 
 
It is also of interest to note that the majority (57%) of the total molar movement in both 
OPG groups occurred within the first 3 days, corresponding with the displacement phase 
of tooth movement. The displacement phase is the initial movement caused by physical 
compression of the viscoelastic periodontal ligament. As it is not the result of tissue 
remodeling, the amount of movement in this phase is dependent on its biophysical 
limitations. During the remaining phases (days 3–21), the high OPG group demonstrated 
almost no additional molar movement. 
 
Considering the substantial decrease in molar tooth movement, it is likely that local OPG-
Fc injections were effectively inhibiting osteoclastogenesis. This was indeed the case as 
the animals in the high OPG group demonstrated 86% (p< 0.001) fewer osteoclasts along 
the compression side of the mesial root when compared to controls. The low-dose OPG 
group also showed a non-significant trend towards decreased osteoclasts. 
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One of the advantages of the mesial molar movement model that was used in the present 
study is that incisor retraction also can be measured. This allowed for evaluation of the 
effects of OPG on neighboring teeth. While there was a decreased rate of incisor 
retraction with increased levels of OPG, the overall treatment efficacy as measured by the 
ratio of incisor retraction to molar anchorage loss was greatly improved in the 5.0 mg/kg 
OPG-Fc group (incisor:molar movement=5.2:1) compared to the low-dose OPG group 
(2.0:1) or controls (2.3:1). As differentially regulating rates and magnitudes of tooth 
movement is the ultimate goal in maintaining orthodontic anchorage, this was an 
encouraging observation. This finding also demonstrates relative localization of the 
effects of the OPG-Fc-injected in proximity to the molar teeth. While these findings are 
promising, future research is recommended in order to determine the optimal dose 
regimen (quantity/frequency) that permits the greatest amount of incisor retraction with 
the least molar movement, and optimal time-release methods for administering OPG-Fc 
to obtain highly localized and long-term pharmacologic effects. 
 
Using three-dimensional imaging, we were also able to evaluate the quantity of tooth-
supporting alveolar bone. Not only did the animals in the high OPG group show greater 
BVF than the control and low OPG groups but they were also actually higher than the 
baseline sacrificed animals that never received any tooth movement appliances or tooth 
movement (Fig. 5.5). The modest but significant reduction in BVF associated with the 
low dose of OPG-Fc is consistent with the possibility that anti-human OPG-Fc antibodies 
that were induced by repeated injections resulted in some cross-reactive neutralization of 
endogenous rat OPG as well. Rat and human OPG are highly homologous and cross-
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reactive antibodies have been observed in previous rat studies (P. Kostenuik, personal 
communication). The potential for this phenomenon in the current study is supported by 
data obtained at the end of the study, wherein serum TRAP-5b values were slightly 
elevated in the low-dose OPG-Fc group, drug levels were not different from vehicle 
controls, and BVF was reduced. It is likely that this low dose produced pharmacologic 
effects for the first half of the study, followed by rapid immune-related clearance of the 
drug, and possible neutralization of endogenous OPG at the end of the study. 
 
While the low-dose group had no significant effect on serum TRAP-5b, there was 
significant suppression of this resorption marker in the high-dose group (Fig. 5.6). It is 
likely that the reduced TRAP-5b suppression with low-dose OPG is related to an immune 
response to the foreign protein. In other words, it is likely that there was significant 
serum TRAP-5b suppression during the first part of the study, but at some point 
(probably between days 10 and 14), the immune response was sufficient to clear or 
neutralize the drug. With the high-dose group, an immune response also probably 
occurred but enough protein was delivered to overwhelm the immune response and 
maintain therapeutic circulating levels of OPG-Fc to effectively suppress bone resorption. 
By 21 days the TRAP-5b suppression was reduced, indicating that the immune response 
was likely eventually sufficient to neutralize even the high dose administration. 
 
The effects of the local gingival delivery method employed in this study were not entirely 
contained as demonstrated by TRAP-5b assays (Fig. 3-C.6). Given its transient effect, the 
minimal safety concerns with systemic RANKL inhibition, and potential improvement in 
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bone mineral density, this result does not appear to be of significant concern [23, 24]. 
However, the targeted, primarily localized effects of OPG particularly with the high-dose 
group were demonstrated for therapeutic tooth anchorage. This phenomenon suggests 
that local OPG concentrations at the site of anchorage may have been higher than at other 
sites, perhaps due to simple diffusion of the protein within the gingivae. 
 
Inhibition of tooth movement using pharmacological anchorage could have many 
applications for orthodontics and dentistry beyond simply maintaining molar anchorage 
during incisor/canine retraction and may have benefits in molar distalization, molar 
protraction, vertical anchorage of posterior teeth and other applications where dental 
anchorage is critical for a favorable functional and esthetic result. Overall, this study 
demonstrates for the first time that local delivery of the recombinant RANKL inhibitor, 
OPG, effectively inhibits mechanically induced osteoclastogenesis resulting in improved 
bone quantity, orthodontic anchorage, and would likely lead to enhanced treatment 
efficacy. 
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5.6. FIGURES 
 
Figure 5.1. (A) Intraoral photographs of orthodontic appliances in place at day 21 prior 
to sacrifice. Animals received twice weekly injections of vehicle, 0.5 mg/kg OPG-Fc, or 
5.0 mg/kg OPG-Fc into the mucosa just mesial to the maxillary first molars. Note the 
amount of space visible between the first and second molar teeth. (B) Three-dimensional 
coronal and sagittal micro-computed tomography views of the same animals shown in 
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panel A. Note the interdental distance visible between the first and second molar teeth as 
well as the differences in bone quantity around the first molars. Arrows indicate 2-D 
force direction. 
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Figure 5.2. Inhibition of tooth movement by local delivery of OPG-Fc. (A) Molar tooth 
movement over the course of time in vehicle, 0.5 mg/kg OPG-Fc, and 5.0 mg/kg OPG-Fc 
injected groups. No tooth movement was noted in sham control animals (inactive spring) 
(data not shown). (B) Incisor retraction measured at day 21. (C) Ratio of incisor 
retraction to molar tooth movement at day 21. All results are expressed as the 
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mean ± SEM, n = 10: p < 0.05; p < 0.01; p < 0.001. Comparisons made versus 
time-matched vehicle groups. 
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Figure 5. 3. TRAP-stained histological sections (4–5 µm) counterstained with 
hematoxylin taken from the mesial tooth root of the maxillary first molar. (A) TRAP-
positive multinucleated osteoclasts (40× magnification); (B) control group (4× 
magnification); (C) low-dose OPG group (4× magnification); (D) high-dose OPG group 
(4× magnification), which lacks osteoclasts. MR, mesial root; Co, compression side 
alveolar bone; T, tension side alveolar bone; OC, osteoclast. Arrows indicate osteoclasts. 
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Figure 5. 4. Osteoclasts per root surface on the tooth compression surface (A), tension 
side (B), and total osteoclasts (C) along the alveolar bone adjacent to the mesial root of 
the maxillary first molar. All results are expressed as the mean ± SEM, n = 10 (vehicle), 9 
(low-dose OPG, high-dose OPG): p < 0.05; p < 0.001. Comparisons made versus 
time-matched groups. 
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Figure 5. 5. Comparison of bone volume fraction measured from the furcation area to 
tooth root apex of the maxillary first molar with micro-computed tomography. Specimens 
were placed on a rotating stage allowing polychromatic X-rays to penetrate the sample, 
pass through an image intensifier, and be captured by a CCD camera, producing 2-D 
slices of 18 µm thickness. These cross-sectional images were then reconstructed into a 3-
D structure by GE Healthcare reconstruction utility. Results are expressed as the 
mean ± SD, n = 3 (baseline), n = 10 (vehicle, high-dose OPG), n = 9 (low-dose OPG): 
p < 0.05; p < 0.01; p < 0.001. Comparisons made versus time-matched groups. 
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Figure 5. 6. Concentrations of TRAP-5b in serum as measured by ELISA. Blood was 
drawn from the lateral tail vein at days 0, 7, 14, and 21 prior to the next administration of 
OPG-Fc or vehicle. Results are expressed as the mean ± SEM, n = 10; p < 0.05. 
Comparisons made versus time-matched groups. 
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CHAPTER SIX 
 
ANALYSIS OF TISSUE NEOGENESIS IN GBR-TREATED EXTRACTION 
SOCKETS: CLINICAL, HISTOLOGICAL, AND MICRO-CT RESULTS 
 
Neiva RF, Pagni G, Duarte F, Yi E, Park CH, Rayburn LA, Giannobile WV. 
International Journal of Periodontics and Restorative Dentistry 2010 (in press) 
 
 
6.1. ABSTRACT 
AIMS: To perform a detailed evaluation of the healing of extraction sockets covered 
with a resorbable collagen membrane 12 weeks following exodontia, and to determine if 
this device has ossifying properties. 
 
METHODS: Ten consecutive subjects in need of extraction of maxillary premolars were 
recruited. Each subject had a hopeless maxillary premolar extracted with minimal trauma. 
Sockets were then covered with a collagen barrier membrane alone. At 12 weeks, a re-
entry surgery was performed, clinical measurements were repeated, and bone core 
biopsies were obtained prior to dental implant placement for histological and micro-CT 
analysis. 
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RESULTS: Study sites showed mean bone regeneration horizontally of 7.7 mm (B-L) 
and 4.6mm (M-D). Vertical bone repair showed a mean 10.9 mm of gain. Subtraction 
radiography showed a mean apical shift of the crestal bone at the center of the socket of 
2.1mm (range: 0.7 - 4.3mm). Micro-CT and histology revealed formation of well-
mineralized tissue at 12 weeks, with mean percentage of vital of bone of 45.87% + 
12.35%. No signs of membrane ossification were observed. 
 
CONCLUSION: A detailed analysis of tissue neogenesis in extraction sites protected by 
this barrier membrane has demonstrated that adequate bone formation for implant 
placement occurs as early as 12 weeks following exodontia, with minimal changes in 
alveolar ridge dimensions. No evidence of membrane ossification was observed. 
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6.2. INTRODUCTION 
Tooth extraction leads to alveolar bone loss due to atrophy of the edentulous ridge [1,2]. 
Significant bone resorption occurs in the first 6 months following tooth extraction [3,4,5]. 
Reduction in alveolar ridge height and width may complicate or even prohibit optimal 
implant placement, and often compromises the esthetic and functional treatment outcome 
[6]. Alveolar ridge preservation has been evaluated in many studies [7-11]. A variety of 
bone grafting materials and barrier membranes have been studied for their ability to 
enhance bone formation in alveolar ridges [6,12], and to evaluate their bone healing and 
bone-forming capacity in extraction sockets [13,14]. However, these studies have only 
partially evaluated the events following tooth extraction. The aim of this study was to 
evaluate in detail bone tissue neogenesis that takes place following tooth extraction 
through clinical, histological, and microcomputed tomography (micro-CT) analyzes using 
a long-lasting collagen membraneα to protect the osseous defect from soft tissue invasion, 
maximizing the natural healing potential of the extraction socket. The secondary aim of 
this study is to further investigate the combination of histological, clinical and 
tomographic measures to model bone repair in vivo. 
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6.3. MATERIALS AND METHODS 
The research protocol for this case-series clinical trial was approved by the University of 
Michigan committee governing the use of human subjects in clinical experimentation 
(IRB). This study was registered on the clinicaltrials.gov registry NCT00639860. 
 
Inclusion & Exclusion Criteria - Ten consecutive subjects requiring extraction of 
maxillary premolars were selected from the patient pool of the Michigan Center of Oral 
Health Research (MCOHR), University of Michigan, School of Dentistry. Patient 
inclusion criteria for this study included: 1) systemically healthy subjects with 1 
maxillary premolar tooth requiring extraction; 2) contained residual extraction sockets 
possess <80% bone loss in all dimensions (4-walled bony defects); 3) nonsmokers; 4) 
subjects willing and able to comply with all study-related procedures; and 5) subjects 
who read, understood, and were willing to sign an informed consent statement. Subjects 
with any of the following conditions were excluded from the study: 1) inadequate zone of 
keratinized gingiva or alveolar mucosa to obtain primary wound closure of the surgical 
site; 2) presence of acute infections at the time of tooth extraction; 3) clinically 
significant or unstable systemic diseases affecting bone or soft tissue growth; or other 
renal, hepatic, cardiac, endocrine, hematological, autoimmune or acute infectious 
diseases; 4) a history of head & neck radiation therapy; 5) subjects taking steroids, 
tetracycline or tetracycline analogues, bone therapeutic levels of fluorides, 
bisphosphonates, and other medications affecting bone turnover, or any investigational 
drug; 6) patients who were or become pregnant during the length of the study; 7) sites in 
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which one or both adjacent teeth were missing; 8) sites in which the buccal plate was 
missing or damaged during exodontia. 
 
Preoperative Procedures - At the initial screening examination, a complete medical and 
dental history was obtained, and the goals of the study, potential risks and benefits were 
explained. Each subject received full-arch alginate impressions for fabrication of study 
models. Customized radiographic templates were created using the study models and 
stock radiograph positioning devices (XCP®, Rinn Corp., Elgin, IL) modified with a 
malleable acrylic (Triad®, Dentsply  orp, York, PA) that was adapted to fit around an 
occlusal aluminum step wedge (Stanley M. Dunn, PhD, Neshanic Station, NJ). The study 
models were also used to fabricate occlusal templates to permit reproducible clinical 
measurements of the alveolar ridge dimensions.  
 
Outcome Measures - The primary outcome variables evaluated included bone gain or loss 
in millimeters, radiographic bone changes, and percentage of new bone formation of the 
alveolar bone core biopsies. Bone topography was documented using UNC probes and 
occlusal templates. The following clinical measurements were made at baseline and re-
entry: 1) distance from the occlusal template to the mesial, distal and mid crestal bone; 
and 2) socket depth (or template to crest distance at the 3-month re-entry surgery). 
Thickness of the buccal plate was measured 3 mm below the osseous crest at the center of 
the mesio-distal aspect of the socket using a boley-gauge caliper. All measurements were 
rounded to the nearest one-half millimeter. 
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Surgical Protocol & Treatment Assessment – A summary of study-related procedures is 
listed in Figure 6.1. To help minimize technical variances in the surgical treatment 
protocol, a single surgeon (RN) performed both baseline & 3-month re-entry surgeries. 
Under local anesthesia, full-thickness mucoperiosteal flaps were elevated; the selected 
tooth was extracted atraumatically15, followed by debridement of the sockets, and 
collection of all clinical measurements. Resorbable collagen barrier membranes 
(OSSIXTM PLUSTM is a trade mark of OraPharma, Inc. Warminster, PA USA) were used 
to cover the extraction sockets and flaps were advanced to achieve primary wound 
coverage. Flaps were secured with 4.0 and 5.0 polyglactin 910 sutures, utilizing an 
interrupted technique (Fig. 6.2). Postoperatively, a standardized periapical radiograph 
was taken of each surgical site utilizing a custom radiographic template and an aluminum 
step wedge (Stanley M. Dunn, PhD, Neshanic Station, NJ). All radiographs for each 
subject used the same digital x-ray unit, voltage & amperage (70 kV, 5 mA); and step 
wedge. The exposure time was recorded and the same settings were used again in 
subsequent radiographs. All subjects were prescribed ibuprofen (2.4 g/day), and either 
oral amoxicillin (1.5 g/day) or clindamycin (0.6 g/day) for 5 days. Subjects were 
instructed to change their diet to semi-liquid for 48 hours, followed by soft foods for the 
first 2 weeks. Subjects were also instructed to avoid toothbrushing close to the surgical 
site and to rinsetwice daily with a 0.12% chlorhexidine solution. At 1 and 2 weeks post-
surgery, the extraction sites were inspected and gently cleaned with chlorhexidine-soaked 
gauze, health histories were reviewed, and photographs were taken. At 12 weeks, these 
procedures were repeated, and standardized periapical radiographs were taken. Soft tissue 
healing was assessed at 1, 2 and 12 weeks with a wound-healing index (WHI) according 
  159 
to the following scheme: score “1” for uneventful wound healing with no gingival edema, 
erythema, suppuration, discomfort or membrane exposure; score “2” for uneventful 
wound healing with slight gingival edema, erythema, or discomfort, or membrane 
exposure and no suppuration; score “3” for poor wound healing with significant gingival 
edema, erythema, discomfort, loss of membrane or any suppuration. At 12 weeks, re-
entry surgeries were performed and all clinical measurements were repeated. Bone core 
biopsies approximately 3 x 10 mm in size were harvested with a 3.7-mm (external 
diameter) trephine drill (Ace Surgical Supply Co., Inc., Brockton, MA) from the area 
corresponding to the center of the previous extraction socket. These biopsies were 
obtained through a flapless approach to include gingival tissues in the specimens (Fig. 
6.2). The cores were immediately placed in bottles of 10% neutral buffered formalin 
(NBF) for fixation, and labeled for histological and micro-CT analysis. Following biopsy 
removal, flaps were elevated for additional clinical assessment and measurements and 
dental implants were placed in a single-stage approach. 
 
Radiographic Image Analysis - Computer-assisted densitometric image analysis (CADIA) 
was used for evaluation of the radiographic bone density, utilizing a previously described 
technique.16 Radiographs obtained at baseline and 12 weeks were aligned using a real-
time subtraction program17 and digitized in this spatial orientation. Images were then 
analyzed using CADIA (Fig. 6.3).  
 
Micro-CT Analysis: Bone core specimens were scanned with 18x18x18um3 voxel and 
2x2 binning sizes. For beam filtration, 0.01 in. aluminum was used in front of the x-ray 
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source and polymethylmethacrylate (PMMA) bath-block was placed surrounding the 
sample in the PBS chamber, for prevention of beam hardening phenomena and 
equalization of the x-ray beam, respectively. The voltage and current were 80kV and 
80uA. The region of interest (ROI) consisted of a 0.5mm thick and 6.0mm long hollow 
tube-shaped. ROI and original entire bone cores were analyzed volumetrically from 
apical to coronal sites. The assessment of 0.5mm thick outer layer samples was used to 
represent the osseous structure that surrounded the implants placed following bone core 
harvesting. The entire bone core measurements represent the mineralized tissue present in 
each biopsy (Fig. 6.4). 
 
Histologic Processing and Analysis - Pictures were taken of each bone core biopsy prior 
to processing. The cores were demineralized in 10% formic acid to remove the calcium; 
dehydrated in a series of graded alcohols (Clear Rite, Richard Allen); and then embedded 
in glycol methacrylate (JB-4, PolySciences Inc.). Each core was cut into 5 µm sections, 
mounted on slides, and stained with Hematoxin & Eosin. The central most section of the 
bone cores was chosen for histomorphometric analysis. The sample was examined after 
its length was subdivided into 1.5mm long sections from the coronal to the apical portion 
of the core in a saggital orientation. The same sections were also divided longitudinally 
into 3 zones. Zones 1 and 2 represent the outer 0.5 mm layer, while zone 3 represents the 
innermost cylinder of bone. This histomorphometric approach was considered given that 
the most external layer, in relation to the inner core, more closely represents the bone 
quality of the bone in which the implant fixture will subsequently engage. The area of the 
analyzed section/layer was then divided by its total value in order to measure the bone 
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fraction area using image analysis (Image-Pro Plus). Total bone fraction areas for each 
sample and the mean SD of all samples is also included, as previously reported18. (Fig. 
6.5) 
 
Statistical Analysis - The data was analyzed on a per subject basis. Mean values of each 
parameter were calculated for each subject and each site at all time points and averaged 
within a subject and then across subjects. 
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6.4. RESULTS 
Demographics – Mean age of research subjects was 47.7 y/o (range: 25-64 y/o). Six 
females and 4 males were included in this study. 
 
Clinical Measurements – Table 1 shows pre- and post-treatment values of all clinical 
parameters. 
Mean buccal plate thickness at baseline was 1.12mm (range: 0.5-2.0 mm). Study sites 
showed mean horizontal neogenesis of 7.7 mm (buccal to lingual) and 4.6 mm (mesial to 
distal). Vertical bone neogenesis measured 12 weeks following exodontia showed a mean 
value of 10.9 mm. Insignificant changes in ridge dimensions were observed at re-entry. 
 
Subtraction Radiography – The position of the crestal bone at the center of the extraction 
socket appeared to be, on average, 2.1mm below its original position (range: 0.7 - 
4.3mm). Subtracted images of the area of the extraction sockets revealed 13.5% of mean 
changes (STD: 0.27%) from baseline to 12 weeks, resulting in a mean value of 86.5% of 
radiographic bone fill. 
 
Micro-CT – Statistically significant differences with the entire bone core measurements 
of bone volume fraction (BVF) and bone mineral density (BMD) were observed. 
However, in the outer layer measurement, there was no significant difference (Table 6.1). 
The statistical comparison between entire bone core measurements and outer layer 
measurements demonstrated that even though the inner zone (1.7 mm inner-diameter) of 
the bone core still had relatively different mineralization, the outer zone already had well-
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mineralized tissue formations on the most coronal 6.0 mm. Therefore, based on micro-CT 
analysis it is clear that the collagen membrane used in this study successfully prevented 
epithelial down growth into the extraction socket, maximizing bone formation (Fig. 6.6). 
 
Histomorphometry – Mean vital bone values for each section were the following: S1 = 
46.34%. (+13.08%), S2 = 46.11% (+13.79%), S3 = 49.22% (+14.67%), and S4 = 50.47% 
(+10.89%). When these values were combined and divided by the number of section, the 
total mean percentage of vital bone was 45.87% (+12.35%). Mean vital bone values for 
the external and internal layers of the cores were 47.96% (+15.42%) and 44.24% 
(+10.46%), respectively. When these values were combined and divided by the number 
of layers, the total mean percentage of vital bone was 46.09% + 12.47%. These values are 
schematically represented. It is not clear from the statistical analysis used whether the 
bone quality was superior in the apical or in the coronal portion of the regenerated bone. 
However, it is evident that a higher bone fraction area was encountered in the external 
layer when compared to the inner core, suggesting the possibility that the overall bone 
fraction area of the whole sample might indeed be lower that that of the bone surrounding 
a dental implant (Fig. 6.6). 
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4-A.5. DISCUSSION 
Tooth extraction results in alveolar bone loss due to resorption of the edentulous ridge 
[19-22]. An average of 40-60% of original height and width is expected to be lost after 
tooth extraction, with the greatest loss occurring during the first 2 years [23-27]. This can 
negatively influence bone volume that is needed for future dental implant placement. 
Research has demonstrated that the alveolar ridge in the maxillary anterior area can be 
reduced by 23% in the first 6 months after exodontia, and an additional 11% in the 
following 5 years [8]. In the posterior mandible, resorption happens primarily in the 
buccal/labial direction, resulting in a lingual displacement of the alveolar crest8. The rate 
of reduction of residual alveolar ridges has shown to be greater in mandibular (0.4 
mm/year) than in maxillary arches (0.1 mm/year) [28]. As a consequence, alveolar ridge 
atrophy may prohibit optimal implant placement, compromising the final esthetic and 
functional outcomes [29].  
 
Alveolar ridge preservation (a.k.a., socket preservation; socket augmentation) has been 
evaluated in many studies [9-11]. Multiple bone grafting regimens and techniques have 
been suggested to limit alveolar ridge atrophy, and to evaluate the osteogenic capacity of 
extraction sockets [30-32]. Generally, these procedures are primarily aimed at 
maintaining current bone level and secondarily, regenerating new bone [15]. Studies have 
also shown negative results when alveolar ridge preservation was attempted, possibly due 
to utilization of inadequate techniques and/or materials [33-36]. For example, Zubillaga 
et al. (2003) evaluated a combination of demineralized freeze-dried bone allograft and a 
bioresorbable membrane for socket augmentation. The negative results observed were 
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attributed to the slow resorption of the gelatin carrier of the graft material and possible 
inhibition of new bone formation [36]. Hence, utilization of certain materials may in fact 
inhibit tissue neogenesis. Other forms of bone grafting materials have also been 
suggested for this purpose. However, the need to fill an extraction socket following 
exodontia is controversial. This study intended to better understand the healing of 
extraction sockets without grafting materials by maximizing the healing potential that 
these defects have. Research has demonstrated the utility of resorbable and non-
resorbable barrier membranes in preserving alveolar ridges following tooth extraction 
[37-43]. When combined with barrier membranes, bone graft materials have also shown 
to prevent collapse of the barrier membrane [43-49]. This study failed to support this 
hypothesis since it demonstrated that the clot that is formed following tooth extraction 
appears to prevent membrane collapse in this type of osseous defect. 
 
This study aimed to describe tissue neogenesis following exodontia, when the extraction 
site was protected from epithelial down growth using a collagen membrane, following a 
controlled and detailed analysis. Collagen membranes are preferable due to their 
resorbable property that eliminates membrane retrieval procedures and are highly 
biocompatible with the surrounding oral tissues [50, 51]. The device evaluated in this 
study is a resorbable porcine-derived collagen membrane, which is manufactured using a 
special cross-linking technology that utilizes a sugar-based agent, as opposed to 
chemicals (glutaraldehyde) or physical techniques (UV or gamma irradiation). The 
nonenzymatic glycation process provides ability to control biodurability of the barrier 
membrane for 4-6 months, allowing sufficient time for osseous defects to achieve optimal 
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bone regeneration. Evidence of this capacity was noted since all sites showed some 
remnants of this barrier at re-entry. No adverse events (i.e. membrane exposure, infection) 
following GBR therapy were noted throughout the study and the device used appeared to 
be well tolerated clinically and histologically during the healing process of all subjects. It 
has been suggested in the literature that the device used in this study possesses ossifying 
properties [52, 53]. Despite the excellent handling and barrier properties demonstrated in 
this study, no signs of membrane ossification were identified. In order to evaluate tissue 
neogenesis in extraction sites in a controlled manner, it is important to attempt to 
standardize the size of the osseous defects and the location of these defects in the dental 
arches. The maxillary premolar region was selected for its consistent root length, 
common need for tooth replacement, and anatomical features that would allow 
reproducibility of study-related procedures. Table 4-A.1 demonstrates that a short range 
of defect sizes was observed. It is unclear if significant differences in terms of tissue 
neogenesis exist when maxillary and mandibular sites arecompared, but it can be 
hypothesized that differences may exist due to morphometric characteristics of 
mandibular and maxillary alveolar bone. Hence, in order to exclude a possible variable, 
only maxillary sites were included. 
 
Given the importance of landmarks for clinical measures, occlusal guides were utilized, 
using a supposedly fixed reference point (occlusal surface of adjacent teeth). This device 
allows the examiner to simply slide the probe through groves, allowing measurement to 
be recorded from the exact same location and angulations. Clinical measurement revealed 
insignificant morphologic changes from baseline to re-entry procedures. It is important to 
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emphasize that all sites presented with intact socket walls following exodontia. A 
common factor known to limit the healing potential of extraction sockets and to indicate 
the use of bone grafting materials for ridge preservation, is the absence or the thickness of 
the buccal plate of the socket [54-56]. Despite the reduced mean thickness of the buccal 
plates (1.12 mm) evaluated, ridge dimensions were preserved and new bone formation 
occurred. It can be hypothesized however, that less favorable results should be expected 
when only a barrier membrane is used and one or more socket walls are missing.  
 
Radiographic analysis of bone formation is limited by the two-dimensional nature of 
radiographs. When a series of radiographs is compared, it becomes difficult to determine 
if changes have occurred, mainly due to differences in film positioning and angulations. 
To compensate for these limitations, standardized radiographs were used in this study. A 
radiographic film holder was created for each subject, and the same device was used for 
additional radiographs. Subtraction radiography revealed that this method of radiographic 
standardization is valid, since comparable images were obtained. When images were 
compared, the follow-up position of the crestal bone at the center of the defect appeared 
to be in average, 2.1mm below its original position. Previous studies have reported 
similar findings [57-59]. What is important to note is that the mean degree ofradiopacity 
within the socket at 12 weeks compared to the radiopacity of the surrounding alveolar 
bone showed 86.5% percentage of bone fill. This is a significant finding since no bone 
substitutes were used in this study, although for ethical reasons only contained lesions 
were selected for treatment. 
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Histomorphometric analysis of bone cores has been used to evaluate bone quality, and 
particularly the percentage of vital bone, when bone substitutes were used [59]. In this 
study, a more detailed evaluation was performed. Bone cores were harvested using a 
flapless approach to obtain a detailed observation of the bone/soft tissue interface and to 
detect changes in bone quality along an apical-coronal axis. Hence, slides were divided in 
1.5mm sections, with each section being analyzed independently. Surprisingly, no 
significant differences were observed, meaning that a very homogenous pattern of 
neogenesis was observed within the entire bone core. An additional evaluation was 
performed, by stratifying the bone cores in outer and inner layers. A significant 
difference was observed, which supports the knowledge that tissue neogenesis in an 
extraction site is mostly originated from the socket walls rather than the apical region. 
Based on the nature of tissue neogenesis following exodontia, analysis of the entire core 
may underestimate the quality and the composition of the newly formed tissue. Hence, a 
more detailed evaluation of these bone cores was performed using micro-CT images. 
This technology enables a three-dimensional evaluation of the entire core, instead of only 
a slide. Micro-CT confirmed the finding of histomorphometry, with more mineralization 
present on the outer layers of the core. This is a significant finding since it may better 
represent the area of interest, i.e., the alveolar bone immediately adjacent to the location 
of the biopsy harvest (zone adjacent to implant-anchoring osseous support). It is 
important to emphasize that these biopsies were composed of newly formed bone from a 
protected blood clot, and not from graft particles that became incorporated into newly 
developed mineralized tissue. Graft particles undergo a slow process of resorption, which 
may or may not be followed by new bone formation. 
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6.6. CONCLUSIONS 
Based on these results it can be concluded that a detailed analysis of tissue neogenesis in 
extraction sites protected by a barrier membrane has demonstrated that adequate bone 
tissue formation for implant placement occurs as early as 12 weeks following exodontia, 
with minimal changes in alveolar ridge dimensions. No signs of membrane ossification 
were observed. 
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6.7. FIGURES 
 
Figure 6.1. Timeline of study procedures in months. (0) Tooth extraction, alveolar 
ridge preservation and initial measurements; (3) Re-entry procedures including core 
biopsy and implant placement; (7) Implant restoration; (13) Final follow-up appointment. 
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Figure 6.2. Steps of clinical assessment of GBR therapy for extraction sockets.  (A) 
Baseline; (B) Atraumatic exodontias; (C) Flap elevated for clinical measurements; (D) 
Barrier membrane placed over the socket; (E) Flap advancement for primary wound 
coverage; (F) 12-week follow-up; (G) Flapless core biopsy; (H) Re-entry for second 
clinical measurements.  
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Figure 6.3. Subtraction radiography. (A) Standardized digital radiograph immediately 
following tooth extraction; (B) 12-week follow-up radiograph; (C) Subtracted image. 
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Figure 6.4. Micro-CT analysis. (A) Bone core biopsy harvested with a flapless approach; 
(B) corresponding micro-CT image. 
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Figure 6.5. Histomorphometry. (A) Original image; (B) 1.5mm sections; (C) sectional 
histomorphometry; (D) outer and inner layers; (E) longitudinal histomorphometry. 
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Figure 6.6. GBR promotes bone repair as measured histomorphometrically. (A) 
Bone volume fraction for the entire bone core (red) and the outer 0.5mm (blue); (B) bone 
mineral density for the entire bone core (red) and the outer 0.5mm (blue); (C() percentage 
of vital bone on each 1.5mm section (1=most coronal, 4=most apical); (D) mean values 
for outer (1) and inner (2) layers. 
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6.8. TABLE 
 
Table 6.1. Clinical open bone measurements following GBR of contained extraction 
sockets. 
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7.1. ABSTRACT 
There has been increased interest in the therapeutic potential of bone marrow derived 
cells for tissue engineering applications. Bone repair cells (BRCs) represent a unique cell 
population generated via an ex vivo, closed-system, automated cell expansion process, to 
drive the propagation of highly osteogenic and angiogenic cells for bone engineering 
applications. The aims of this study were (1) to evaluate the in vitro osteogenic and 
angiogenic potential of BRCs, and (2) to evaluate the bone and vascular regenerative 
potential of BRCs in a craniofacial clinical application. BRCs were produced from bone 
marrow aspirates and their phenotypes and multipotent potential characterized. Flow 
cytometry demonstrated that BRCs were enriched for mesenchymal and vascular 
phenotypes. Alkaline phosphatase and von Kossa staining were performed to assess 
osteogenic differentiation, and reverse transcriptase-polymerase chain reaction was used 
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to determine the expression levels of bone specific factors. Angiogenic differentiation 
was determined through in vitro formation of tube-like structures and fluorescent labeling 
of endothelial cells. Finally, 6 weeks after BRC transplantation into a human jawbone 
defect, a biopsy of the regenerated site revealed highly vascularized, mineralized bone 
tissue formation. Taken together, these data provide evidence for the multilineage and 
clinical potential of BRCs for craniofacial regeneration. 
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7.2. INTRODUCTION 
The demand for tissue replacements has led to the emergence and significant expansion 
of the field of tissue engineering [1]. Craniofacial regenerative medicine applications 
have demonstrated significant impacts for oral soft and hard tissue repair [2, 3]. In 
preclinical model systems, multipotent cells derived from bone marrow have become a 
popular source of cells for regenerating bone, ligament, tendon, and cartilage [4-8]. More 
recently, autologous grafts utilizing various formulations of bone marrow or bone-
marrow-derived cells have been investigated in clinical studies for skeletal bone repair [9, 
10] and craniofacial regeneration [11-14]. Although there has been modest success 
achieved in these approaches, major limitations still include crude isolation techniques 
and poorly defined cell preparations appropriate for grafting, inability to produce 
sufficient cell numbers for transplantation without multiple passages in traditional open 
tissue culture systems, and a lack of identification of an ideal cell type or cell population 
for transplantation. Despite the specific limitations of currently defined cell isolation and 
preparation protocols, an overarching challenge common to all cell and tissue 
transplantation strategies is the inability to produce a supportive vasculature for graft 
incorporation and cell survival. 
 
It has been well-established that key to the development of bone tissue is not only the 
formation of bone but also the coordinated development of a supportive blood supply 
[15]. Thus, when employing cell transplantation strategies, not only does the 
osteoprogenitor cell type need to be considered, but formation of a functional vasculature 
to support cell viability and maturation of the tissue warrants serious consideration as 
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well. As a result, some strategies used to engineer and regenerate bone tissue employ 
cotransplantation of osteoprogenitor cells with either hematopoietic or endothelial cells to 
help establish a supportive blood supply to the transplanted cells [16- 19]. Although these 
approaches all hold great promise, it would be more desirable to transplant a cell 
population that contains cells capable of establishing both a blood supply and 
regenerating bone. 
 
An automated cell-manufacturing process has been developed that utilizes a single-pass 
perfusion (SPP) process; this enables a clinical-scale expansion of autologous, primary, 
human bone repair cells (BRCs) derived from bone marrow. In SPP, the culture medium 
is continuously replaced with a fresh medium at a slow, controlled rate without the 
disturbance, removal, or passaging of cells. This technology results in significant 
expansion of primary human cells [20, 21] and has previously demonstrated clinical 
success in the expansion of bone marrow and blood cells for replenishment of 
hematopoietic cells after treatment of various blood dyscrasias [22-25]. Additionally, 
results of recent in vitro and in vivo studies have generated interest in using this process 
to produce cells for bone tissue regeneration [26].  
 
The hypothesis underlying the current study is that BRCs have osteogenic and angiogenic 
potential that could manifest in their ability to regenerate bone and vascular tissue in a 
clinical craniofacial application. To address this hypothesis, we aimed to first examine 
the multipotency of BRCs in vitro, with particular emphasis on elucidation of their 
angiogenic and osteogenic capacities. Second, we sought to determine if BRCs could 
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form bone and accelerate osteogenesis clinically when implanted within an osseous 
defect in the jaw. 
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7.3. MATERIALS AND METHODS 
4-B.3.1. Bone marrow harvest and BRC production  
The production of BRCs has been previously described [26]. Briefly, after U.S. Food and 
Drug Administration (FDA) and University of Michigan Institutional Review Board 
approval, 10 healthy subjects giving informed consent underwent a bone marrow 
aspiration of the posterior ilium under conscious sedation and local anesthetic. Of these 
10 subjects, where indicated, subsets of them (marrow) were used for phenotypic 
characterization of cells. Collected marrow was transferred to a sterile blood bag and 
bone marrow mononuclear cells (BMMNCs) were purified by Ficoll density gradient 
centrifugation. BMMNCs were then inoculated into a bioreactor, which is a proprietary 
computer-controlled, automated cell-processing unit, the Aastrom Replicell® System 
(Aastrom Biosciences). The Cell Cassette within this system provides a functionally 
closed, sterile environment in which cell production occurs. The fluid pathway in the Cell 
Cassette includes the cell growth chamber, a medium supply container, a mechanism for 
medium delivery, a waste medium collection container, and a container for the collection 
of harvested cells. All components are interconnected with sterile barrier elements 
throughout to protect the culture from contamination during use. The culture medium 
consists of Iscove's modified Dulbecco's medium, 10% fetal bovine serum, 10% horse 
serum, and 5 µM hydrocortisone. This system incorporates SPP in which a fresh medium 
flows slowly over cells without retention of waste metabolites or differentiating cytokines 
[20]. In-process safety test (absence of bacterial and fungal contaminants and endotoxins) 
was conducted on an sampled effluent medium at 48 h before harvest. After cultivation 
for 12 days at 37°C and 5% CO2, the BRC product was harvested by trypsinization, 
washed in a physiologic buffer, and collected into a sterile bag and resuspended in Isolyte 
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and 0.5% human serum albumin, where it was stored until the time of transplantation Fig. 
4-B.1). Sterility, endotoxin, and mycoplasma testing were all conducted on the BRCs. 
 
The Replicell System is an automated one-cycle system that requires the input to be 
derived from fresh bone marrow aspirates; as a result, once BRCs are removed from the 
system, it is not possible to regrow or resume culture of cells within this same system. 
Thus, further culture of BRCs for in vitro assays required conventional tissue culturing 
techniques in both experimental and control conditions. Excess BRC product not utilized 
for transplantation was cultured in a medium consistent with culture of bone-marrow-
derived stem cells [27], consisting of minimum essential alpha medium (αMEM) (Gibco–
Invitrogen #12571) with 15% fetal bovine serum (Gibco-Invitrogen-16000), 100 µM 
ascorbic acid 2 phosphate (Sigma A-8960), and 5 µg/mL Gentamicin (Invitrogen 
#15750060), and grown in a 37°C humidified tissue culture incubator under 5% CO2. 
This medium was used for control conditions (without incorporation of 
differentiation/inductive factors) in the in vitro assays and it should also be noted that this 
open culture system and media used were distinctly different from those used to produce 
the BRC product. Cell culture media were changed every 2 or 3 days. Cells were grown 
in T-150 flasks to 80% confluence, followed by cell washing with phosphate-buffered 
saline (PBS) and trypsinization before being split into 12-well plates or 60 mm tissue 
culture dishes for differentiation assays. 
 
7.3.2. Flow cytometry  
Phenotypic comparison of cell surface marker expression was made between the starting 
BMMNCs and the final BRC product from a subset of four subjects who had marrow 
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harvested for generation of BRCs. Flow cytometry was performed on the same day of 
isolation of the BMMNCs and immediately after production of BRCs (i.e., neither 
BMMNCs nor BRCs were cultured, as described in the Cell Culture section, before 
performance of the flow cytometry). BMMNCs or BRCs were washed and resuspended 
in 1× Dulbecco's PBS (Gibco) containing 1% bovine serum albumin. Samples were Fc 
receptor blocked with normal mouse IgG for approximately 10 min. Tubes containing 0.5
× 106 cells in approximately 0.1 mL were then stained at 2°C–8°C with phycoerythrin (PE) 
or PE cyanin 5-conjugated anti-CD90 (Thy1) antibodies, PE-conjugated anti-CD11b, 
anti-Gly-A, anti-CD34, anti-AC133, anti-CD19, anti-vascular endothelial growth factor 
(VEGF)R1, anti-Tie2, anti-CD145, fluourescein isothyocyanate-conjugated anti-CD66b, 
anti-CD14, anti-CD45, anti-CD3, anti-CD144 antibodies, and PE cyanin 5-conjugated 
anti-CXCR4 (CD184) (Beckman Coulter). After 15 min, cells were washed and 
resuspended in 0.5 mL PBS/bovine serum albumin for analysis on the Epics XL-MCL 
(Beckman Coulter) or FC500 flow cytometer. 
 
7.3.3. In vitro multilineage differentiation  
Multipotency of BRC cultures was determined by in vitro differentiation assays of 
osteogenesis, chondrogenesis, and adipogenesis. BRCs were plated at a density of 30,000 
cells per well in 12-well plates. At >90% confluency, cells were induced, according to 
previously described protocols [28], with osteogenic (BRC medium including 5 mM β-
glycerol phosphate, 100 nM dexamethasone, and 50 µM ascorbic acid 2-phosphate), 
chondrogenic (BRC medium including 50 µM ascorbic acid 2-phosphate, 100 nM 
dexamethasone, 5 µg/mL human insulin, 1 ng/mL transforming growth factor-β, 400 µM 
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proline, and 1× Nonessential amino acids), or adipogenic (BRC medium including 0.5
mM isobutylmethylxanthine, 1 µM dexamethasone, 10 µg/mL human insulin, and 200 µM 
indomethacin) medium. BRCs were grown at 37°C in a humidified 5% CO2 incubator. 
The medium was changed every 2–3 days. After 2 weeks, the cells were fixed and stained 
as outlined below. 
 
7.3.4. Mesenchymal differentiation staining  
To detect chondrogenic differentiation, induced BRCs were fixed in cold 100% methanol 
for 30 min and then exposed to 1% Alcian blue in 0.1 N HCl for 30 min. Cells were 
washed twice with 0.1 N HCl. Cells in PBS were viewed or stored at 4°C. 
 
To detect mineralized matrix formation indicative of osteogenic differentiation, induced 
BRCs were fixed in 4% paraformaldehyde for 30 min, immersed in fresh 5% silver nitrate, 
and incubated in the dark for 30 min. After washing in water, the BRCs were exposed to 
ultraviolet light for 30 min followed by a 4-min incubation in 1% sodium thiosulfate to 
neutralize the silver nitrate. Cells were washed and stored in PBS at 4°C. 
 
To detect adipogenic differentiation by identifying lipid vesicles, induced BRCs were 
fixed in 4% paraformaldehyde for 30 min and then immersed in 0.3% Oil Red O solution 
(in isopropanol) for 30 min. Cells were washed and stored in PBS at 4°C. 
 
7.3.5. Alkaline phosphatase activity and detection  
Early osteogenic differentiation was detected and quantified by alkaline phosphatase 
(ALP) staining and ALP enzyme assays. ALP activity was confirmed with reverse 
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transcriptase–polymerase chain reaction (PCR). Cells were plated at a density of 30,000 
cells per well in 12-well plates. At 80% confluence, cells were induced with the 
osteogenic medium as described above. The medium was changed every 2–3 days and 
after 1 week, and ALP activity was measured. 
 
To detect ALP activity, the BRCs were fixed in 70% ethanol for 30 min. They were then 
incubated with freshly made substrate containing naphthol AS-TR phosphate (Sigma) and 
Fast blue for 30 min. Cells were washed twice with PBS and then viewed or stored at 4°C. 
 
To quantify the ALP activity and normalize the results, BRCs were lysed in Passive Lysis 
Buffer (Promega) according to manufacturer's instructions. Cell lysates were then 
sonicated, and centrifuged (10,000 rpm for 10 min at 4°C). The supernatant was 
recovered for the quantitative colormetric ALP assay [29], and the cell pellet was used 
for DNA isolation and the determination of the DNA concentration using the Quant-iT™ 
dsDNA BR Assay (Invitrogen) per the manufacturer's instructions. 
 
7.3.6. Reverse transcriptase–PCR  
To further confirm osteogenic differentiation, after 1 week of osteogenic induction total 
BRC cellular RNA was extracted, reverse transcribed, and amplified using osteoblast-
specific gene primers: Runx2, osteocalcin (OCN), and bone sialoprotein (BSP). Media 
from the wells of induced BRCs were aspirated. Cells were immediately resuspended in 1
mL of Trizol (Invitrogen) and RNA was isolated according to the manufacturer's 
instructions. cDNA was synthesized using Invitrogen's SuperScriptII kit and oligo dT. 
PCR reaction components and concentrations were as described in the Invitrogen 
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Platinum Taq polymerase instructions using the primer sets below. An MJ themorcycler 
(MJ Resarch Model PTC-200) was used for the two PCR reaction conditions (Table 7.1). 
 
7.3.7. Angiogenic potential  
The angiogenic potential of BRCs was investigated through the fluorescent labeling of 
endothelial cells and capillary tube formation in culture. Collagen culture dishes were 
prepared by dispensing 2.5 mL of an ice-cold collagen solution, containing 2.4 mg/mL 
PureCol® bovine collagen (Advanced BioMatrix) in PBS at pH 7.4 into 60 mm plates. 
Collagen plates were solidified at 37°C for 90 min and then equilibrated in the growth 
medium for 2 h. BRC cultures were plated with 200,000 BRCs and incubated overnight at 
37°C. One day after plating the cells, the medium was changed with a medium containing 
50 ng/mL VEGF (R&D #293-VE). The medium was changed every 2–3 days. After 1 
week, cells were fed the medium containing 10 µg/mL fluorescently labeled lipoprotein 
(DiI-Ac-LDL; Biomedical Technologies) for 4 h at 37°C to specifically label the 
endothelial cells. The medium was aspirated and the cells were washed three times with 
PBS before being fixed in 4% paraformaldehyde for 60 min. After fixing, the cells were 
washed three times with water before 3 mL of PBS was added to each plate, and then 
viewed or stored at 4°C. 
 
To measure angiogenic cytokine production, BRCs from a subset of eight subjects were 
centrifuged to pellet the cells, and resuspended in X-Vivo 15 (Lonza) medium. X-Vivo 
15 is a serum-free medium that was used in these assays to eliminate potential serum 
interference and nonspecific binding with some of the reagents (i.e., lack of human 
specific antibodies) used in the assays. All fractions were quantified and diluted to 1× 106 
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mL−1 in X-VIVO 15 medium. The cells (100 µL) were added to the wells of a 96-well 
round-bottom plate in triplicate. The culture medium alone or supplemented with 300
ng/mL endotoxin lipopolysaccharide was added in a volume of 50 µL to all wells. Twent-
four hours later, 100 µL of supernatant from each well was collected and stored at −70°C 
until analysis. Human Cytokine/Chemokine LINCOplex kits (Millipore Corporation) 
were used for multiplex analysis of VEGF and IL-8 concentrations in BRC supernatant 
fluids. The kits were used for cytokine determination as defined by the manufacturer's 
protocol (HCYTO-60K-Rev. 12/07/05) located at the following link: 
 
www.millipore.com/userguides.nsf/a73664f9f981af8c852569b9005b4eee/09dc59783f6430ab85257259004
f0203/$FILE/hcyto-60k.pdf. 
 
ELISA kits (R&D Systems) were used to quantify the individual analytes Tie-1 and Tie-2 
according to the manufacturer's protocol. 
 
7.3.8. Surgical transplantation of BRCs to a localized craniofacial osseous defect  
A nonrestorable tooth was extracted under local anesthesia from a patient in need of tooth 
extraction due to dental decay and periodontal disease associated with the tooth. Due to 
the preexisting condition of the tooth, its removal resulted in an area of a localized bone 
defect. According to a protocol approved by the U.S. FDA and the University of 
Michigan's Institutional Review Board, a full-thickness mucoperiosteal flap was elevated 
for access and hemostasis of the surgical defect achieved. One milliliter of the BRC cell 
suspension (approximately 1.5 × 107 cells/mL) was absorbed onto a gelatin sponge 
(Gelfoam; Pfizer) sized to a dimension of 2 cm3. The sponge was then transplanted into 
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the extraction site to the level of the interproximal bone. The flap was then coronally 
repositioned, and a bioabsorbable collagen barrier membrane (Biomend®; Zimmer Dental) 
was placed over the sponge to contain the cell construct. The tissues were approximated 
and closed with a 4-0 bioabsorbable suture material. The subject was prescribed 500 mg 
amoxicillin, three times a day (t.i.d.) for 7 days, decreasing doses of dexamethasone (8, 4, 
2, 2 mg) for 4 days, and 600 mg Ibuprofen four times a day (q.i.d.) for 3 days. Surgical 
reentry of the treated osseous defect was performed 6 weeks postsurgery, and a bone core 
of 2× 7 mm was harvested with a trephine drill (Ace Surgical Supply Co., Inc.). To 
ensure harvesting of bone from the area where the BRCs were grafted, pre- and 
postsurgical measurement templates were used to identify the area corresponding to the 
center of the previous extraction socket. The core was prepared for microcomputed 
tomography (µCT) imaging and descriptive histological evaluation. 
 
7.3.9. µCT and histology  
The nondecalcified core was captured with the scanning direction parallel to the 
longitudinal axis of the core specimen. High-resolution scanning with an in-plane pixel 
size and slice thickness of 24 µm was performed. To cover the entire thickness of the 
bone core biopsy, the number of slices was set at 400. GEMS MicroView® software was 
used to make three-dimensional (3D) reconstructions from the set of scans as previously 
described [30]. 
  
After scanning, the core was decalcified for 2 weeks in 10% ethylenediaminetetraacetic 
acid. After decalcification, the core was transferred to 70% ethanol stored at 4°C until 
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ready for embedding in paraffin. Standard hematoxylin and eosin staining was performed 
to assess bone morphology and blood vessel formation. 
 
7.3.10. Statistical analysis  
Statistical analysis was performed with the use of Instat software (GraphPad Software). 
All data were plotted as mean ± standard error of the mean, unless otherwise noted. 
Statistically significant differences were determined by two-tailed Student's t-tests, and 
statistical significance was defined as p < 0.05. 
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7.4. RESULTS 
7.4.1. Phenotypic characterization of BRC population  
For all BRC formulations produced after cell processing, flow cytometry was performed 
to characterize the phenotype of the BRCs, and in some instances, the initial BMMNCs 
were also assessed before production of BRCs. For 10 subjects from whom BRCs were 
produced, including the subject treated with BRCs in this study, cell surface marker 
expression of the final BRC product is shown (Table 7.2). There are high percentages of 
CD31+, CD90+ (Thy1), and CD105+ cells. When compared to cell surface marker 
expression from typical BMMNC fractions used to produce these cells (unpublished 
proprietary data), CD90+ (Thy1) and CD105+ are highly enriched in the BRC product. 
 
7.4.2. Mesenchymal potential of BRCs  
BRCs were assessed for their capacity to differentiate toward different cellular lineages 
after culture under adipogenic, chondrogenic, and osteogenic conditions. After 2 weeks 
of culture, BRCs were subjected to Oil Red O, Alcian blue, and von Kossa staining. In 
control culture conditions, Oil Red O, Alcian blue, and von Kossa staining were all 
negative. In adipogenic conditions, Oil Red O staining was used to detect intracellular 
lipid-rich vacuoles and morphological changes in cell shape. The results confirmed that 
cells were differentiated toward an adipogenic lineage (Fig. 7.2a). Similarly, in cells 
grown under chondrogenic conditions, the presence of chondrogenic proteoglycans was 
indicated by positive Alcian blue staining (Fig. 7.2a), confirming chondrogenic 
differentiation. Under osteogenic culture conditions, deposition of mineralized matrix 
indicative of osteoblasts was evident through positive von Kossa staining (Fig. 7.2a). To 
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further evaluate osteogenic differentiation, alkaline phophatase activity was also analyzed 
qualitatively and quantitatively after 1 week of culture in osteogenic conditions (Fig. 
7.2b). With ALP staining, there was a significantly more robust and widespread degree of 
staining in the osteogenic conditions relative to the control culture conditions. When this 
difference was measured quantitatively, there was a significant threefold increase (p <
0.05) in ALP activity in osteogenic relative to control conditions. Commitment toward an 
osteogenic lineage was further confirmed through gene expression of Runx2, OCN, and 
BSP (Fig. 7.2c), and although Runx2 was expressed at a lower level in the control 
condition (data not shown), OCN and BSP were not detectable in control conditions at 
this timepoint. 
 
7.4.3. Angiogenic potential of BRCs  
In addition to standard phenotypic marker characterization of the final BRC product 
(shown from 10 patients treated with BRCs in Table 7.2), further analysis was performed 
on BRC products produced from smaller subsets of healthy volunteer subjects who 
provided donor marrow specifically to evaluate marker expression of angiogenic 
phenotypes. First, phenotypic comparison of cell surface marker expression was made 
between the starting BMMNCs and the final BRC product from a subset of four subjects. 
After expansion of the BMMNCs using the BRC process, the enrichment of vascular 
phenotypes in BRCs is shown in Table 7.3. Cell surface expression of vascular 
phenotypes associated with endothelial cells (Angiopoietin and flt1) and pericytes 
(Thy1+ and MUC-18) are all highly enriched. Next, when BRCs from a subset of eight 
volunteer donors (from the 10) were cultured in a medium (X-VIVO) without addition of 
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VEGF, cells were shown to produce appreciable levels of potent angiogenic cytokines 
VEGF, and angiopoietin (Ang)-1 and -2 (Fig. 7.3a). It should be noted that none of these 
cytokines were detected in the supernatant from the initial BMMNCs used to produce 
BRCs. Another angiogenic cytokine, interleukin-8 (Il-8), was produced by BRCs at a 
concentration (7.5 ng/mL/100,000 cells) significantly higher than that in the initial 
BMMNCs (4.6 ng/mL/100,000). 
 
To examine the differentiation of BRCs into endothelial and vascular cells, BRCs were 
cultured in 3D collagen gels in the presence of VEGF. In these assays, VEGF is typically 
incorporated to induce endothelial cell differentiation [31-33]. Over the course of 1 week, 
cells elongated and formed spindle-like interconnecting structures resembling those seen 
by endothelial cells forming capillary tubes when grown under similar culture conditions 
(i.e., 3D extracellular matrices) (Fig. 7.3b). To further confirm the differentiation of 
BRCs into endothelial cells, a fluorescently labeled lipoprotein (DiI-Ac-LDL) that is 
metabolized specifically by endothelial cells was added to BRC 3D cultures. After 4 h of 
incubation with DiI-Ac-LDL, cells were examined under fluorescence microscopy and 
demonstrated uptake of the fluorescently labeled dye (Fig. 7.3c and 3d), characteristically 
seen by endothelial cells [34]. Taken together, these data demonstrate that BRCs have the 
capacity to differentiate into endothelial cells in 3D extracellular matrices and produce 
soluble angiogenic factors. 
 
7.4.4. Clinical osteogenic and vascular regenerative potential of BRCs  
The ultimate test of the osteogenic and angiogenic potential of BRCs is their ability to 
regenerate bone and vascular structures in a clinical model. To address this clinical 
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situation, we grafted BRCs into an osseous defect of the jawbone. After tooth extraction, 
a bone defect resulted in the area that the tooth previously occupied. The BRCs (in liquid 
suspension) were carefully placed (Fig. 7.4a) onto a resorbable material matrix (gelatin 
sponge) to the point of saturation (Fig. 7.4b). Cells were allowed 15 min to adhere to the 
gelatin sponge before their placement into the recipient graft site. After the extent of the 
bone defect (created as a result of tooth removal) was assessed (Fig. 7.4c), the sponge 
matrix containing the BRCs was grafted into the bone defect (Fig. 7.4d), a collagen 
membrane was placed for containment of the graft (Fig. 7.4e and 4f), and the area then 
closed with sutures and allowed to heal for 6 weeks. 
 
After 6 weeks of healing, the grafted defect site was reentered for examination of 
regenerated tissue and dental implant placement. Clinical examination revealed the 
appearance of bone tissue, with no evidence of the previous bone defect (Fig. 7.5a), and a 
core biopsy was harvested from the center of the area in which the BRCs were grafted. 
Upon retrieval of the specimen with the trephine drill, it was found that the tissue was 
very dense, indicative of mature bone tissue (Fig. 7.5b). The clinical appearance of the 
biopsy specimen clearly showed a highly vascular tissue that, consistent with retrieval of 
viable bone tissue, produced bleeding after harvest (Fig. 7.5c). µCT analysis was 
performed on the biopsied tissue, and 3D reconstruction of the specimen showed highly 
mineralized tissue throughout the entire length of the core (Fig. 7.5d). After this analysis, 
histology was performed on the specimen and hematoxylin and eosin staining clearly 
showed widespread distribution of mature bone tissue with an abundance of blood vessels 
distributed throughout (Fig. 7.5e). These results provide preliminary evidence that BRCs, 
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produced from BMMNCs, have the regenerative capacity to produce highly vascular 
bone tissue in a human craniofacial bone defect. 
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7.5. DISCUSSION 
Cell transplantation of stem cells has tremendous potential for craniofacial regenerative 
applications; yet, identification of the appropriate cell types and cell processing protocols 
are two of the most critical determinants in producing successful outcomes. In the present 
study, our aim was to assess the capacity of a cell production process, which utilizes an 
automated closed-system bioreactor, to produce clinical-scale numbers of autologous 
cells (BRCs) capable of regenerating clinically viable bone. Through cell surface marker 
characterization of BRCs, it was determined that the SPP ex vivo cell expansion 
processing of bone marrow aspirate was capable of producing cell populations highly 
enriched for mesenchymal and vascular progenitor cells. This was confirmed through cell 
characterization of BRCs, where cells within this heterogeneous population demonstrated 
the capacity to be induced to differentiate down chondrogenic, adipogenic, osteogenic, 
and angiogenic lineages. Finally, the test of the clinical regenerative capacity of BRCs 
demonstrated their ability to regenerate highly vascular bone in a human jawbone defect. 
 
The cell-processing system employed to produce these cells utilizes an SPP protocol [20, 
22, 25, 35]. Gastens et al. [35] examined this system and its ability to expand bone-
marrow-derived cells to produce clinical-scale cell numbers. These initial studies 
compared cell phenotypes of cells produced with this closed SPP system to phenotypes of 
cells cultured with an open system utilizing conventional tissue culture parameters. 
Although mesenchymal cell numbers were observed to be higher in cells cultured with 
the SPP closed system, the limitation of the study was that the initial BMMNC fractions 
tested in the two different systems came from different donors; thus, differences observed 
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between the final cell products could have been, at least in part, attributed to donor–donor 
variability. In the present study, although we did not compare cell populations from 
closed and open culture systems, we did compare BRCs directly to the phenotypes of the 
BMMNCs from which they were produced. The final BRC population showed marked 
enrichment for mesenchymal and vascular cell phenotypes, suggesting that for 
therapeutic regenerative strategies, the SPP process supports the production of a more 
favorable cell population for transplantation than protocols using transplants comprised 
of unfractioned, whole bone marrow. Although there is often a wide degree of variability 
in the phenotypic expression of these markers from donor to donor, the relative 
differences in cell phenotype before and after cell processing is consistent in that the final 
product is enriched in expression of mesenchymal and angiogenic phenotypes after cell 
processing with the SPP system. Additional studies need to be performed comparing cell 
phenotypes and differentiation potential of cells derived from the same donor, when 
processed with either this closed system or a traditional tissue culture open system 
technique. It is also important to note that although the objectives of the differentiation 
assays were to examine the osteogenic and angiogenic potential of the BRCs, it is not 
possible to regrow or resume culture of cells in the Replicell system once they have been 
removed from the system. As such, further culture of BRCs required conventional tissue 
culturing techniques. However, it is recognized that this additional culture step could 
have potentially resulted in a cell population not identical to the population produced 
from the Replicell system; yet, because the Replicell system is a closed system, there is 
not a viable alternative to performing or adapting the aforementioned assays to cells 
cultured while in the Replicell system. 
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The ability of the SPP process to form bone-forming cells has also been recently studied 
in vitro and in ectopic animal models [26]. In these studies, the levels of bone formation 
seen in vivo followed the same trends of the osteogenic differentiation observed in vitro. 
Additionally, cell surface markers, including CD90+ (Thy1) and CD105+ (endoglin), 
were positively correlated with ectopic bone formation in mice. CD105, originally 
identified as a marker of mesenchymal stem cells [36], has more recently been associated 
with vascular endothelium in angiogenic tissues [37] and expression of CD90 has been 
linked to bone marrow subpopulations of colony-forming mesenchymal stem cells (CFU-
F, colony-forming unit–fibroblasts) [38]. In our study, cell surface marker expression of 
BRCs from the subject who underwent cell transplantation in the bone defect showed 65-
fold and 5-fold increases in CD90+ and CD105+, respectively (data not shown). This 
served as an indication that the BRC product was highly enriched with cells possessing 
mesenchymal and angiogenic potential and is in accordance with previous reports 
demonstrating enrichment of theses cell types with this cell-processing protocol [26, 35]. 
  
Although the cell product is highly enriched for vascular and mesenchymal cells as 
indicated by cell surface marker expression and in vitro differentiation capacity, it is clear 
that in vitro osteogenic differentiation of cell populations does not guarantee bone-
forming capacity in vivo. Meijer et al. performed a clinical study evaluating the repair of 
jawbone defects in six subjects treated with autologous cells expanded using an open 
system [39], similar to the protocol used in traditional tissue culture of mesencyhmal 
stem cells [40, 41]. In this study, cells were cultured anywhere from 12 to 25 days before 
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implantation and the last 7 days in culture cells were grown on a mineral substrate, 
hydroxyapatite (HA) particles, in the presence of the osteoinductive agent dexamethasone. 
When cells grown under these osteogenic conditions were analyzed for their osteogenic 
capacity, all six bone marrow specimens produced cells capable of osteogenic 
differentiation in vitro (as determined by ALP expression) and bone formation in vivo 
(subcutaneous implants of HA/cell constructs in athymic mice). However, after 
implantation of these HA/cell constructs into various human jawbone defects of the six 
patients, biopsy specimens taken at 4 months showed that bone formation by implanted 
cells was able to regenerate bone in only one of the six patients treated. The authors made 
the important observation that in vitro osteogenic assays and bone formation in 
preclinical mouse models may not necessarily correlate to successful bone regeneration 
in the more challenging clinical applications. They concluded further that inadequate 
vascularity could have resulted in the reported disappointing outcome of the study [39]. 
In accordance with the authors' conclusion from this study, it is our belief that not only is 
vascularization from the host environment essential to clinical bone regeneration, but 
even further, that the angiogenic potential of the transplanted cells themselves should 
play an active role in this vascularization process. 
 
The BRCs used to treat the human jawbone defect in our study were not produced in the 
presence of any osteogenic factors, and a gelatin sponge (with no known osteoinductive 
or osteoconductive properties) was used as a carrier matrix to transplant the cells, as 
opposed to a mineralized matrix such as HA. Additionally, the biopsy specimen 
harvested at 6 weeks showed significant new bone formation containing abundant blood 
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vessels. Although no direct evidence (i.e., labeling) is provided relative to the source of 
cells that produced the regenerated tissue, we make the assumption that the transplanted 
cells at least partly contributed to the regeneration because the bone core specimen 
analyzed was harvested from the central region of the defect and graft site. We were able 
to identify this exact region through the use of surgical measurement templates/guides. 
Yet, even still, despite these promising clinical results, the fact that they were obtained in 
a single patient can be viewed as a study limitation and minimizes the general 
conclusions that can be drawn. An additional note is that this case presentation is part of a 
larger, U.S. FDA-regulated, randomized, controlled Phase I/II trial where a larger number 
of patients are to be treated with BRCs. This larger study is still ongoing as it includes a 
1-year patient follow-up; however, upon study completion, all the clinical data will be 
analyzed and the results outlined in a future report. While it is realized that the feasibility 
of this process for routine tooth extraction surgeries is most likely not practical, this study 
was conducted as an FDA Phase I/II study to examine safety and efficacy of this therapy 
for regeneration of craniofacial bone. If results are favorable, this type of therapy may 
certainly be feasible for larger, more challenging craniofacial reconstructions. 
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7.6. CONCLUSIONS 
There is a growing interest in cell therapy strategies to regenerate craniofacial tissues, 
particularly bone. However, key questions to be considered in utilizing these strategies 
are the following: What is the source of cells used in these approaches? How will the 
cells be processed and expanded to reach appropriate cell numbers for clinical 
applications? What is the phenotype and regenerative capacity of the cells produced? 
Through the current investigation, we report a novel approach to craniofacial 
regeneration with the utilization of an automated, closed-system, cell expansion process 
for the clinical-scale production of autologous cells, enriched in mesenchymal and 
vascular cell phenotypes. Additionally, it was demonstrated clinically that these cells 
possess the capacity to give rise to highly vascular bone, 6 weeks after transplantation 
into a jawbone defect. Although the findings presented herein cannot fully elucidate the 
answers to the aforementioned questions, they provide important insight toward that end. 
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7.7. FIGURES 
 
Figure 7.1. Bone repair cell (BRC) production. After harvest of bone marrow aspirates, 
cells are cultured using an automated, closed-system, single-pass perfusion (SPP) process. 
After 12 days of cell expansion in this bioreactor system, cells are packaged and 
delivered to the bone regenerative site on a biodegradable sponge. 
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Figure 7.2. Multipotent and osteogenic potential of BRCs. (a) After induction of 
BRCs in osteogenic, chondrogenic, and adipogenic media, photographs and 
corresponding photomicrographs show multipotent mesenchymal differentiation as 
measured by phenotypic expression of osteogenic mineralized matrix (von Kossa), 
chondrogenic proteoglycans (Alcian blue), and adipogenic lipid vacuoles (Oil Red O); 
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low magnification images were taken at 40×; high magnification images are shown at 
200 ×. (b) Osteogenic induction potential of BRCs is further evaluated qualitatively 
(staining) and (c) Quantitatively through measurement of alkaline phosphatase (ALP) 
activity of cells grown in the control medium versus cells grown in the osteogenic 
medium (*p < 0.05; alkaline phosphatase assays were performed in triplicate, and high-
magnification nonosteogenic and osteogenic panels shown on the ends represent the same 
wells shown at lower magnification in middle panel); low magnification images were 
taken at 40×; high magnification images are shown at 200×. (d) BRC expression of 
bone-specific transcripts (Runx2, osteocalcin [OCN], and bone sialoprotein [BSP]) was 
also measured with reverse transcriptase–polymerase chain reaction. 
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Figure 7.3. In vitro angiogenic phenotype of BRCs. (a) BRCs (n = 8) were shown to 
produce clinically appreciable levels of potent angiogenic cytokines, vascular endothelial 
growth factor (VEGF), and angiopoietin (Ang)-1 and -2. (b) After BRCs were cultured 
over 5 days in the presence of 50 ng/mL VEGF within three-dimensional collagen 
extracellular matrices, photomicrographs were taken and show sprouting structures 
indicative of endothelial cell capillary tube formation (100× magnification). (c) 100× 
and (d) 200× photomicrographs of fluorescently labeled BRCs after 4-h incubation with 
a (w/a) fluorescent-labeled lipoprotein (DiI-Ac-LDL) metabolized specifically by 
endothelial cells. 
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Figure 7. 4. Grafting of BRCs into localized jawbone defects. (a) Initial placement of 
BRCs onto gelatin sponge and (b) saturation of sponge with BRCs just before 
implantation into jawbone defect. Photographs of (c) jawbone defect after tooth removal, 
(d) placement of BRC-loaded gelatin into jawbone defect (arrows point to cell loaded 
gelatin), and (e, f) placement of a protective collagen membrane (arrows) for graft 
containment. 
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Figure 7. 5. BRC regeneration of highly vascular bone in jawbone defect. 
Photomicrographs of (a) regenerated jawbone defect 6 weeks after grafting of BRCs, (b) 
harvesting of bone core biopsy using trephine bur (just before placement of dental 
implant), and (c) bone core biopsy. (d) Microcomputed tomography three-dimensional 
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reconstruction of bone core biopsy from BRC-regenerated bone demonstrating 
mineralized tissue formation throughout specimen. (e) Histological evaluation 
(hematoxylin and eosin staining) of bone formation showing areas of mature cortical 
bone (B) with high vascularity, as indicated by abundance of blood vessels (arrows; low 
magnification at 4× and high magnification at 200×). 
 
  217 
 
7.8. TABLES 
 
Table 7.1. Polymerase chain reaction primer pairs. 
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Table 7. 2. Frequency of cell phenotypes in bone repair cells (n=10) produced by 
single-pass perfusion (Mean±Standard Deviation). 
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Table 7.3. Presense and enrichment of vascular phenotypes in bone marrow 
mononuclear fraction and bone repair cell product. 
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8.1. ABSTRACT 
A major clinical challenge in the reconstruction of large oral and craniofacial defects is 
the neogenesis of osseous and ligamentous interfacial structures. Currently, oral 
regenerative medicine strategies are unpredictable for repair of tooth-supporting tissues 
destroyed as a consequence of trauma, chronic infection or surgical resection. Here, we 
demonstrate multiscale computational design and fabrication of composite hybrid 
polymeric scaffolds for targeted cell transplantation of genetically modified human cells 
for the formation of human tooth dentin-ligament-bone complexes in vivo. The newly-
formed tissues demonstrate the interfacial generation of parallel- and obliquely-oriented 
fibers that grow and traverse within the polycaprolactone (PCL)-poly(glycolic acid) 
(PGA) designed constructs forming tooth cementum-like tissue, ligament, and bone 
structures. This approach offers potential for the clinical implementation of customized 
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periodontal scaffolds that may enable regeneration of multi-tissue interfaces required for 
oral and periodontal engineering applications. 
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8.2. INTRODUCTION 
Collectively, periodontal disease afflicts over 80% of adults worldwide and nearly 15% 
display severe disease concomitant with early tooth loss [1]. In periodontitis, the 
detrimental changes that the tooth-supporting tissues undergo are primarily the result of 
specific microbial challenges [2]. These challenges in a susceptible host disrupt the 
functional and structural integrity of the tooth supporting apparatus and may progress to 
affect a number of systemic conditions [3]. Therefore, the periodontium represents a 
critical barrier that if breached by invasive pathogens, triggers local and systemic 
inflammatory responses that characterize oral infection.  
 
Structurally, regeneration of the lost periodontium involves the formation of new 
cementum, periodontal ligament (PDL) and alveolar bone. However, the proper 
interfacial connection of this multi-tissue complex is what determines its function and 
stability in health. Its strength and mechanical integrity is the result of adequate PDL-
fiber orientation and its incorporation to the newly formed bone and cementum. This 
interconnection allows the periodontal system to dissipate and translate the mechanical 
stimuli that are generated from the tooth to the surrounding structures [4]. Biologically, 
this arrangement facilitates crucial cell-matrix interactions, which within a mechanically 
dynamic environment, determines normal dental-alveolar adaptive responses [5]. Current 
available regenerative therapeutic approaches show promising results [6-8]. However, 
complete regeneration and adequate fiber organization in large defects remains a 
challenging and unpredictable clinical dilemma [9].   
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In regenerative medicine, many different factors have been reported to promote multiple 
tissue integration and cell/tissue directionality [10-16]. Novel approaches, such as the use 
of multi-phasic scaffold designs as well as stem cell therapies represent a significant step 
forward in tissue engineering [13, 14, 17, 18]. Today, the ability to establish a 3-
dimensional polarity and patterning within a predetermined inherent scaffold geometry to 
guide and establish cell/tissue directionality is a feasible concept [15, 19-21]. Cell-based 
research has started to focus on designing and developing various physical and geometric 
approaches using biomaterials [22, 23]. However, the orchestration of multiple tissue 
formation, spatial fibrous tissue organization, and endpoint functional restoration using a 
single in vivo scaffold system remains a significant challenge. To address these 
limitations, a computational topology design and a solid free-form fabrication technique 
was used to create a hybrid periodontal-inspired model system containing PDL-specific 
and bone-specific polymer compartments [24, 25] 
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8.3. MATERIALS & METHODS 
8.3.1. Hybrid scaffold design and fabrication 
Periodontal ligament and bone architectures for the hybrid scaffold were designed and 
modeled with Unigraphics NX 5.0 (Siemens PLM software, Plano, TX USA). The 
designed structures were exported to the 3-D wax-printing system (ModelMaker II, 
Solidscape, Inc., Merrimack, NH USA) and manufactured using different wax molds (fig 
1B). After dissolving the Protobuild (Solidscape, Inc.) of PDL mold by 70% ethanol, two 
different biopolymers poly(glycolic acid) (PGA; MW>100KDa, Polysciences Inc. 
Warrington, PA USA) and poly-ε-caprolactone (PCL; MW 43-50KDa, Polysciences Inc.). 
25w/v% PGA was dissolved in 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP, Sigma-
Aldrich®, St. Louis, MO USA) solvent and the solution was cast for PDL interface 
architecture. 25 w/v% PCL solution in acetone (Sigma-Aldrich®) was cast in the bone 
architecture mold. These 2 different manufactured and fabricated architectures were 
assembled with PCL thin film membrane and BioAct® VSO (Petroferm Inc. Gurnee, IL 
USA) was used to remove Protosupport (Solidscape Inc.) for 2 days. The rest of 
Protosupport and BioAct VSO were dissolved in 100% ethanol overnight and hybrid 
scaffolds were stored in 70% ethanol.  
 
8.3.2. Human tooth dentin slice preparation  
Healthy human teeth were extracted from patients as previously described by the 
University of Michigan-Institutional Review Board (UM-IRB)-approved protocol. 
Approximately 3.0 x 4.0 x 0.8 mm3 dimensioned dentin blocks, which were fit into the 
PDL interface of the hybrid scaffold, were sliced and surface-treated by 37% 
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orthophosphoric acid to expose dentinal tubule topology and promote fibrous tissue 
attachment.  
 
8.3.3. Cell cultures and gene delivery  
Primary human gingival fibroblast (hGF) cells were provided as a kind gift from 
professor Martha Somerman (University of Washington, Seattle, WA USA). Passages 4-
6 hGF cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco BRL 
Life Technologies Inc., Grand Island, NY USA) supplemented with 10% fetal bovine 
serum (FBS; Gemini Bio-Products, Woodland, CA USA), antibiotics (100 units/ml 
penicillin and 100µg/ml streptomycin) and 2mM glutamine. During culturing in a 
humidified atmosphere of 5% CO2 in air at 37°C, the hGF cells were transduced with 
AdCMV-BMP-7, recombinant adenovirus-encoding murine bone morphogenetic protein-
7 (BMP-7), at a multiplicity of infection (MOI) of 500 and incubated for 1 day before cell 
seeding into the bone portion of hybrid scaffolds. Passages 4-6 human periodontal 
ligament cells (hPDL) were derived from tooth biopsy samples from 3 healthy human 
patients and cultured in media.  
 
8.3.4. Cell seeding in the hybrid scaffolds  
Bovine plasma fibrinogen (Sigma-Aldrich®) was dissolved in DMEM to make 5 mg/ml 
concentration and sterilized with a 0.2µm syringe filter (Nalgene®, Rochester, N.Y. 
U.S.A.). Bovine plasma thrombin (Sigma-Aldrich®) was dissolved in Hanks’ Balanced 
Salt Solution (HBSS, InvitrogenTM) at 100 U/ml concentration.  For the bone region, 
2.4x105 BMP-7-hGF modified cells in the bone region and 1.4x105 hPDL cells in the 
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PDL interface of hybrid scaffolds were suspended within fibrinogen solution. 1.6µl 
thrombin was pipetted on the PDL interface and 8.0µl hPDL-fibrinogen solution was 
dropped. After the gelation of the PDL interface, the treated tooth dentin slice was 
immediately positioned on the PDL scaffold. For BMP-7-hGF cell seeding, 3.0µl 
thrombin solution was pipetted inside of the bone architecture and 15.0µl hGF + 
fibrinogen solution was drop-wise added for fibrin gelation. 
 
8.3.5. In vivo experimental design  
Two different surgical pockets on the dorsa of immunodeficient 6 week-old NIH III nude 
mice (approximately 50-55g from Charles River Laboratories International Inc., 
Wilmington MA USA) were created. Four different groups were designed with 3 and 6 
week time-points in order to implant surgically created subcutaneous pockets of the nude 
mouse with sample n-values=8-9/group for each time point. The experimental groups 
consisted of 1) no cell seeding, 2) hPDL cell-seeded in PDL interface, 3) Ad-BMP-7-hGF 
cell seeded in bone region, and 4) hPDL and Ad-BMP-7-hGF cell seeded in PDL 
interface and bone region of hybrid scaffolds, respectively. Ad-BMP-7-hGF was the 
adenovirus encoding BMP-7 transduced human gingival fibroblast cells. Under 
isofluorane anesthesia, dentin-associated hybrid scaffold complex was implanted 
subcutaneously into a surgically-created pocket and the incisions were approximated 
using surgical staples. All animals were euthanized with carbon dioxide (CO2) prior to 
specimen harvest. All animal surgeries were performed under a protocol approved by the 
University of Michigan-University Committee on Use and Care of Animals (UM-
UCUCA).  
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8.3.6. Quantitative micro-computed tomography (Micro-CT)  
The harvested specimens were fixed in 10% buffered formalin phosphate solution for 1-2 
days and transferred in 70% ethanol. The tissue-fixed specimens were scanned by micro-
CT (GE Healthcare Inc., London, ON Canada) with 18 x 18 x 18 µm3 voxel size. Based 
on the Hounsfield unit (HU) scale, mineralized tissue regeneration was quantified around 
the hybrid scaffold, bone region and PDL interface below the treated human tooth dentin 
slice by MicroView Analysis+ 2.1.2 (GE Healthcare Inc.). The region of interests (ROIs) 
for PDL interface and bone region were 3.5 x 4.5 x 0.8mm3 and 5.0 x 6.0 x 3.0mm3, 
respectively to assess quantification of mineralized tissue formation.  
 
8.3.7. Histomorphometry for cementum-like tissue and tissue orientation formation  
After the micro-CT scanning, harvested specimens were decalcified with 10% EDTA 
(Ethylenediaminetetraacetic acid, Sigma-Aldrich®) for 2 weeks and then paraffin-
embedded for histology sections for hematoxylin and eosin (H&E) staining. Image-Pro 
plus software (Media Cybernetics Inc., Bethesda MD USA) was utilized to calculate 
length percentage of cementum-like layer on the human tooth dentin slice. The % length 
of cementum-like tissue formation (lcementum) was determined by comparing the newly-
deposited cementum length and the total dentin surface (ldentin), which contacted to PDL 
interface of the hybrid scaffold. 
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The orientation of fibrous cells and connective tissues in PDL interface was analyzed 
with four different indices, percentile of cellularity and orientation score (Fig. 4b). The 
best orientation was the perpendicular alignment to the dentin surface.  
 
8.3.8. Scanning electron microscopy (SEM)  
The scaffold constructs and dentin slices were washed, sonicated, dehydrated and the 
surface prepared for evaluation using the Environmental Scanning Electron Microscope 
(Philips XL30E SEM FEI Company, Hillsboro, OR USA). Briefly, after dehydration, the 
specimens were attached to a stub and sputtered with gold/palladium. The 
gold/palladium-coated specimens were examined by use of a FEI/Philips XL30 field 
emission environmental scanning electron microscope (SEM).  
 
8.3.9. Immunofluorescence and immunohistochemical stainings 
Tubulin and 4',6-diamidino-2-phenylindole (DAPI) staining were performed. Briefly, the 
samples were dissected and fixed in 4% paraformaldehyde at 4°C overnight, 
demineralized in 10% EDTA solution over 3 weeks, dehydrated, embedded in paraffin 
and processed for sectioning (6µm thickness). Fluorescence staining to tubulin (1:100 
dilution; Abcam, Inc. Cambridge, MA) was performed on paraffin sections using an 
affinity purified rat monoclonal antibody. Immunological reaction was visualized by 
using a rabbit polyclonal secondary antibody to rat conjugated to Fluorescein 
isothiocyanate (FITC) (1:200 dilution; Abcam, Inc. Cambridge, MA). The Sections were 
then treated with an antifade agent containing DAPI (ProLong Gold antifade reagent with 
DAPI; Invitrogen Corporation; Eugene, OR) and covered with glass coverslip. The 
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stained slides were imaged using an OLYMPUS Fluroview 500 confocal microscope 
(Olympus America Inc; Center Valley, PA).  
 
Immunostaining of Human Leukocyte Antigen (HLA) (1:200 dilution; Santa Cruz 
Biotechnology, Inc. Santa Cruz, CA) was performed on paraffin sections using an affinity 
purified goat polyclonal antibody. Immunological reactions were visualized by use of the 
goat ABC kit staining system and a peroxidase-diaminobenzidine reaction (Santa Cruz 
Biotechnology, Inc. Santa Cruz, CA). Sections were counterstained with hematoxylin and 
mounted on glass slides. Negative controls were obtained by substituting the primary 
antibody with serum.  
 
8.3.10. Customized, reversed-engineered scaffold design  
After iCAT-CT (Xoran Technologies® Inc.; Ann Arbor MI USA) scanning of a porcine 
periodontal defect site with the 200µm voxel-size resolution, the DICOM file was 
transferred to a STL file format to import CAD-based Unigraphics NX 5.0. Based on the 
tooth root-surface, micro-channels perpendicularly oriented to the root surface were 
designed and booleaned with STL-formatted in order to generate a similar surface-
morphology. Approximately, the dimension of PDL interface was 300µm-thick (Fig. 8; 
red-colorized architecture) to cover from the apical side of periodontal defect to cemento-
enamel junction (CEJ). After the hybrid scaffold, rapid prototyping technology was 
utilized to manufacture the molds to cast polymer. 25wt/v% PCL solution was casted into 
to printed wax molds and fabricated polymeric scaffold was placed to the periodontal 
defect to scan micro-CT to evaluate adaptation of defect geometry. 
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8.3.11. Adaptation evaluation of Hybrid scaffold-tooth root surface using the contrast 
agent and micro-CT  
After the customized hybrid scaffold was designed and manufactured, 35% barium 
sulfate (BaSO4) in distilled water was used to coat the 25% PCL hybrid scaffold to obtain 
the higher intensity and grayscale Hounsfield Unit. Surgically created periodontal defect 
region was harvested and scanned with/without the scaffold using micro-CT, which set 
up for 25 x 25 x 25µm3-voxel size resolution. On the 2-D coronal cross-sectioned view, 
3.00mm distance from the interface between the dental pulp and tooth dentin was 
selected to generate the grayscale-based histogram. This region covered from the tooth 
root, PDL interface, and middle of bone region. Adaptation ratio was linearly calculated 
using the entire length of PDL interface (dtotal) and the gap distance (dgap) between tooth 
dentin surface and the surface of PDL interface architecture in the hybrid scaffold. 
 
The scaffold had six different layers and each layer had three PDL channel-like structures 
(n=3 per layer).  
 
8.3.12. Statistical analysis  
The PASW Statistics 17.0 (SPSS Inc. Chicago, IL USA) was used for statistical analysis. 
Nonparametric two-tailed Kruskal-Wallis one-way ANOVA for unequal variance (Table 
8.1). After the overall determination of statistical results from the Kruskal-Wallis test, 
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pair-wise Mann-Whitney U-test were utilized to define the statistical differences among 
groups. We demonstrated the results were significantly different with the α value set at 
0.05 level of significance. 
 
  238 
8.4. RESULTS 
A 0.8mm thickness PDL interfacial structure was designed with multiple perpendicularly 
oriented channels, devised for the guidance of fibrous connective tissue formation and 
alignment of fibroblast-like cells (Fig. 8.1a). The structure was fabricated in 25% 
poly(glycolic acid) (PGA), a hydrophilic and rapid degradable biomaterial. For the bone 
compartment, a global porous geometry with approximately 0.75 x 0.50 x 0.05 mm3 
dimensions using 25% poly-ε-caprolactone (PCL) was designed (Fig. 8.1a). The PDL and 
bone components were then fused with a 15% PCL thin layer to form one single hybrid 
scaffold structure.   
 
The new scaffold design was evaluated using an in vivo model system. For this model, 
acid-treated human tooth dentin slices were sectioned to fit the PDL dimension and 
provide an avascular tooth surface with close proximity to the PDL microchannel-
grooved scaffold design (Fig. 8.1b).  The four different hybrid scaffold-dentin complexes 
were subcutaneously implanted in the dorsa of immunodeficient mice. The bone and PDL 
regeneration capacity was evaluated and the feasibility to adapt the model hybrid scaffold 
designed to the irregular periodontal defect topography was also determined.  
 
Micro-computed tomography (micro-CT) and serial histological sections were utilized 
for the qualitative and quantitative assessment of the mineralized tissue formed and to 
evaluate potential invasion of bone within the PDL region (Fig. 8.2; [26]. The 3-D 
reconstructed images provided qualitative information regarding the patterning and 
spatial distribution of the newly formed bone in relation to the scaffold geometry (Fig. 
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8.2; colorized micro-CT images). Bone volume fraction (BVF) and bone mineral density 
(BMD) were quantified using grayscale Hounsfield Units (HU). Specified regions of 
interest (ROIs) for PDL interface and bone region were created in 3.5 x 4.5 x 0.8mm3 and 
5.0 x 6.0 x 3.0mm3 dimensions, respectively. A robust mineralized tissue formation was 
observed in the groups containing the transduced osteogenic factor. These groups within 
the bone region demonstrated statistically significant higher values for BVF and BMD 
(*p<0.05 and **p-value<0.01; Fig. 8.3a and b). On the other hand, the only bone formed 
outside the bone region, was localized to the peripheral surface of the scaffold and dentin 
construct. No bone was found to be invading the PDL at either of the two time points for 
non BMP-treated constructs (Table 8.1). Histological evaluation of the PDL and bone 
regions provided further evidence of the lack of osteogenesis within the PDL region 
while corroborating the presence of bone within the other compartment (Fig. 8.2).  
 
Hematoxylin and eosin (H&E) serial images of the PDL-dentin interface were 
histomorphometrically evaluated to determine the length of new cementum formation 
(Fig. 8.3). At 3 weeks, limited evidence of cementum-like tissue deposition was observed. 
However, at 6 weeks the length of cellular cementum in the groups transduced by with 
BMP-7 were significantly greater compared to the other groups. (Fig. 8.3c and d, 
*p=0.024 and **p=0.007). The histomorphometric analysis showed that new cementum-
like tissue formed in 20.62% of the hPDL/BMP-7-hGF cell-seeded group and 17.70% of 
BMP-7-hGF cell-seeded group, compared with 0% and 1.2% of the no cell and hPDL-
seeded groups, respectively (Fig. 8.3c). Interestingly, the newly formed cementum was 
observed in association with vascular structures and fibrous connective tissue (Fig. 8.3d). 
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The associated fibrous tissue is speculated to represent a transition cue of the 
cementogenesis process on the dentin surface and the initial integration of fibrous 
bundles to the dentin slice [27]. 
 
These findings are particularly important as they emphasize the potential biological effect 
of the hybrid scaffold system. The designed PDL interface architecture was initially 
conceived to increase angiogenic development and enhance biological molecule 
diffusivity. This theoretical concept is supported by the in vivo findings, which reflect an 
increased number of vascular structures and mature fibers oriented along the patterned 
surface scaffold architecture (Figs. 8.2 & 8.4). This was especially observed in the two 
different hPDL cell-seeded groups. At 3 weeks, these observations were primarily 
reflected in the BMP-7 transduced groups (Fig. 8.4). However, by the 6th week, a more 
generalized increased level of tissue orientation was observed in different proportions for 
all groups (Fig. 8.4).  
 
To evaluate the viability of the human-seeded cells within the scaffold complex, the 
harvested constructs were immunostained for human leukocyte antigen-A (HLA-A). 
Distinct membrane staining was noted in the PDL and bone regions of the groups where 
human cells were transplanted. These groups of cells within the PDL were preferentially 
localized along the polymer architecture and at the center of more mature fibrillar 
structures. Within the bone scaffold region, the HLA-A positive cells were clearly 
localized primarily around the new bone surface and presented an osteoblast-like 
phenotype.  Multiple osteocyte like cells were also positive for HLA-A (Fig. 8.6).   
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5.5. DISCUSSION 
The current system still has limitations compared to the highly complex native multi-
tissue formation [12-14], especially bone-PDL-tooth complex [9, 28, 29].  One of the 
most important variables is the lack of a mechanically-modulated environment as well as 
a symmetric design which does not completely reflect the irregular and complex 
morphology of typical periodontal defects [4]. Therefore, supported by the biological 
advantages demonstrated in this novel hybrid scaffold, a more periodontally relevant 
design was constructed using surgically created defects in porcine mandibulae to 
determine the ability to conform to the anatomical specifications of the periodontium (Fig. 
8.5). The customized scaffold displayed perpendicularly oriented internal channel-
structures within the PDL portion and a similar bone topology in the open-box format to 
follow and coalesce with the adjacent residual bone.  The inter-root defect scaffold was 
designed to possess two separate components with a key (buccal)–lock(lingual) system to 
make easier the assembling and adaptation through the defect region (Fig. 8.5a). The 
adaptability/fitting of the fabricated scaffold was evaluated using 3-D and cross-sectional 
analysis to establish the approximation of the scaffold construct in relation to the 
periodontal tissues and defects (Fig. 8.5b-d). This possibility of customization and, 
therefore, guidance of each tissue represents an additional advantage with a significant 
clinical relevance. 
 
Together, these observations support the added value of designing a compartmentalized 
hybrid scaffold with biomimetic architecture to influence cell behavior and tissue 
orientation.  The combined hPDL cells and Ad-BMP-7-hGF cells not only surpassed 
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most of the measured variables when compared to the other test groups, but also 
produced a more predictable formation of tissue similar to healthy periodontium. 
Therefore, our principal finding was that a combinational system of hPDL fibroblast-like 
cells and osteogenic stimulation can enhance the regeneration of the multi-layered 
periodontal complex. This approach offers strong potential for an “off-the-shelf scaffold 
construct for repair of oral and craniofacial defects.  
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8.6. CONCLUSIONS 
We demonstrate the consistent generation of newly-formed tissues possessing interfacial 
neogenesis of parallel- and obliquely-oriented ligamentous fibers that sprout and traverse 
through the polymer designed constructs forming tooth cementum-like tissue, ligament, 
and bone structures. This approach offers potential for the clinical implementation of 
customized periodontal scaffolds that may enable regeneration of multi-tissue interfaces 
required for oral, craniofacial, and periodontal engineering applications. 
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8.7. FIGURES  
 
Figure 8.1. a) Schematic illustration of the 3-D wax printing system and dimension 
of hybrid scaffold shows polymeric architecture manufacturing. For the PDL 
interface, column-like structures were 0.8 mm diameter and 0.3 mm exposed heights and 
casted using PGA-HFIP solution. For the bone region of the hybrid scaffold, PCL-
acetone solution was used for casting. PCL-acetone, pasted on the PCL-casted mold and 
PDL interface architectures were placed on it. b) After the acid-treatment of human tooth 
dentin slices, the complex with a polymer-casted hybrid scaffold and a dentin slice was 
assembled using fibrin gel with or without cells. The left is the 3-D designed hybrid 
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scaffold and the right panel is the micro-CT scanned and 3-D reconstructed hybrid 
scaffold and a dentin slice. The scale bar: 50 µm. 
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Figure 8.2. 3-D reconstructed colorized micro-CT images and hematoxylin and eosin 
(H&E) stained histology. The mineralized tissue (blue-colorized) was formed around 
the hybrid scaffolds and there was no ankylosis, bone fusion to the dentin surface (white-
colorized). Red and blue dashed lined-boxes represent the PDL interface and bone 
regions, respectively. H&E stained histology slices showed PDL interfaces and bone 
region tissues to evaluate fibrous tissue orientation along the column-like structures in 
PDL interface, which were designed with perpendicular direction to the dentin surface. 
At 6 weeks, hPDL cell seeded specimens demonstrated perpendicular orientation to the 
dentin slices and along the column-like structures with limited evidence of cementum-
like cells on the dentin surface. Yellow dash-line is the borderline of channel-type PDL 
architecture and black arrowed lines represent the fibrous cell/tissue directionality 
following the wall of PDL interface structure. Red triangles indicate the blood vessels 
and yellow triangles point cementum-like tissue layer or cell deposition for 
cementogenesis on the dentin surface. The scale bar: 50 µm. 
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Figure 8.3. Quantitative analysis of micro-CT and histomorphometry for 
cementum-like tissue length. At 3 week time point, a) bone volume fraction (BVF) and 
b) bone mineral density (BMD) at 3 and 6 weeks were measured and analyzed 
statistically for bone regions of the hybrid scaffolds. a and b) In the aspects of BVF and 
BMD, there were statistically significant differences between the osteogenic factor and 
non-osteogenic factor groups in bone regions at 3 weeks (**p < 0.01) and 6 weeks 
(*p < 0.05 and **p < 0.001). c) The cementum-like tissue length percentage represented 
of mineralized layer deposition on the dentin surface at 3 and 6 weeks. Full surface length 
of dentin slice, which faced to the PDL interface was measured and divided the measured 
the cementum-like tissue length (%). At 6 weeks, hPDL/BMP-7-hGF cell seeded group 
had statistically significant differences with no cell and hPDL cell seeded groups 
(*p = 0.02433 and **p = 0.00722). d) Qualitative results using H&E staining for the 
cementum-like tissue formation on the dentin surface. In 3 weeks, there was limited 
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evidence of the mineralized layer formation but, in 6 weeks, significantly increased 
mineral deposition can be determined with the cementocyte-like cell embedded indicated 
by yellow triangles. For all statistical data analysis, two-tailed Kruskal–Wallis one-way 
ANOVA test and Mann–Whitney U-Test were utilized and data were mean ± standard 
error of mean (S.E.M.). Scale bar: 50 µm. 
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Figure 8.4. Cellularity and cell/tissue orientation in PDL interface using H&E 
staining and Immunofluorescence images. The fibrous tissue orientation was measured 
by semi-quantitative analysis with four different indexes; no cellularity, cellularity 
without fiber formation, cellularity with disorganized fiber, and cellularity with 
perpendicularly oriented fiber formation to the dentin surface. The H&E staining pictures 
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are the representatives for these four indices. The percent number of the semi-quantitative 
analysis was calculated with total number of samples in each group/time point and the 
number of each observation index. Immunofluorescent images represent four typical 
examples of indexes with DAPI (blue) and tubulin (green) staining in cytoplasm. Scale 
bar: 50 µm.  
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Figure 8.5. The reverse-engineered periodontal defect-fit scaffold modeling and the 
adaptation of customized designed scaffold on the root surface. a) The computer-
aided design (CAD)-based software, NX5 was utilized to create PDL (red-colorized) and 
bone (blue-colorized) interfaces of the hybrid scaffold. The anatomical defect-fit scaffold 
had the perpendicular oriented PDL internal channel-structures and topological 
similarities of the periodontal defects. The Furcation defect design had separated two 
different parts with key (buccal)–lock (lingual) system to make easier assembling and 
implanting through the buccal-lingual penetration defect region. b–c) The red line was 
porcine mandible image with the customized scaffold and the blue line was the exposed 
periodontal defect site. b) The histogram represented the 99.9% adaptable scaffold to the 
root surface. The measured length was 3.00 mm and scaffold was coated by 35% BaSO4 
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solution. The yellow lines on the 2-dimensionally digitized slices represented the 
measured regions with 3.00 mm length from the dentin (dental pulp side) to the middle of 
defect site. The abbreviations were that AB: alveolar bone, R: tooth root, and Sc: hybrid 
scaffold. c) The histogram was from 83.5% adaptable scaffold image. The concaved 
region of the red line can represent the gap distance (dgap) between tooth root surface and 
PDL interface scaffold. d) Based on the method in Figure 5.5-C and d, total PDL 
interface length (dtotal) and dgap were linearly measured and the adaptation ratio was 
calculated in each layer, which had 3 different channel-type structures. There was no 
statistically significant difference (N.S.) among 6 different layers (p = 0.1143) and the 
rage of adaptation was 83.3%<mean value of adaptation ratio < 99.0% and data were 
mean ± standard deviation (S.D.). For the statistical analysis, the nonparametric Kruskal–
Wallis one-way ANOVA test was used. 
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Figure 8.6. Immunohistochemical staining to probe transplanted human cells. Using 
human leukocyte antigen (HLA-A) molecules and the Avidin-Biotin Complex (ABC) 
staining kit, the difference of cell-types was determined and characterized between 
transplanted human cells (hPDL and BMP-7-hGF cells) and host NIH-III nude mouse 
cells. The panel, titled no human cell transplanted demonstrated hematoxylin staining of 
cell nucleus enabled to host cell infiltration into the hybrid scaffold as a negative control. 
However, the panel, titled human cell transplanted (hPDL and BMP-7-hGF cell 
transplantation) showed the white arrow-indicated, brow-colored regions were 
represented as staining of human cell membrane with ABC kit. The yellow dash line 
represented scaffold-tissue interface. Scale bar: 50µm.  
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8.8. TABLE 
 
Table 8.1. Statistical analysis for mineralized tissue formations in PDL interface and 
bone region of the hybrid scaffold. In PDL interface, the result of the analysis indicated 
that overall examination demonstrated that it was not significantly different using the 
two-tailed Kruskal-Wallis one-way ANOVA method (p>0.05)1. The significant 
differences (p<0.001) show in bone volume fraction and bone mineral density. Because 
these overall examinations were significant using Kruskal-Wallis test, the pair-wise 
comparisons, Mann-Whitney U-test1 among four different groups per time point should 
be completed (see Fig. 3-a,b). 
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CHAPTER NINE 
 
SUMMARY AND DISCUSSION 
 
 
There are four main themes, which have been demonstrated in this dissertation: 1) 
development of the micro-computed tomography (micro-CT) methodology to assess the 
alveolar bone structure to quantify the periodontal disease, regeneration, and orthodontic 
tooth movement; 2) development of methodology for applications in pre-clinical and 
clinical studies; 3) computer-aided design (CAD)-based hybrid scaffold evaluation to 
induce ectopic periodontal tissue regeneration.  
 
In Chapter Two, we developed a novel and accurate methodology to analyze alveolar 
bone volumetric parameters for the quantitative assessment of periodontal hard tissue 
regeneration. This methodology allows highly accurate and precise quantification 
assessment of alveolar bone regeneration rather than using conventional two-dimensional 
dental x-ray radiographic techniques. For validation of this methodology, we have found 
that following training of evaluators, a typical agreement of approximately 1% between 
examiners can be achieved. Of the statistical analysis methods, Coefficient of Variation 
(CV) demonstrated precise error for reproducibility of developed volumetric 
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measurements. CV was less than 1.5% in inter- and intra-examiner calibrations 
demonstrating that this methodology has very high reproducibility and reliability of 
measurement. Moreover, micro-CT scanning showed to be highly reproducible and 
repeatable with very low precision errors. Bone volume fraction (BVF) and bone mineral 
density (BMD) had 0.84% and 2.1% precision errors, respectively. Bone loss by 
experimentally induced disease was found to be significantly different between healthy 
and diseased groups.  
 
In Chapter Three, we have addressed different pre-clinical applications for periodontal 
disease quantification and orthodontic tooth movement. AAV2/1-TNFR:Fc gene delivery 
method can play a role in the blockade of TNF-α inflammation in animal models and 
inhibit  osteoclastogenesis-related bone resorption. A periodontal disease induction model 
in rats was designed and evaluated with systemic AAV2/1TNFR:Fc administration. The 
experimental design was follows: 1) control (vehicle), 2) AAV-TNFR:Fc, 3) AAV-
TNFR:Fc + Pg-LPS, and 4) Pg-LPS only. For micro-CT analysis, the ROI was selected 
from the roof of furcation (ROF) to root apex (RA) of the 1st molar (on the sagittal view) 
with measurements made  around the 1st molar, from the mesial 1st molar to the mesial 
2nd molar within the interproximal area (on the coronal view). The qualitative and 
quantitative data from this study resulted in a significant prevention of periodontal 
disease with (Fig. 3.2).  
 
In Chapter Four, osteoprotegerin (OPG) is an inhibitor of osteoclastogenesis and bone 
resorption. The periodontitis induction model was designed with the 3/0 cotton ligatures 
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around the first molar tooth. Human recombinant OPG fusion protein (rhOPG-Fc) was 
delivered to the region of tooth ligatures at 3 and 6 week time-points. Using the same 
ROI criteria as the AAV2/1-TNFR:Fc study, the periodontal alveolar bone structure was 
quantified by micro-CT.  Linear bone loss analysis showed OPG +disease induction 
yielded no significant difference between the no treatment animals and OPG injection 
only animals at 3 and 6 weeks. Results from volumetric measurements (parameters: BVF 
and BMD) showed no significant difference between the no treatment healthy group and 
the OPG+periodontitis induction group at both time-points.  
 
In Chapter Five, a Sprague-Dawley rat tooth movement model was designed and 
established by placing nickel-titanium springs between incisors and the 1st molar. The 
spring provided forces and induced the 1st molar movement toward the incisor within rat 
mandibulae. In this experiment, external forces from spring placement induced tooth 
movement and the movement had been a cause of alveolar bone deformation. The 
experimental groups were as follows: 1) control, or baseline, 2) vehicle with spring 
placement, 3) low dose OPG injection (0.5 mg/kg), and 4) high dose OPG injection (5.0 
mg/kg) in order to analyze OPG efficacy. Biomechanical tooth movement was dependent 
on osteoclastogenesis. The high dose OPG injection group showed less bone resorption 
(via bone volume fraction) and the 1st molar-movement distance was different for each 
group depending on degree of bone resorption. The degree of tooth movement due to 
bone resorption (or lack of) was more accurately prognosed with micro-CT imaging 
technique and three-dimensional volumetric measurements. The results demonstrated an 
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inhibition of osteoclastogenesis with high dose OPG injection, significantly blocking 
tooth movement.  
 
In Chapter Six, we have demonstrated the clinical applications for evaluating alveolar 
bone healing and mineralized tissue formation within tooth-extraction sockets. Collagen 
membrane, which covered the tooth-extraction socket, was evaluated for prevention of 
soft fibrous tissue invasion into the socket site and for accelerated induction of natural 
bone healing. Following membrane treatments of 10 patients at 12 weeks, re-entry 
surgery was performed and bone core biopsies were collected to analyze bone quality for 
dental prosthetic implantation. Based on the resultant micro-CT analysis, there was 
statistical significance and down-growth of epithelium was prevented into the dental 
socket-site, without any mineralization on the collagen membrane barrier surface.  
 
In Chapter Seven, bone repair cells (BRCs; produced from bone marrow aspirates) were 
harvested and cultured in an automated, closed system, single-pass perfusion (SPP) 
process. After cultivation for 12 days in the SPP system, BRCs were surgically 
transplanted with a gelatin sponge into the dental extraction socket. Surgical re-entry was 
performed after 6 weeks and bone core biopsies were harvested and histomorphometric 
analysis was utilized for evaluation of BRC angiogenic and osteogenic differentiation. 
Micro-CT was analyzed qualitatively with 3-D reconstruction to observe the bone growth 
patterns. Highly mineralized tissue formation was visualized and angiogenic blood vessel 
formation was observed following analysis of hematoxyline and eosin (H&E) staining.  
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In Chapter Eight, the computer design-based hybrid scaffolding system was evaluated 
for ectopic periodontal tissue regeneration. An acid-treated human tooth dentin slice was 
placed on the PDL interface of the designed hybrid scaffold and seeded as follows with 
different cell types to induce multiple tissue formation: 1) no cells control; 2) human PDL 
cells seeded within the PDF interface only; 3) BMP-7 transduced human gingival 
fibroblast cells (BMP-7-hGF) seeded within the bone region only; 4) human PDL cells 
within the PDL interface and BMP-7-hGF transplanted within the bone region of the 
hybrid scaffold. Results were evaluated using histomorphometric analysis, micro-CT 
quantification and qualification, and immunohistochemistry. In the results, the computer-
designed, multi-layered hybrid scaffolding system successfully compartmentalized to 
regenerate different tissues and the periodontal ligament tissue orientation was in a 
perpendicular direction to the dentin surface. Furthermore, the CT, image-based scaffold 
system had high adaptability to the periodontal defect topology. Therefore, the CT image-
based, customized defect-fit scaffold has significant clinical relevance.  
 
Collectively, the micro-CT methodology has been shown to quantify alveolar bone 
structure during periodontal disease progression. This novel methodological approach 
using micro-CT image analysis can accurately and reproducibly measure tooth-
supporting alveolar bone loss or regeneration. The methodology has demonstrated strong 
agreement between examiners with significant reliability and reproducibility. Therefore, 
these methods can serve as a standard for assessing both periodontal disease progression 
and bone regeneration. The use of micro-CT and its associated software can provide 
effective 3-D visualization and image analysis of the bone-tooth interface to compliment 
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craniofacial and orthopedic studies. The complicated topology can provide optimal, 
nondestructive natural landmarks to create regions of interest for volumetric assessments. 
In addition to reproducibility and reliability, this methodology has wide applications 
within dental science and tissue engineering, showing more feasibility for indirect 
analysis and prediction of orthodontic tooth movement as well as predicting periodontal 
disease progression and periodontal tissue regeneration. 
 
The tissue-guidable scaffolding architectures were designed and manufactured by the 
rapid prototyping technique. Biomimetic hybrid scaffold was comprised of PDL interface 
with vertically oriented architectures for perpendicular orientation of fibrous tissue and 
bone region with high porosity. This multi-layered complex with untreated human PDL 
cells and BMP-7 transduced human gingival fibroblast-like cells was transplanted 
subcutaneously in the ectopic model system. In spite of conditions with no biomechanical 
loading, the physical and topographical design approach provided periodontal tissue 
organization. The newly formed PDL cells/tissues were correctly guided along the 
designed, perpendicularly-oriented architecture to the human tooth dentin slice. The 
mineralized tissues were not formed into the PDL interface of the hybrid scaffold thus the 
hybrid scaffolding system can demonstrate multiple tissue regeneration can be 
compartmentalized in each region of the hybrid scaffold at 3 and 6 weeks.  
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CHAPTER TEN 
 
FUTURE DIRECTIONS 
 
 
As this dissertation has demonstrated, a novel computer-designed scaffolding system has 
achieved multiple periodontal tissue regeneration. In this study we found that we could 
use CAD-based, periodontal-inspired hybrid scaffolds to realize multi-periodontal tissue 
regeneration and early-stage periodontal integration in a single system. Based upon the 
results in this dissertation we will attempt to perform a clinically-relevant study using 
computer-/medical image-based scaffold design and manufacturing methodology with  
micro-architecture geometry within a large animal model. Using the periodontitis-
induction model system, unpredictable topological destruction and regeneration will be 
evaluated with the medical image-based scaffolding approach instead of surgically 
created periodontal defects. 
 
Within the aspects of periodontal stem cell bioengineering approaches, the micro-scale 
hybrid scaffolding system showed somewhat unpredictable anchorage of PDL connective 
tissue with premature mineralized tissue. A robust anchorage of fibrous connective tissue 
to mineralized tissue surface is crucial for tissue re-functionalization. PDL stem cells can 
potentially differentiate to cementum and bone to induce this periodontal connective 
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tissue anchorage. Unfortunately, the differentiation mechanism of PDL stem cells is not 
well understood and thus its use is difficult to optimize for formation of osteogenic tissue 
layers to support anchorage. Although a tissue-guidable scaffolding system can help to 
regenerate and organize multiple periodontal tissues, micron-scale interface integration 
remains a critical need for functional restoration of newly formed tissue. Therefore, the  
surface-topography scaffold design approach is necessary to help understand the PDL 
stem cell role in stimulating osteogenic differentiation of human PDL stem cells. This 
study will provide a more optimized design concept for periodontal tissue integration and 
periodontal tissue functional restoration following the proliferation, differentiation, and 
mechano-transductive responses of periodontal ligament stem cells. 
 
Physico-mechanical properties of the scaffolding system will also contribute to cell/tissue 
infiltration into the extracellular matrices and mechano-transduction of periodontal 
ligament stem cells. Periodontal in-vivo environments, where various mechanical 
stimulations are generated, may have more complicated stem cell response mechanisms. 
Although many investigators have achieved and demonstrated the control of bone 
marrow stem cell differentiation with different stiffness and elasticity of substrate, 
physico-mechanical properties may contribute to different periodontal ligament stem cell 
behaviors in-vivo, unlike simplified homogeneous geometric approaches or in-vitro 
conditions. So different concentrations of extracellular matrix materials can provide 
further controllable tissue regeneration with the cellular differentiations.  
 
